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ABSTRACT
NEUROPATHY DETECTION, QUALITY OF LIFE TOOLS & TREATMENT
FOR TYPE 2 DIABETES
Jennifer J. Brown
Old Dominion University, 2016
Director: Dr. Sheri Colberg-Ochs

Type 2 diabetes (T2D) mellitus has become the epidemic of the new millennium, with an
estimated 382 million people affected worldwide as of 2013, and statistics projected towards 592
million by the year 2035. With the development of diabetes, complications have risen, with
diabetic neuropathy becoming one of the most prevalent, affecting between 10–90% of those
with the disease. Diabetic peripheral neuropathy (DPN) is difficult to detect in early stages of
pathology, yet devastating once significant damage has taken place. Cardiac autonomic
neuropathy (CAN), which is often silent, is associated with autonomic nervous system (ANS)
dysfunction and increased risk for sudden death. Therefore, the purposes of this dissertation
were early detection, assessment of quality of life (QOL) and disease intervention. Study I
explored the effectiveness of the 128-Hz tuning fork, the 1-g and 10-g monofilaments, and the
QOL-DN as tools for the early detection of DPN in overweight, obese and inactive (OOI),
prediabetes (PD), and type 2 diabetes (T2D) individuals. Study II compared three QOL
assessments: the QOL-DN, the PN-QOL-97 and the NeuroQOL-28, in OOI, PD and T2D
individuals. Study III involved the execution of a double blinded, placebo controlled exploration
of melatonin as a potential intervention for the improvement of ANS and sleep dysfunction in
T2D.
The results of Study I suggest that the 1-g monofilament and QOL-DN measures
correlate to NC-Stat DPN Check portable nerve conduction study (NCS) findings, that these
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measures function well for early detection purposes, and that the 128-Hz tuning fork is a useful
screening tool in OOI, PD and T2D populations, despite lack of correlation to NCS measures.
The results of Study II suggest that the QOL-DN and the NeuroQOl-28 QOL instruments
significantly predict NCS results, indicating that these measures are useful for screening and
accurately assessing neuropathy within our populations of interest. Study III results indicate that
a 10 mg dose of melatonin taken 30 minutes prior to bedtime for four weeks has a positive effect
on PSQI Subjective Sleep Quality, systolic blood pressure (SBP) in deep breathing and Valsalva
maneuvers, and HRV SDNN measures in individuals with T2D.
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CHAPTER I
INTRODUCTION
Diabetes is a metabolic disorder, and when present, indicates that an individual has high
blood glucose (BG) levels relating to insulin production or usage, or potentially both of these
metabolic processes (Center for Disease Control and Prevention, 2014). This elevated BG status,
or hyperglycemia, affects various cells throughout the body that perform both vital and
secondary functions, including key brain, organ and muscle tissue processes. Debilitating by
nature, diabetes often goes undetected, with one out of four unaware that they have developed
the disease until symptoms elevate to the point where significant damage may be present or a
major event may occur (Center for Disease Control and Prevention, 2014).
The debilitating effects of diabetes stretches worldwide, affecting 382-387 million
people, creating an impact on 29.1 million, or 9.3% of the United States population (Center for
Disease Control and Prevention, 2014; Guariguata et al., 2013; International Diabetes
Federation, 2014). With an estimated 21 million who have been diagnosed and another 8.1
million who remain undiagnosed, the International Diabetes Federation and research estimates
the impact of diabetes to climb into the staggering 590-592 million range across the globe by the
year 2035 (Guariguata et al., 2013; International Diabetes Federation, 2014). The largest number
of new diabetes cases are in the 45 to 64 age range, and interventions aiming to stop diabetes
processes at earlier stages in younger populations seem prudent, as the disease is gaining a
tighter grip on the United States and the population worldwide (Center for Disease Control and
Prevention, 2014).
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Great emphasis has been placed on developing management strategies for commonly
associated complications such as neuropathy (Shah & Mueller, 2012) and weight gain
(Courcoulas, 2015; Golomb, Ben David, Glass, Kolitz, & Keidar, 2015); yet long term resolution
remains elusive once disease pathways have set their course. Extensive research has been
performed determining the linkage between diabetes and other diseases, including the effects of
insulin on the brain, metabolic syndrome, depression, and various forms of neuropathy (Alberti
et al., 2009; Chen, Wang, Zhu, Li, & Teng, 2014; Mezuk, Eaton, Albrecht, & Golden, 2008;
Smith, Gerardi, Lessard, Reyna, & Singleton, 2013; Vinik, Nevoret, Casellini, & Parson, 2013).
Existing research provides foundational opportunities for positive impact on the health of
millions who currently suffer with diabetes, as a major focus is on the modification of
management of the disease, in hopes to halt its progression. Yet, there is still much to learn
regarding how to prevent the initial onset in the earliest stages, and how to ignite changes before
long standing hyperglycemia sets in, negatively affecting quality of life (QOL) (Alexander,
Landsman, & Grundy, 2006; Nichols, Alexander, Girman, Kamal-Bahl, & Brown, 2006;
Phillips, Ratner, Buse, & Kahn, 2014).
Hyperglycemia at any stage is an unhealthy process that lays the groundwork for
significant pathophysiological processes (Mustafa, Alemam, & Hamid, 2012; Papanas & Ziegler,
2012). The development of earlier intervention practices is logical for numerous reasons. The
cutoff points dictating glycemic levels that define diabetes relate to the associations found
between particular glucose levels and significant increases in microvascular complications such
as retinopathy and nephropathy (Buysschaert & Bergman, 2011). It is vital to encourage
individuals whose glucose levels reside within cautionary ranges, such as prediabetes (PD), to
take heed and implement aggressive measures to avoid the common progression to type 2
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diabetes (T2D). Research indicates that individuals with PD in the HbA1C range of 6.1–6.4%
are at significant risk for the development of T2D and typically progress to T2D within three to
five years (ADA, 2016). Developing new tools and programs that assess risk prior to this time of
pathophysiological dysfunction is a practical course of action.
Early detection and intervention is key if society desires to attenuate the impending
impact that T2D and prediabetes is expected to have on the modern world in the upcoming years
of 2030 to 2035. Diabetes in its latter forms has already launched its assault on the body, often
in irreparable ways and, thus, early detection of complications and treatment of them is key to
achieve the best scenarios for health and positive outcomes. It is with these concepts in mind
that I built a framework for my research.
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CHAPTER I
PART A: NEUROPATHY SCREENING TOOLS
The Problem
T2D and PD are worldwide health problems, with rapidly increasing numbers
(International Diabetes Federation, 2014; Ruterbusch, 2014). DPN is a significant complication
associated with acute and chronic hyperglycemic conditions such as T2D and PD, yet little
research exists evaluating the ability of low-cost screening tools to effectively detect the earliest
stages of the disease. Given that DPN is frequently debilitating (Vinik et al., 2013), early
detection of the disease would best allow for treatment and management, hopefully deterring
long-term deficits in ambulation (Eikenberg & Davy, 2013; Papanas & Ziegler, 2012). Research
scientists agree that catching the pathology in the earliest stages is important to prevent major
complications and loss of quality of life, thus targeted efforts must be made to detect DPN during
the earliest stages of hyperglycemia (Ferrannini, Gastaldelli, & Iozzo, 2011; Papanas & Ziegler,
2012; Prevention of Type 2 Diabetes: From Science to Therapy, 2012). This involves evaluating
PD and individuals with elevated, but not clinically diagnosable hyperglycemia. Multiple tools
exist to screen T2D populations, yet these tools have not been used extensively in PD or
subclinical populations.

Purpose and Significance of the Study
Evaluating simple screening tools and their ability to effectively detect earlier stages of
DPN in new research populations, such as in overweight, obese and inactive (OOI) subjects,
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alongside PD and T2D subjects allowed a fresh look at how these particular tools could be used.
The hope of this research was that we might uncover simple ways to disclose early DPN or
subclinical neuropathy. PD and T2D populations served as control subjects, allowing us to
compare our data to previous research, while seeking new answers for early DPN and subclinical
neuropathy detection. We aimed to evaluate the effectiveness of three neuropathy screening
tools: the 128-Hz tuning fork, the 1-g and 10-g monofilaments, and the QOL–DN for the
purposes of early DPN detection, utilizing predefined definitions from literature (Tesfaye, 2010).
We also hoped to determine which screening tool was the most effective, while comparing our
results back to a standardized criterion measure of portable nerve conduction in the form of the
NC-Stat DPN Check (Neurometrix Inc., Waltham, MA).

Research Design
Study Design Approach. The proposed study took an observational and correlational
approach paired with a quantitative data collection. Individuals were screened and categorized
by HbA1C values and prior diagnoses, creating specific groups to study (see Appendix A) (OOI,
PD, T2D).
Variables. A criterion variable approach was implemented, with the NC-Stat DPN
Check device providing a nerve conduction testing evaluation of the sural nerve, bilaterally. Our
other variables, the 128-Hz tuning fork, 1-g and 10-g monofilaments, and the QOL–DN (see
Appendix B), were compared to this standard of testing. HbA1C test data combined with
previous PD or T2D diagnosis identified OOI, PD and T2D populations with continuous
numerical data, into 1 of 3 categories: OOI, 4.0–5.6%; PD, 5.7–6.4%, T2D, 6.5% and above.
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Dependent variables (DV) included the tuning fork data, monofilament testing, and QOL–DN
results, which consisted of continuous, interval level data.

Research Questions
RQ1: To what extent will:
1a: the 128-Hz tuning fork detect early DPN in an OOI, PD and T2D population?
1b: the 1-g and 10-g monofilaments detect early DPN in an OOI, PD and T2D
population?
1c: the QOL–DN detect early DPN in an OOI, PD and T2D population?
RQ2: Which tool will be the most sensitive for detecting early DPN?

Research Hypotheses
H1: The 128-Hz tuning fork and QOL–DN tools will provide excellent mechanisms for
detecting early DPN in OOI, PD and T2D populations.
H2: The QOL-DN will be the most sensitive measure to detect early or undisclosed DPN in an
OOI, PD and T2D population.

Assumptions. Assumptions included accurate reporting on the part of our participants.
This includes believing that they would be invested in accurately participating in tests that
involved their voluntary response, such as tuning fork, and monofilament testing and that
participating individuals would answer questions honestly on the provided patient reported
outcome measure (PROM) questionnaires. We justified that individuals choosing to engage in
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our research were likely to report truthfully and be invested in the task at hand, as they were not
paid for their time, and willingly participated of their own free will in the study. The
psychometric properties of the QOL-DN have been previously evaluated for populations with
diabetes and also, for the purposes of revealing undisclosed DPN in varied populations;
therefore, in this research study we assumed that the psychometric properties of this instrument
would be effective in our OOI individuals.
Limitations. Old Dominion University has limited clinical equipment for related to
diabetes testing. The HbA1C testing machine that was used within the study is a validated
machine (Lenters-Westra & Slingerland, 2010), yet oral glucose tolerance testing is preferred by
some research scientists, particularly for individuals with cardiac autonomic neuropathy (CAN)
(Farhan et al., 2012). DPN and CAN often coexist, yet we did not test for CAN and, therefore,
cannot account for unknown discrepancies. Temperature and humidity have been found to affect
monofilament results, by affecting the potential validity of the instrument in extremely high
temperatures as well as high testing volumes in short periods of time (Booth & Young, 2000;
Haloua, Sierevelt, & Theuvenet, 2011). Temperature was accounted for by limiting
monofilament storage and use to normal climate controlled room temperatures and monitored
these values. Humidity was monitored, but not controlled beyond what the Old Dominion
University air-conditioning and heating systems accounted for. Preparation for monofilament
usage followed previously stated guidelines and recommendations, with testing amounting to far
less than 100 compressions per day per instrument (Booth & Young, 2000). The NC-Stat DPN
Check device was used solely to test the sural nerve; therefore, deficits in nerve function relating
to other nerves of the lower leg were not confirmed through this device. Previous research has
not investigated the validity of the QOL-DN specifically within an overweight, obese and
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inactive population and, therefore, we should take this into account in the interpretation of our
findings.
Delimitations. Individuals were screened through the provided screening questionnaire
located in the appendix (see appendix A). None of the research staff were trained physicians.
We did not ask for medical records to confirm individual reporting. We did not evaluate medical
conditions or attempt to diagnose neuropathy, but instead referred individuals to appropriate
medical staff if research findings indicated potential deficits related to DPN.

Operational Definitions
Confirmed DSPN: “The presence of an abnormality of nerve conduction and symptom or
symptoms or a sign or signs of neuropathy confirms DSPN. If nerve conduction is
normal, a validated measure of small fiber neuropathy (SFN) (with class one evidence)
may be used. To assess for the severity of DSPN, several approaches can be
recommended: the graded approach; various continuous measures of sum scores of
neurologic signs, symptoms, or nerve test scores; scores of function of activities of daily
living (ADLS); or scores of predetermined tasks or of disability” (Prevention of Type 2
Diabetes: From Science to Therapy, 2012, p. 120). Additional resources to support this
definition include Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, Lauria, Malik,
Spallone, and Vinik (2010) and Vinik et al. (2013) (Tesfaye, Boulton, Dyck, Freeman,
Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, et al., 2010; Vinik et al., 2013).
Diabetes: The American Diabetes Association clearly classifies diabetes into four categories
(ADA, 2014, 2016; Zhou & Zhou, 2014):
1. Type 1 diabetes (T1D): caused by beta cell destruction, and most often leads to
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complete insulin deficiency.
2. Type 2 diabetes (T2D): caused by a progressive insulin secretory defect combined
with insulin resistance).
3. Gestational diabetes mellitus (GDM): diabetes which is diagnosed during pregnancy,
usually in the second or third trimester, yet is not considered overt diabetes.
4. Diabetes due to other causes, such as neonatal diabetes, maturity-onset diabetes,
pancreatic disease causes (cystic fibrosis), drug or chemical causes (HIV/AIDS treatment,
organ transplants).
Diabetes Diagnostic Criteria: Diabetes may be diagnosed with a hemoglobin A1C (HbA1C)
value of > 6.5% or a fasting glucose of > 126 mg/dL (7.0 mmol/L) (ADA, 2014, 2016;
Zhou & Zhou, 2014) with clear diagnostic criteria. Without clear diagnostic criteria, an
immediate retest should be done to confirm the results, or two diagnostic tests with clear
confirmation confirms diagnosis.
Diabetic neuropathy (DN): “DN is represented by clinical syndromes affecting distinct regions of
the nervous system, singly or combined. It may be silent and go undetected while
exercising its ravages; or it may present with clinical symptoms and signs that, although
nonspecific and insidious, with slow progression, also mimic those seen in many other
diseases” (Vinik et al., 2013, pg. 747).
Diabetic peripheral neuropathy (DPN): DPN is commonly experienced by individuals who have
been diagnosed with diabetes. It is frequently reported as a late complication resulting in
multiple syndromes, with no universal viewpoint for classification (Vinik, Mitchell, et al.,
1995; Vinik et al., 2013). Generally, DPN is viewed in subdivisions, such as:
focal/multifocal neuropathies, diabetic amyotrophy, symmetric polyneuropathies and
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sensorimotor polyneuropathy (DSPN), which is a common type of neuropathy
experienced by diabetes patients (Sadosky, 2008; Vinik, Ullal, Parson, & Casellini, 2006;
Vinik et al., 2013).
Fasting plasma glucose: “a check of a person's blood glucose level after the person has not eaten
for 8 to 12 hours (usually overnight) (ADA, 2014, 2016). This test is used to diagnose
prediabetes and diabetes. It is also used to monitor people with diabetes.”
Glycosylated hemoglobin testing: (HbA1C testing) is a test measuring an individual’s average
blood glucose levels for the past 2 to 3 months (ADA, 2014, 2016). The hemoglobin
(HEE-mo-glo-bin) is the part of a red blood cell that carries oxygen to the cells and
sometimes joins with the glucose in the bloodstream. This test is called hemoglobin A1C
or glycosylated (gly-KOH-sih-lay-ted) hemoglobin, and represents the percentage of red
blood cells with glucose attached to the A1c component, which is proportional to the
amount of glucose in the blood.
Oral glucose tolerance testing: This is a test used to diagnose prediabetes and diabetes. The oral
glucose tolerance test is given by a health care professional after an overnight fast. A
blood sample is taken, then the patient drinks a high-glucose beverage provided by the
health care professional. Blood samples are taken at intervals for 2 to 3 hours and the
results are compared with a standard and show how the body uses glucose over time
(ADA, 2014, 2016).
Possible DSPN: The presence of symptoms or signs of DSPN including any of the following:
symptoms—decreased sensation; positive neuropathic sensory symptoms (e.g. “asleep
numbness,” prickling or stabbing, burning or aching pain) predominantly in the toes, feet
or legs; or signs—symmetric decrease of distal sensation, or unequivocally decreased or
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absent ankle reflexes (Prevention of Type 2 Diabetes: From Science to Therapy, 2012, p.
120). Additional resources to support this definition include Tesfaye et al. (2010) and
Vinik et al. (2013) (Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, Lauria,
Malik, Spallone, Vinik, et al., 2010; Vinik et al., 2013).
Prediabetes: Prediabetes is considered to be a condition of elevated but not yet clinically
diagnosable diabetes blood glucose or HbA1C levels (ADA, 2014, 2016).
Prediabetes Identification Criteria: Prediabetes may be defined with an HbA1C value of 5.7–
6.4% or a fasting glucose of > 100–125 mg/dL (7.0 mmol/L) (ADA, 2014, 2016; Zhou &
Zhou, 2014). These individuals should be considered to be in a place of increased risk
for both cardiovascular disease (CVD) and diabetes development. HbA1C values > 6.0
should be considered very high risk for the development of diabetes and aggressive
interventions are advised.
Probable DSPN: “The presence of a combination of symptoms and signs of neuropathy including
two or more of any of the following: neuropathic symptoms, decreased distal sensation,
or unequivocally decreased or absent ankle reflexes” (Prevention of Type 2 Diabetes:
From Science to Therapy, 2012, p. 120). Additional resources to support this definition
include Tesfaye et al. (2010) and Vinik et al. (2013) (Tesfaye, Boulton, Dyck, Freeman,
Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, et al., 2010; Vinik et al., 2013).
Small fiber neuropathy (SFN): “SFN should be graded as follows: (1) possible: the presence of
length-dependent symptoms and/or clinical signs of small fiber damage; (2) probable: the
presence of length dependent symptoms, clinical signs of small fiber damage, and normal
sural nerve conduction; and (3) definite: the presence of length dependent symptoms,
clinical signs of small fiber damage, normal sural nerve conduction, and altered IENFD
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at the ankle and/or abnormal thermal thresholds at the foot (Prevention of Type 2
Diabetes: From Science to Therapy, 2012, p. 120). Additional resources to support this
definition include Tesfaye et al. (2010) and Vinik et al. (2013) (Tesfaye, Boulton, Dyck,
Freeman, Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, et al., 2010; Vinik et al.,
2013).
Subclinical: Subclinical refers to a condition in terms of being elevated but not yet clinically
diagnostic, symptomology; may apply to blood glucose, HbA1C levels, DPN, or other
diabetes symptomology (Mustafa et al., 2012).
Subclinical DSPN: “The presence of no signs or symptoms of neuropathy is confirmed with
abnormal nerve conduction or a validated measure of SFN (with class 1 evidence)”
(Prevention of Type 2 Diabetes: From Science to Therapy, 2012, p. 120). Definitions
relating to possible, probable and confirmed DSPN can be used for clinical practice and
confirmed DSPN and subclinical definitions can be used for research studies. Additional
resources to support this definition include Tesfaye et al. (2010) and Vinik et al. (2013)
(Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, Lauria, Malik, Spallone, Vinik,
et al., 2010; Vinik et al., 2013).

Expected Outcomes
This study examined the diagnostic utility of the 128-Hz tuning fork, 1-g and 10-g
monofilaments, and QOL-DN for the purposes of subclinical neuropathy screening and to
determine which was the most effective. Previous studies indicated that all three of these
measures have been both sensitive and reliable in T2D populations; therefore, we expected the
same outcome within the study utilizing OOI, PD and T2D volunteer participants. Each tool has
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had limited usage with PD populations, and their utility needs further validation, yet we expected
high reliability and specificity from all three measures in detecting DPN in a PD population. The
unique outcome of the study was determined to be ascertaining which measure is the most
sensitive and specific for determining subclinical DPN detection, and we predicted that the QOLDN would provide a mechanism for detecting sensation loss that is able to be noticed by the
participant. We also expected that the 128-Hz tuning fork would be a useful mechanism for
detecting subclinical DPN in individuals without signs or symptoms.
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CHAPTER I
PART B: NEUROPATHY QUALITY OF LIFE TOOLS
The Problem
DN is often experienced in T2D, and research has also confirmed DN in PD populations,
raising questions as to when DN develops (Marrero et al., 2014; Papanas & Ziegler, 2012) and
how soon it affects QOL. QOL is a significant issue in diabetes management, and quick
assessment seems prudent for medical screenings in research, yet little attention has been given
to the completion burden related to QOL instruments, as the time to complete certain measures
are reported as unknown or somewhat lengthy (Smith, Lamping, & Maclaine, 2012). Accurate
and effective assessment of QOL measures can be a benefit for healthcare providers and patients
alike in a multitude of settings, yet some debate exists regarding which instruments are the most
effective for determining QOL.

Purpose & Significance of the Study
The purpose of the study was to compare the measures of the QOL–DN, the PN-QOL-97,
and the NeuroQOL-28 in a mixed population that included OOI, PD and T2D individuals to
determine which instrument was the most effective at detecting DPN at various stages while
comparing the findings back to a criterion standard of NC–Stat DPN Check (NeuroMetrix,
Waltham, MA). Completion times were tracked for each instrument, allowing a comparison of
the time investment needed to utilize each chosen method.
By determining the effectiveness of these tools to detect DPN within this predefined
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population, it may open up new opportunities to evaluate the effectiveness of these instruments
in early DPN and subclinical populations. Further examination of these instruments could
provide opportunity to strengthen the measures and reveal unknown caveats.

Research Design
Study Design Approach. The proposed study took an observational and correlational
approach paired with a quantitative data collection. Individuals were screened and categorized
by HbA1C values and prior diagnoses, creating specific groups to study (see Appendix A) (OOI,
PD, T2D). A criterion variable was implemented, with NC-Stat DPN Check nerve conduction
testing being presented as the criterion that determining normal or abnormal values for the sural
nerve. The effectiveness of the content of the other variables, the QOL-DN, the NeuroQOL-28
and PN-QOL-97, was compared to this standard of testing (see Appendices B, C and D).

Research Questions
RQ 1: To what extent will the three instruments differ in their ability to detect DN in OOI, PD
and T2D populations?
RQ 2: To what extent will the results of the three instruments correlate with the NC-Stat DPN
Check?
RQ 3: To what extent will the surveys differ in the amount of time they take to complete?
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Research Hypotheses
H 1: We hypothesized that the QOL–DN and PN-QOL-97 would more clearly identify signs
of early DN when compared to the NC-Stat DPN Check results.
H 2: We hypothesized that all three instruments would correlate with the NC-Stat DPN Check
results at 60 or higher, with the QOL-DN yielding the strongest relationship.
H 3: We hypothesized that the NeuroQOL-28 would be quickest to complete, followed by the
QOL-DN and the PN-QOL-97.

Assumptions. Assumptions included accurate reporting on the part of our participants,
that they would answer questions honestly on the provided questionnaires, and be invested in
accurate participation. We justified that individuals choosing to engage in our research were
likely to report truthfully and be invested in the task at hand, as they were not paid for their time
and were involved in the study by their own choice. The psychometric properties of the QOLDN have been previously evaluated for populations with diabetes and also, for the purposes of
revealing undisclosed DPN in varied populations; therefore, in this research study we assumed
that the psychometric properties of this instrument would be effective in our OOI individuals.
Limitations. Old Dominion University has limited clinical equipment for related to
diabetes testing. The HbA1C testing machine that was used within the study is a validated
machine (Lenters-Westra & Slingerland, 2010), yet oral glucose tolerance testing is preferred by
some research scientists, particularly for individuals with cardiac autonomic neuropathy (CAN)
(Farhan et al., 2012). We did not test for CAN and, therefore, cannot account for unknown
discrepancies. Lack of random assignment and use of volunteers for subjects created potential
selection bias, with clinical population research targeting and low available funding heavily
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influencing this method. The NC-Stat DPN Check device was used solely to test the sural nerve;
therefore, deficits in nerve function relating to other nerves of the lower leg were not confirmed
through this device. Previous research has not investigated the validity of the QOL-DN, the PNQOL-97 and the NeuroQOL-28 specifically within an overweight, obese and inactive population
and, therefore, we should take this into account in the interpretation of our findings.
Delimitations. Individuals were screened to help determine eligibility for participation
(see appendix A). The researchers were not trained physicians. We did not ask for medical
records to confirm individual reporting. We did not evaluate medical conditions or attempt to
diagnose neuropathy, but instead referred individuals to medical staff if research findings
indicated potential deficits related to PN or other medical conditions that presented themselves.

Operational Definitions
Confirmed DSPN: “The presence of an abnormality of nerve conduction and symptom or
symptoms or a sign or signs of neuropathy confirms DSPN. If nerve conduction is
normal, a validated measure of small fiber neuropathy (SFN) (with class one evidence)
may be used. To assess for the severity of DSPN, several approaches can be
recommended: the graded approach; various continuous measures of sum scores of
neurologic signs, symptoms, or nerve test scores; scores of function of activities of daily
living (ADLS); or scores of predetermined tasks or of disability” (Prevention of Type 2
Diabetes: From Science to Therapy, 2012, p. 120). Additional resources to support this
definition include Tesfaye et al. (2010) and Vinik et al. (2013) (Tesfaye, Boulton, Dyck,
Freeman, Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, et al., 2010; Vinik et al.,
2013).
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Diabetes: The American Diabetes Association clearly classifies diabetes into four categories
(ADA, 2014, 2016; Zhou & Zhou, 2014):
1. Type 1 diabetes (T1D): caused by beta cell destruction, and most often leads to
complete insulin deficiency.
2. Type 2 diabetes (T2D): caused by a progressive insulin secretory defect combined
with insulin resistance.
3. Gestational diabetes mellitus (GDM): diabetes that is diagnosed during pregnancy,
usually in the second or third trimester, yet is not considered overt diabetes.
4. Diabetes due to other causes, such as neonatal diabetes, maturity-onset diabetes,
pancreatic disease causes (cystic fibrosis), drug or chemical causes (HIV/AIDS treatment,
organ transplants).
Diabetes Diagnostic Criteria: Diabetes may be diagnosed with a hemoglobin A1C (HbA1C)
value of > 6.5% or a fasting glucose of > 126 mg/dL (7.0 mmol/L) (ADA, 2014, 2016;
Zhou & Zhou, 2014) with clear diagnostic criteria. Without clear diagnostic criteria, an
immediate retest should be done to confirm the results, or two diagnostic tests with clear
confirmation confirms diagnosis.
Diabetic neuropathy (DN): “DN is represented by clinical syndromes affecting distinct regions of
the nervous system, singly or combined. It may be silent and go undetected while
exercising its ravages; or it may present with clinical symptoms and signs that, although
nonspecific and insidious with slow progression, also mimic those seen in many other
diseases” (Vinik et al., 2013, pg. 747).
Diabetic peripheral neuropathy (DPN): DPN is commonly experienced by individuals who have
been diagnosed with diabetes. It is frequently reported as a late complication resulting in
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multiple syndromes, with no universal viewpoint for classification (Vinik, Mitchell, et al.,
1995; Vinik et al., 2013). Generally, DPN is viewed in subdivisions, such as:
focal/multifocal neuropathies, diabetic amyotrophy, symmetric polyneuropathies and
sensorimotor polyneuropathy (DSPN), which is a common type of neuropathy
experienced by diabetes patients (Sadosky, 2008; Vinik et al., 2006; Vinik et al., 2013).
Fasting plasma glucose: “a check of a person's blood glucose level after the person has not eaten
for 8 to 12 hours (usually overnight) (ADA, 2014, 2016). This test is used to diagnose
prediabetes and diabetes. It is also used to monitor people with diabetes”.
Glycosylated hemoglobin testing: (HbA1C testing) is a test measuring an individual’s average
blood glucose levels for the past 2 to 3 months (ADA, 2014, 2016). The hemoglobin
(HEE-mo-glo-bin) is the part of a red blood cell that carries oxygen to the cells and
sometimes joins with the glucose in the bloodstream. This test is called hemoglobin A1C
or glycosylated (gly-KOH-sih-lay-ted) hemoglobin, and represents the percentage of red
blood cells with glucose attached to the A1c component, which is proportional to the
amount of glucose in the blood.
Oral glucose tolerance testing: This is a test used to diagnose prediabetes and diabetes. The oral
glucose tolerance test is given by a health care professional after an overnight fast. A
blood sample is taken, then the patient drinks a high-glucose beverage provided by the
health care professional. Blood samples are taken at intervals for 2 to 3 hours and the
results are compared with a standard and show how the body uses glucose over time
(ADA, 2014, 2016).
Possible DSPN: The presence of symptoms or signs of DSPN including any of the following:
symptoms—decreased sensation; positive neuropathic sensory symptoms (e.g. “asleep
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numbness,” prickling or stabbing, burning or aching pain) predominantly in the toes, feet
or legs; or signs—symmetric decrease of distal sensation, or unequivocally decreased or
absent ankle reflexes (Prevention of Type 2 Diabetes: From Science to Therapy, 2012, p.
120). Additional resources to support this definition include Tesfaye et al. (2010) and
Vinik et al. (2013) (Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, Lauria,
Malik, Spallone, Vinik, et al., 2010; Vinik et al., 2013).
Prediabetes: Prediabetes is considered to be a condition of elevated but not yet clinically
diagnosable diabetes blood glucose or HbA1C levels (ADA, 2014, 2016).
Prediabetes Identification Criteria: Prediabetes may be defined with an HbA1C value of 5.7–
6.4% or a fasting glucose of > 100–125 mg/dL (7.0 mmol/L) (ADA, 2014, 2016; Zhou &
Zhou, 2014). These individuals should be considered to be in a place of increased risk
for both cardiovascular disease (CVD) and diabetes development. HbA1C values > 6.0
should be considered very high risk for the development of diabetes and aggressive
interventions are advised.
Probable DSPN: “The presence of a combination of symptoms and signs of neuropathy including
two or more of any of the following: neuropathic symptoms, decreased distal sensation,
or unequivocally decreased or absent ankle reflexes” (Prevention of Type 2 Diabetes:
From Science to Therapy, 2012, p. 120). Additional resources to support this definition
include Tesfaye et al. (2010) and Vinik et al. (2013) (Tesfaye, Boulton, Dyck, Freeman,
Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, et al., 2010; Vinik et al., 2013).
Small fiber neuropathy (SFN): “SFN should be graded as follows: (1) possible: the presence of
length-dependent symptoms and/or clinical signs of small fiber damage; (2) probable: the
presence of length dependent symptoms, clinical signs of small fiber damage, and normal
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sural nerve conduction; and (3) definite: the presence of length dependent symptoms,
clinical signs of small fiber damage, normal sural nerve conduction, and altered IENFD
at the ankle and/or abnormal thermal thresholds at the foot (Prevention of Type 2
Diabetes: From Science to Therapy, 2012, p. 120). Additional resources to support this
definition include Tesfaye et al. (2010) and Vinik et al. (2013) (Tesfaye, Boulton, Dyck,
Freeman, Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, et al., 2010; Vinik et al.,
2013).
Subclinical: Subclinical refers to a condition in terms of being elevated but not yet clinically
diagnostic, symptomology; may apply to blood glucose, HbA1C levels, DPN, or other
diabetes symptomology (Mustafa et al., 2012).
Subclinical DSPN: “The presence of no signs or symptoms of neuropathy is confirmed with
abnormal nerve conduction or a validated measure of SFN (with class 1 evidence)”
(Prevention of Type 2 Diabetes: From Science to Therapy, 2012, p. 120). Definitions
relating to possible, probable and confirmed DSPN can be used for clinical practice and
confirmed DSPN and subclinical definitions can be used for research studies. Additional
resources to support this definition include Tesfaye et al. (2010) and Vinik et al. (2013)
(Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, Lauria, Malik, Spallone, Vinik,
et al., 2010; Vinik et al., 2013).

Expected Outcomes
This research attempted to evaluate the QOL-DN, the PN-QOL-97 and the NeuroQOL28 in a mixed population in order to determine which instrument was the most effect at detecting
DN at various stages, while further comparing the results back to a standardized measurement of
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the sural nerve provided by the NC-Stat DPN Check (NeuroMetrix, Waltham, MA). Average
completion times were determined, allowing an estimated time investment for each instrument.
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CHAPTER I
PART C: MELATONIN AND AUTONOMIC NERVOUS SYSTEM FUNCTION
The Problem
CAN is a serious complication of diabetes, presenting with various degrees of severity
throughout research. While the concept of neuropathy research is well represented for the
diabetic foot, CAN dysfunction and appropriate treatment for this disorder has not been well
investigated. Circadian patterns are often disrupted in T2D and associated dysfunction and
pathology aligns with this disruption.
Autonomic nervous system function (ANS) is frequently affected in T2D, leaving an
altered state of dysfunction that negatively affects circadian rhythms. This altered state affects
sleep quality, ANS function, and creates a state of CAN, which ultimately places individuals at
significant risk for early mortality.

The Purpose & Significance of the Study
Melatonin supplementation provides an opportunity for rebalancing the ANS in T2D.
Melatonin has been found to be effective in resetting the circadian clock of the ANS, and we
postulated that it may help improve ANS function in T2D patients, providing relief from sleep
dysfunction, ANS pathology, and ultimately attenuate the pathophysiology of CAN.
The overall purpose of this research was to investigate whether the underlying central,
cardiac, and peripheral defects that were observed in T2D could be improved or reversed by a
known chronotropic hormone, melatonin, given as a daily supplement. The physiological impact
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was evaluated through the effects of a high dose supplemental melatonin on autonomic balance
in baroreflex sensitivity (BRS).

Research Design
This study investigated the potential positive effects of a single, high dose of nightly
melatonin supplements on autonomic balance and baroreflex sensitivity in adults with T2D.
Autonomic balance in T2D subjects was studied at baseline and following 4 weeks of 10 mg
dose of melatonin or placebo in a double-blinded, randomized design, with no washout period
between the melatonin and placebo trials. Variables of interest included autonomic balance and
baroreflex sensitivity.

Research Questions
RQ1: To what extent is the ANS altered in individuals with T2D at baseline testing?
RQ2: To what extent will melatonin improve baseline study measures of ANS function?

Research Hypotheses
H1: We hypothesized that the ANS misconducts, causing a neuroinflammatory response,
leading to impairment and that the proposed study measures would evaluate this
phenomenon.
H2: We hypothesized that ANS function would improve in participants when engaging in
melatonin supplementation.

30

Assumptions. Assumptions included accurate reporting on the part of our participants.
This includes the basic assumption that individuals would answer questions honestly on the
provided questionnaires, be invested in accurately participating in tests that involve their
voluntary response, and accurately report consumption of the provided pills for each leg of the
study. The Eastern Virginia Medical School Strelitz Diabetes Center provided the ANSAR and
Sudoscan testing for patient evaluation on location at their outpatient facility. We assumed that
all equipment beyond our control was well maintained and in proper working order for the use of
this study.
Limitations. Old Dominion University has excellent movement exercise laboratory
testing equipment, still, limited clinical testing equipment for clinical diabetes testing. The
hemoglobin A1C (HbA1C) testing machine that was transported to Eastern Virginia Medical
School is valid and reliable, yet oral glucose tolerance testing is preferred for working with CAN
patients with diabetes (Farhan et al., 2012). Our sample was quite small for this pilot study, and
all inferences within the written literature should take this into account.
Delimitations. We did not ask for medical records to confirm individual reporting. Oral
glucose tolerance testing was not performed with the CAN patients due to financial limitations.
Bloodwork was not drawn to confirm fasted states of participants due to financial limitations.

Operational Definitions
Diabetes: The American Diabetes Association clearly classifies diabetes into four categories
(ADA, 2014, 2016; Zhou & Zhou, 2014):
1. Type 1 diabetes (T1D): caused by beta cell destruction, and most often leads to
complete insulin deficiency.
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2. Type 2 diabetes (T2D): caused by a progressive insulin secretory defect combined
with insulin resistance).
3. Gestational diabetes mellitus (GDM): diabetes which is diagnosed during pregnancy,
usually in the second or third trimester, yet is not considered overt diabetes.
4. Diabetes due to other causes, such as neonatal diabetes, maturity-onset diabetes,
pancreatic disease causes (cystic fibrosis), drug or chemical causes (HIV/AIDS treatment,
organ transplants).
Diabetes Diagnostic Criteria: Diabetes may be diagnosed with a hemoglobin A1C (HbA1C)
value of > 6.5% or a fasting glucose of >126 mg/dL (7.0 mmol/L) (ADA, 2014, 2016;
Zhou & Zhou, 2014) with clear diagnostic criteria. Without clear diagnostic criteria, an
immediate retest should be done to confirm the results, or two diagnostic tests with clear
confirmation confirms diagnosis.
Diabetic neuropathy (DN): “DN is represented by clinical syndromes affecting distinct regions of
the nervous system, singly or combined. It may be silent and go undetected while
exercising its ravages; or it may present with clinical symptoms and signs that, although
nonspecific and insidious with slow progression, also mimic those seen in many other
diseases” (Vinik et al., 2013, pg. 747).
Diabetic peripheral neuropathy (DPN): DPN is commonly experienced by individuals who have
been diagnosed with diabetes. It is frequently reported as a late complication resulting in
multiple syndromes, with no universal viewpoint for classification (Vinik, Mitchell, et al.,
1995; Vinik et al., 2013). Generally, DPN is viewed in subdivisions, such as:
focal/multifocal neuropathies, diabetic amyotrophy, symmetric polyneuropathies and
sensorimotor polyneuropathy (DSPN), which is a common type of neuropathy

32

experienced by diabetes patients (Sadosky, 2008; Vinik et al., 2006; Vinik et al., 2013).
E/I Ratio: Represents a ratio of expiration to inspiration; standardized cardiac reflex test based on
deep breathing recommended by American Diabetes Association for the evaluation of
CAN; primarily tests cardiac parasympathetic functions (Gulichsen, Fleischer, Ejskjaer,
Eldrup, & Tarnow, 2012; Vinik et al., 2013).
Fasting plasma glucose: “a check of a person's blood glucose level after the person has not eaten
for 8 to 12 hours (usually overnight) (ADA, 2014, 2016). This test is used to diagnose
prediabetes and diabetes. It is also used to monitor people with diabetes”.
Glycosylated hemoglobin testing: (HbA1C testing) is a test measuring an individual’s average
blood glucose levels for the past 2 to 3 months (ADA, 2014, 2016). The hemoglobin
(HEE-mo-glo-bin) is the part of a red blood cell that carries oxygen to the cells and
sometimes joins with the glucose in the bloodstream. This test is called hemoglobin A1C
or glycosylated (gly-KOH-sih-lay-ted) hemoglobin, and represents the percentage of red
blood cells with glucose attached to the A1c component, which is proportional to the
amount of glucose in the blood.
Heart rate variability: Heart rate variability (HRV) is a measureable, physiological phenomenon
involving the variation of intervals of time between successive heart beats and is
measured in beat to beat intervals.
High frequency (HF) component: Refers to a primarily parasympathetic dominant pathway in the
autonomic nervous system (Heathers, 2014; Lieb, Parson, Mamikunian, & Vinik, 2012).
Low frequency (LF) component: Refers to low frequency component of HRV; often reflected in
literature as a sympathetically dominant component; however, debate exists on the
interpretation of this measure (Heathers, 2014; Lieb et al., 2012).
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Oral glucose tolerance testing: This is a test used to diagnose prediabetes and diabetes. The oral
glucose tolerance test is given by a health care professional after an overnight fast. A
blood sample is taken, then the patient drinks a high-glucose beverage provided by the
health care professional. Blood samples are taken at intervals for 2 to 3 hours and the
results are compared with a standard and show how the body uses glucose over time
(ADA, 2014, 2016).
Prediabetes: Prediabetes is considered to be a condition of elevated but not yet clinically
diagnosable diabetes blood glucose or HbA1C levels (ADA, 2014, 2016).
Prediabetes Identification Criteria: Prediabetes may be defined with an HbA1C value of 5.7–
6.4% or a fasting glucose of > 100–125 mg/dL (7.0 mmol/L) (ADA, 2014, 2016; Zhou &
Zhou, 2014). These individuals should be considered to be in a place of increased risk
for both CVD and diabetes development. HbA1C values > 6.0 should be considered very
high risk for the development of diabetes and aggressive interventions are advised.
RMSSD: The square root of the mean of the sum of the squares of differences between
successive NN intervals; a measure primarily of parasympathetic activity (American
Heart Association Inc.; European Society of Cardiology, 1996; Vinik & Ziegler, 2007).
SDNN: Refers to the standard deviation of NN intervals (normal R to R intervals); a measure
that reflects both sympathetic and parasympathetic pathways within the autonomic
nervous system; is a reflection of cyclic components that are responsible variability
during the period of recording (American Heart Association Inc.; European Society of
Cardiology, 1996; Lieb et al., 2012).
Subclinical: Subclinical refers to a condition in terms of being elevated but not yet clinically
diagnostic, symptomology; may apply to blood glucose, HbA1C levels, DPN, or other
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diabetes symptomology (Mustafa et al., 2012).
Valsalva Ratio: Evaluates sympathetic adrenergic pathways by utilizing HR and BP responses;
evaluates parasympathetic pathways in the form of HR responses; involves timed,
dynamic breathing patterns which create a dynamic, active exhalation against pressure
(Gulichsen et al., 2012).
30:15 Ratio: A ratio derived from the duration of inspiration to the duration of exhalation; taken
from the lowest heart rate after position change (standing) in relationship to the fastest
heart rate. Typically, the ratio is derived from the 30th and 15th heart beats.

Expected Outcomes
We expect that melatonin will have a positive effect on the ANS, attenuating some of the
effects of T2D pathophysiology demonstrated in altered baseline HRV measures and disrupted
sleep patterns. We expect that individuals will likely experience better sleep during the
melatonin part of the trial and that sleep will likely remain the same during the four-week period
placebo part of the study.
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CHAPTER II
REVIEW OF THE LITERATURE
This purpose of this chapter is to review the pertinent literature relating to neuropathy
detection, screening, and treatment. Chapter II Part A, Neuropathy Screening Tools, discusses
diabetic peripheral neuropathy (DPN), its pathophysiological basis, and examines the diagnostic
accuracy of specific tools for the assessment of DPN, including the 128-Hz tuning fork, 1-g and
10-g monofilaments, the QOL-DN, the NC-Stat DPN Check and HbA1C testing. Chapter II Part
B, Neuropathy Quality of Life Tools, discusses health-related quality of life (HQOL) within the
context of T2D and DPN, and examines neuropathy specific QOL instruments of interest,
including the QOL-DN, the PN-QOL-97, and the NeuroQOL-28 in conjunction with the NC-Stat
DPN Check and HbA1C testing. Each of these modules of the study (Part A and B) will present
research findings and synthesize the current literature relating to reliability and validity for the
aforementioned diagnostic tools, questionnaires, and testing methods within the context of
screening for and identifying neuropathy in healthy, PD and T2D populations.
Chapter II Part C, Melatonin and the Autonomic Nervous System, discusses melatonin
and its effect on autonomic nervous system function in T2D, symptoms of cardiovascular
autonomic neuropathy (CAN) in diabetes, symptoms and measurement of cardiac dysfunction.
This section presents research findings and synthesizes the current literature relating to these
concepts and instruments, including their reliability and validity. The focus of the literature
reviewed is on T2D populations.
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CHAPTER II
PART A: NEUROPATHY SCREENING TOOLS
Diabetic Peripheral Neuropathy
The International Diabetes Federation (IDF) estimates the global problem of diabetes to
have reached 387 million people as of 2014, and estimate the reach of diabetes to increase to 592
million by the year 2035 (International Diabetes Federation, 2014). With such significant
impact, it is easy to understand why the complications of T2D draws significant attention. DPN
is one of the most common and troublesome complications that T2D patients may encounter as it
is both a silent and damaging opponent, even in early stages (Divisova, 2012; Mustafa et al.,
2012; Papanas & Ziegler, 2012). Chronic or acute hyperglycemia, microvascular insufficiency,
oxidative and nitrosative stress, defective neurotropism or autoimmune-related nerve destruction
all may contribute to the destruction of nerve cells or structures, and produce damage to key
organs and systems, such as the kidneys, retina or neurons (Marcovecchio, Lucantoni, &
Chiarelli, 2011; Vinik et al., 2013). Such damage may lead to diabetic cardiac autonomic
neuropathy (CAN), retinopathy, diabetic nephropathy, damage to various organs, or our focus,
DPN.
Evaluating DPN is not a simple task, and physicians generally rule out other possible
causes for any presenting symptoms before assigning a DPN diagnosis (Tesfaye, 2010; Tesfaye,
2015; Vinik et al., 2013). Diagnosis is difficult, and misdiagnosis is common as many specialists
are not trained to recognize the signs and symptoms of the disease, and this ultimately aids in the
progression of DPN without treatment (Herman & Kennedy, 2005). DPN is also viewed in
subdivisions, or branches, including focal/multi focal neuropathies, diabetic amyotrophy,
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symmetric polyneuropathies and sensorimotor polyneuropathy (DSPN), further elaborating the
scenario for proper diagnosis. DSPN presents as the most commonly occurring neuropathy to
date, manifesting with length-dependent, symmetrical sensorimotor polyneuropathy, often
developing in patients with a history of extended hyperglycemia (Marcovecchio et al., 2011;
Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, Lauria, Malik, Spallone, & Vinik, 2010).
Glycemic control, therefore, is an important prevention implementation or risk covariate, and is
dependent on the history of the patient and whether stabilization is achievable. The damage
caused is microvascular by nature, linking this manifestation to similar diabetes complications
such as retinopathy and nephropathy (Tesfaye, 2010).
Literature is divided relating to the true prevalence of DPN, with variability in reporting
ranging from 30–90% (Dixit & Maiya, 2014; Duby, Campbell, Setter, & Rasmussen, 2004;
Vinik, 1999; Vinik et al., 2013). Reporting rates vary based on the testing methods used, with
the highest rates of reporting associated with sophisticated testing equipment such as nerve
conduction studies (NCS) or in research reporting, neuropathic pain syndromes (Rota, 2005,
2007). Both type 1 diabetes (T1D) and T2D patients are affected by the disease, and may or may
not present with neurologic signs or symptoms (Boulton, 2015; Singh, Armstrong, & Lipsky,
2005; Vinik et al., 2013). Strong community reporting indicates rates of DPN prevalence at
25%, with DPN contributing to 30% of diabetes related hospitalizations, and some research
reports that as many as one out of four diabetes patients will develop foot ulcers within the
course of their lifetime (Lipsky et al., 2006; Vinik et al., 2013; Zgonis, Stapleton, Girard-Powell,
& Hagino, 2008).
DPN has been commonly reported as a late complication of diabetes, and described as a
combination or variety of syndromes, rather than a particular clinical presentation (Vinik et al.,
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2013). A lack of universal classification makes DPN especially difficult to diagnose, even for
seasoned professionals (McKinlay, Piccolo, & Marceau, 2013). This is even more true for the
untrained eye, as physicians will offer competing diagnoses with great levels of certainty
(McKinlay et al., 2013). DN affects distinct areas of the nervous system in a singular or
combined fashion, and may do so silently for quite some time (Vinik et al., 2013). Conversely,
DPN may present with very distinct symptoms that are diagnosable or, nonspecific, difficult to
diagnose symptoms and, therefore, these symptoms may be confused with other illnesses. While
symptoms vary, common complaints may include burning, tingling, or numbness in the lower
extremities (Dixit & Maiya, 2014), see Table IIA.1.
When classifying sensation loss, there are several fiber types, including small, large, and
sensory fiber involvement. Small fiber sensation loss generally affects thermal and pain
perception while large fiber dysfunction will result in dysfunction related to touch and vibration
sensations (Vinik et al., 2013). Sensory fiber involvement causes variations of pain or abnormal
sensations such as tingling, pins and needles or prickly sensations.

Neuropathy Screening & Assessment
The clinical assessment of DPN is recommended when receiving a T2D diagnosis or
within five years of receiving a T1D diagnosis, and a detailed examination is key in order to
reveal the presence of DPN (ADA, 2016; Baraz, Zarea, Shahbazian, & Latifi, 2014; Dixit &
Maiya, 2014; Katon, Reiber, & Nelson, 2013). Screening should include an examination of
ankle reflexes and sensory tests associated with DPN, along with a full examination of feet.
Sensory function may be evaluated in a number of ways, including the Wartenberg Pinwheel
(pinprick sensation), temperature, 128-Hz tuning fork (vibration), or the 1-g or 10-g
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monofilament applied at the distal halluces. It is recommended for examinations to utilize more
than one test during screenings, as previous research indicates an 87% sensitivity for the
detection of DPN when two tests are combined (Boulton et al., 2005; Vinik et al., 2013; Vinik,
Suwanwalaikorn, et al., 1995).
Small fiber neuropathy may be examined with Neurotips, which evaluates nociceptors for
pain and warmth, or a cold tuning fork, which evaluates cold thermoreceptors (see Table IIA.2;
Vinik et al., 2013). Large fiber neuropathy may be evaluated via vibration distributed through a
128-Hz tuning fork, which tests the mechanoreceptors and Ruffini corpuscle, or alternatively one
may choose to implement a wisp of cotton, which evaluates Meissner corpuscles through light
touch (see Table IIA.2, Vinik at al., 2013). Pacinian corpuscle may be tested via 1-g or 10-g
monofilament, which ultimately tests pressure and large fiber sensitivity.
The staff of the Strelitz Diabetes Center, which is part of the Eastern Virginia Medical
School in Norfolk, VA has compiled the following definitions for the diagnostic assessment of
DPN:
1. “Possible DSPN. The presence of symptoms or signs of DSPN and may include the
following: symptoms—decreased sensation, positive neuropathic sensory symptoms (e.g.,
“asleep numbness”, prickling or stabbing, burning or aching pain) predominantly in the
toes, feet, or legs; or signs—symmetric decrease of distal sensation or unequivocally
decreased or absent ankle reflexes.
2. Probable DSPN. The presence of a combination of symptoms and signs of neuropathy
including any two or more of the following: neuropathic symptoms, decreased distal
sensation, or unequivocally decreased or absent ankle reflexes.
3. Confirmed DSPN. The presence of an abnormality or nerve conduction and a symptom
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or symptoms, or a sign or signs, of neuropathy confirm DSPN. If nerve conduction is
normal, a validated measure of small fiber neuropathy (SFN) (with class one evidence)
may be used. To assess for the severity of DSPN, several approaches can be
recommended: for example, the graded approach outlined (see Table IIA.3); various
continuous measures of sum scores of neurologic signs, symptoms, or nerve test scores;
scores of function of activities of daily living; or scores of predetermined tasks of
disability.
4. Subclinical DSPN. The presence of no signs or symptoms of neuropathy are confirmed
with abnormal nerve conduction or a validated measure of DSPN (with class 1 evidence).
Definitions 1, 2, or 3 can be used for clinical practice, and definitions 3 or 4 can be used
for research studies.
5. Small fiber neuropathy (SFN). SFN should be graded as follows: (1) possible: the
presence of length-dependent symptoms and/or clinical signs of small-fiber damage; (2)
probable: the presence of length-dependent symptoms, clinical signs of small-fiber
damage, and normal sural nerve conduction; and (3) definite: the presence of lengthdependent symptoms, clinical signs of small-fiber damage, normal sural nerve
conduction, and altered intra-epidermal nerve fiber (IENF) density at the ankle and/or
abnormal thermal thresholds at the foot” (Vinik at al., 2013, p.755–756).
As previously mentioned, presentation of neuropathy differs based on the type of
neuropathy present. Vinik & Mehrabyan (2004) prepared a simple, clear figure to represent this
(see Figure IIA.1). Neuropathy is a worldwide concern, with many organizations making great
efforts to not only advance research, but also classify the disease. Accepted testing parameters
for assessment are further elaborated in Table IIA.3. Mayo Clinic has efficiently presented
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options for staging neuropathy as presented in Table IIA.4.
The Tuning Fork. The 128-Hz tuning fork has been effectively used in research to test
for vibration sensation loss (Divisova et al., 2012; Perkins, Olaleye, Zinman, & Bril, 2001;
Robinson, Balbinot, Silva, Achaval, & Zaro, 2013) by detecting the loss of sensation in the
associated Ruffini mechanoreceptors of the large nerve fibers (Vinik et al., 2013). It is a low
cost means of assessing vibration thresholds (VT), easily accessible and has been widely used in
the assessment of the diabetic foot for diagnosing polyneuropathy (Meijer et al., 2005).
The Canadian Diabetes Association clearly outlines practices for the rapid screening of
diabetic neuropathy and includes exact methodology for the tuning fork on/off test, including test
scoring, site application and reproducible familiarization details ("Rapid Screening for Diabetic
Neuropathy," 2013). This method, within research, has presented as one of the most clearly
defined methodologies and has been recommended by clinical practitioners.
Jayaprakash et al. (2011) investigated the validation of bedside testing methods
specifically for the evaluation of DPN (Jayaprakash et al., 2011). Vibration perception
thresholds (VPT) were measured via a biothesiometer probe and compared to the 10–g
monofilament, and the 128-Hz tuning fork. Detailed histories were taken from 1044 patients
with DM, questionnaires were filled out relating to Diabetic Neuropathy Symptom scoring, with
a score greater than 1 being considered as significant. Results indicated that tuning fork testing
and 10-g monofilament testing resulted in lower sensitivity (62.5 and 62.8%); however, more
desirable specificity (95.3 and 92.8%). Accuracy was relatively high for both instruments (78.9
and 77.9%) for tuning fork testing and monofilament screening, respectively. The final
interpretations of the study indicate these tools as useful in the assessment of DPN (Jayaprakash
et al., 2011).
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Pourhamidi evaluated clinical tools and their diagnostic usefulness in detecting distal
symmetric polyneuropathy and found sensitivity to be relatively low in the tuning fork compared
to electronic measures such as the biothesiometer (Pourhamidi, Dahlin, Englund, & Rolandsson,
2014). In contrast to the study, other research has found the tuning fork to be quite useful for
detecting large fiber related sensation loss, even when compared to a neurothesiometer
(Kastenbauer, Sauseng, Brath, Abrahamian, & Irsigler, 2004).
The 1-g and 10-g Monofilaments. While monofilaments have been widely used for PN
detection (Gregg et al., 2004; Katon et al., 2013), literature indicates a lack of continuity in
testing across studies and debate regarding which monofilament methods (sites, grams, number
of trials) are the most effective and reliable for detecting early sensation loss (Dros, Wewerinke,
Bindels, & van Weert, 2009). Studies suggest numerous site testing possibilities ranging from
one to ten, including four-site SWM testing (Dixit & Maiya, 2014), three-site (Katon et al.,
2013), two-site (Lee et al., 2003), or one-site monofilament testing (Bourcier et al., 2006). Baraz
et al. chose multiple tests to evaluate with their research, testing at three, four, eight and ten sites,
and found that three and four sites were significantly accurate and that adding additional points
did not increase accuracy (Baraz et al., 2014). Varying approaches have been established, with
some studies utilizing full kits and multiple sites for testing, and others relying solely on one site,
while utilizing the 1-g and 10-g for testing.
The 10-g monofilament has been widely used in neuropathy screening both as a simple
bedside screening tool and during general diabetes exams, and in the United States is considered
a target tool for the evaluation of “loss of protective sensation” (Lavery & Gazewood, 2000;
"Rapid Screening for Diabetic Neuropathy," 2013). The Canadian Diabetes Association
supports the “Rapid Screening for Diabetic Neuropathy”, and provides simple, easy to use
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screening methods that physicians have utilized and approved ("Rapid Screening for Diabetic
Neuropathy," 2013). This standardized screening method highlights protocols for the 10-g
monofilament and the 128-Hz tuning fork on/off method.
As research literature points out, monofilaments are highly desirable for their portability,
ease of use, and non-invasiveness in detecting developing problems within the insensate foot,
and more recently have been used in subclinical neuropathy screening efforts (Divisova, 2012;
Lavery & Gazewood, 2000). Monofilaments have been used to help define DPN previously in
literature: for example, Katon, Reiber, and Nelson (2013) utilized the 10-g monofilament data
from the NHANES study (1999–2004), which used this screening tool to detect insensate sites
on the foot in a massive study that examined 7818 individuals (Gregg et al., 2004; Katon et al.,
2013). DPN was defined as one or more insensate sites on the foot. Relative risks were
calculated relating to diabetes and DPN, and results indicated modest increases in risk and DPN
for those with PD and undiagnosed diabetes and a 74% higher risk of DPN for those with
diagnosed diabetes. Such ventures in literature demonstrate the usefulness of the 10-g for simple
screening in large populations.
The precision and accuracy of the 10-g monofilament may come into question when used
in a repeated loading fashion, without rest (Lavery et al., 2012). This factor should be taken into
consideration in how testing is administered by limiting testing loads per day. If high volume
testing is to take place, monofilament loading force should be regularly checked during research
testing and clinical exams, as high repeated (200 cycles per day, 15 consecutive days) use will
shorten the service life of this instrument. Lavery et al. (2012) endorses the use of this unique
instrument, but recommends seeking a quality manufacturer and combining this tool with other
neuropathy screening tools for the best identification of sensory dysfunction (Lavery et al.,
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2012).
Other issues which must be addressed are age, temperature and humidity, as
monofilaments are affected by all three (Haloua, Sierevelt, & Theuvenet, 2011). Age had a
relatively minor effect within this research; however, temperature and humidity both
significantly contributed to buckling force changes, as much as 39%. When unaccounted for,
this has the potential to mislead the examiner regarding the levels of sensation detected. Haloua
et al. (2011) recommends awareness regarding the environmental effects of temperature and
humidity (Haloua et al., 2011). Controlling for environmental factors and screening with
multiple bedside tests to confirm lack of sensation seems prudent.
The Norfolk Quality of Life Diabetic Neuropathy Tool. The Norfolk Quality of Life
Diabetic Neuropathy Tool (QOL-DN) was developed as a neuropathy screening tool, aiming to
differentiate between typical features that present in DPN (Vinik, Hayes, Oglesby, & Vinik,
2004; Vinik et al., 2005), particularly issues related to changes in sensation in small and large
fibers, as well as typical alterations to autonomic nervous system functioning (see Appendix B)
(Vinik et al., 2005). Twenty-eight questionnaire items were developed through 1000 structured
patient interviews and combined with activities of daily living (ADLs), general health and status
items of interest and tested on DPN patients. Initial testing revealed that the QOL-DN
successfully identified domains of a fiber–specific nature relating to DPN with reliability, and
discriminates between individuals who do and do not have DPN in an English-speaking
population.
The QOL-DN instrument is comprised of a Total QOL score, and five subscale items
(symptoms, ADLS, small fiber, large fiber, autonomic), each targeting to measure a specific area
of interest. Furthering its impact and validation, it was translated into German and tested as a
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fiber-specific QOL tool in this new population in 2014 (Vinik, Paulson, Ford-Molvik, & Vinik,
2008). This research demonstrated the tool’s ability to cross language barriers, and confirmed
prior findings relating to the same factors as previously identified in the English version.
Important findings include the Norfolk QOL-DN’s ability to detect levels of neuropathy within
and across different populations (Vinik, Vinik, et al., 2014). This fiber specific, self-report
questionnaire was translated into Romanian and effectively revealed a high prevalence of
undisclosed neuropathy in 25,000 Romanian patients (Veresiu et al., 2015). The QOL–DN
effectively and accurately determined the QOL of the participants, while also establishing its
ability to operate within a new language and population to ferret out undisclosed neuropathy
(Veresiu et al., 2015; Vinik et al., 2008).
The QOL-DN has also been used to assess baseline and improved QOL in randomized,
double-masked, placebo-controlled, clinical studies and was sensitive enough to differentiate
where improvement developed within fiber types (Boyd, Casselini, Vinik, & Vinik, 2011;
Casellini, 2007). The questionnaire has been successfully used in research to detect both the
severity and impact of neuropathy on the QOL experiences in 61 patients diagnosed with
transthyretin familial amyloid polyneuropathy (TTR-FAP) (Coelho et al., 2012; Coelho et al.,
2013; Vinik, Vinik, et al., 2014) and in patients with neuroendocrine tumors (Vinik, Silva, &
Vinik, 2010). This questionnaire has been effectively utilized to perform cost analyses of the
financial impact of DPN within research and used within postal surveys within research efforts
(Currie et al., 2006; Happich, John, Stamenitis, Clouth, & Polnau, 2008).
Smith et al. analyzed the QOL-DN in relationship to other available measures in 2012
and recommended it for DN screening (Smith et al., 2012). Furthermore, this research points out
the strengths of the QOL-DN as being able to serve effectively in multiple languages, being
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fiber-specific, demonstrating test/re-test reliability and emphasizes the strong clinical
background that serves as the foundation for the instrument. The time to complete the
instrument is unknown and criterion validity had not yet been assessed when the article was
written.
NC-Stat DPN Check. The NC-Stat DPN Check (Neurometrix Inc., Waltham, MA) is a
point-of-care nerve conduction device that has been developed with the intent to serve as a
substitute for more advanced nerve conduction study (NCS) devices (Lee et al., 2014). It is a
simple, portable device that was made to be both user and patient friendly. This method of
evaluation of the sural nerve allows for a quick assessment (less than 10 minutes), with results
that are easily uploaded to a laptop computer for evaluation. The NC-Stat DPN Check has been
proposed as being able to serve as a potential substitute for the more expensive and less
accessible clinic driven NCS (Lee et al., 2014) and provides an opportunity for accessibility in
community health care that has not been previously available. This point of care device (POCD)
requires limited training and supplies to operate it and flexible options for testing, thus enabling a
low-cost and short time investment to screen for potential nerve damage in the lower leg in order
to determine if further evaluation is warranted at a more complex facility.
The NC-Stat DPN Check was tested as a POCD across multiple sites with 72 patients in
order to determine its potential as an alternative to traditional NCS (Perkins et al., 2008).
Patients underwent extensive testing that included neurological examination and NCS.
Spearman correlation coefficients indicated a relationship between the POCD and other
measures ranging from .76 to .91, confirming reasonable accuracy for the device to serve as an
alternative. Lee et al. (2014) continued the validation of this device when his research team
evaluated 44 T1D and T2D subjects with the NC-Stat DPN Check POCD and standardized NCS
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(Lee et al., 2014). The sural nerve conduction velocity (SNCV) and sural nerve action potential
(SNAP) were recorded. Reliability and validity were evaluated via intraclass correlation
coefficients, Bland-Altman analysis, and receiver operating characteristic curves and results
indicated. Two trained testers were utilized and interrater reproducibility ICC values were .97
for SNAP (interrater value, .83) and .94 for SNCV (interrater value, .79), with 88% sensitivity
and 94% specificity for SNAP reference values and 94% sensitivity and 71% specificity.
Excellent reliability and acceptable accuracy was demonstrated by the device, and POCD
normative threshold values were validated.
This validated POCD has been shown to be a reliable and accurate alternative to
traditional NCS through successful evaluation of the sensory nerve action potential (SNAP) and
sensory nerve conduction velocity (SNCV) of the sural nerve in multiple research studies (Lee et
al., 2014; Perkins, Grewal, Ng, Ngo, & Bril, 2006; Perkins et al., 2008). Multiple methodologies
have been employed in its validation within these studies, including unilateral and bilateral
applications, with one to two trials.
Glycohemoglobin Testing. Glycohemoglobin testing, or HbA1C, testing has been
reliably used to categorize BG values within research and has been proven as a simple, portable
method of screening for diabetes that is accurate, relatively quick to perform on-site (10
minutes), and results are easily relayed (Feng, Schlosser, & Sumpio, 2009; Sumpio et al., 2013).
This method of screening also provides the unique caveat of accessible health care upon demand
to individuals that might not otherwise engage in or be able to afford more expensive tests such
as oral glucose tolerance testing (OGTT). When considering the validity of HbA1C screening
for diabetes, it should be noted that the Canadian Task Force on Preventive Health Care,
American Task Force and WHO recommendations all support HbA1C testing of > 6.5% for the
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screening and diagnosis of diabetes (American Diabetes Association, 2012; Canadian Task
Force, 2012; World Health Organization, 2011). In a clinical setting, if positive results are
obtained, results should be confirmed with repeated testing.
HbA1C testing has been shown in research to be strongly associated as an accurate
predictor of glycemic control, especially when compared to fasting plasma glucose (FPG) (ADA,
2016; Bernal-Lopez et al., 2011; Mannarino, Tonelli, & Allan, 2013). While agreement is strong
between HbA1C testing and FBG, issues arise with nonparallel findings between HbA1C and
oral glucose tolerance testing (OGTT) (Farhan et al., 2012; Mannarino et al., 2013). Studies
independently performed by Mannarino et al. and Farhan et al. point out that there is discordance
between OGTT and HbA1C regarding T2D diagnosis outcomes, with Farhan’s findings
indicating discordance when cardiac autonomic neuropathy (CAN) is present. Such issues may
lower the incidence of diagnosis when using HbA1C as a determining test (Farhan et al., 2012).
Additionally, HbA1C testing is not appropriate in situations with individuals who have
hemoglobinopathies, as it may not be reliable (Hare, Shaw, & Zimmet, 2012). Current
recommendations by the American Diabetes Association, however, align HbA1C as a valid test
in equal measure to other diagnostic tests that may be used and that one test is not preferred over
the other (ADA, 2016).
The DCA Vantage from Siemens Corporation has been evaluated within research as a
POCD for HbA1C testing and found to have good correlation with laboratory methods and
acceptable precision (Lenters-Westra & Slingerland, 2010; Sanchez-Mora et al., 2011).
Sanchez-Mora et al. examined 53 blood samples from diabetic patients over a wide range of
HbA1C values (4–14%), with results examined by both a DCA Vantage Analyzer and a POCT
Analyzer. These results were compared to on-site lab testing, and both were found to be highly
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correlated (r = 0.973) with clinical lab testing results.
HbA1C testing remains as a recommended test for the screening and diagnosis of
diabetes. Increased accuracy over FPG, high portability, and financial accessibility in
comparison to OGTT make it an excellent screening test, despite limitations with certain diabetic
populations. The DCA Vantage Analyzer provides quality, on-site testing for HbA1C values,
with a proven wide range of testing capabilities that are clinically acceptable.

Summary
In summary, symptoms and testing results are reviewed in combination to present a
background for which a determination may be made regarding the presence of neuropathy.
Defining what types of sensory receptor deficiency is present aids in the determination of which
fibers may be affected and ultimately, contributes to the determination of the type of neuropathy
that the individual is experiencing. The usefulness of these three tests have been well established
in addition to their clinical diagnostic assessment applications in the literature. Both large and
small fiber deficiencies may be evaluated with simple bedside tests that have been repeatedly
validated within research literature. It would be beneficial to evaluate the effectiveness of three
neuropathy screening tools with specific aims to determine early DPN detection. Therefore, the
purpose of the study was to evaluate the 128-Hz tuning fork, 1-g and 10-g monofilaments, and
the QOL-DN for the purposes of DPN screening to determine which of the tools or combinations
thereof would be the most effective for early DPN detection.
The potential for the study lies in investigating to what extent will the 128-Hz tuning
fork, 1-g and 10-g monofilaments, and the QOL–DN detect DPN in an OOI, PD, and T2D
population. Ascertaining which screening tools are the most effective for early or subclinical
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DPN detection, specifically by fiber type, is a lofty, but worthy goal and an achievable aim for
these tools. Establishing which screening tools provide the greatest reliability and accuracy for
detecting early or subclinical DPN is a promising hope for the study. We hypothesized that the
tuning fork will detect early sensation loss, indicating large fiber neuropathy, in OOI and PD.
Furthermore, we hypothesized that the QOL–DN and the 128-Hz tuning fork would both provide
excellent mechanisms for detecting early or subclinical DPN in HN and PD populations. This
being said, we believed the QOL–DN has the potential to detect DPN in a HN and PD
populations with the greatest reliability and accuracy. It is with these things in mind that we
moved forward in discussion of our methods and how we executed the study (Alam, Ezhova,
Kotovskaya, Dogotar, & Kobalava, 2015).
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TABLES

Table IIA.1
Descriptors of different kinds of neuropathic pain
Dysesthesia

Paresthesia

Pins and
needles
Skin tingles
Electric like
Numb but
achy
Knife like
Painful sensation when bed sheet and
shooting
stockings touch me
Pain,
lancinating
pain
(Dixit & Maiya, 2014; Journal of Postgraduate Medicine)
Burning sensation

Muscular Pain
Dull ache
Night cramps
Band like
sensation
Deep aches,
spasms
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Table IIA.2
Diagnostic Assessment of DPN Using Bedside Tests
Associated
Sensory
Receptors
Ruffini corpuscle
mechanoreceptors
Nociceptors for
pain and warmth

Sensory Modality

Nerve
Fiber

Instrument

Vibration

Aβ(large)

128-Hz tuning
fork

Pain (pinprick)

C (small)

Neurotips

Pressure

Aβ, Aα
(large)

1-g and 10-g Pacinian
monofilaments corpuscle

Light touch

Aβ, Aα
(large)

Wisp of cotton

Cold

Aδ(small)

Cold tuning
fork

(Vinik et al., 2013, p.755)

Meissner
corpuscle
Cold
thermoreceptors
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Table IIA.3
Advanced objective testing for diabetic neuropathy
Type of
Neurologic Test

Neuropathy

Measurement

Quantitative
sensory testing

Small and large
fiber
neuropathies

Assessment of sensory deficits Uses controlled
quantifiable stimuli
with standard
procedures

Skin biopsy and
intro epidural
nerve fiber
(IENF) density

Small fiber
neuropathy

Small-caliber sensory nerves
including somatic
unmyelinated IENFS, dermal
myelinated nerve fibers, and
autonomic nerve fibers

Quantitates small
epidermal nerve fibers
through various
antibody staining

Corneal confocal
microscopy

Small fiber
neuropathy

Detects small nerve fiber loss
in the cornea

Noninvasive technique
that correlates with
neuropathy severity

Contact heat
evoked potentials

Small fiber
neuropathy

Uses nociceptive heat as a
stimulus that is recorded
through
electroencephalographic
readings

Detects small fiber
neuropathy in the
absence of other indices

Sudomotor
function

Distal small
fiber
neuropathy

Assesses the sweat response
by analyzing sweat production
or sweat chloride
concentrations

Detects early
neurophysiological
abnormalities in
peripheral autonomic
function

Nerve conduction
studies

Small and large
fiber
neuropathy

Measure the ability of nerves
to conduct an electrical
stimulus

Standardized universal
technique that is well
documented and
recommended

(Vinik et al., 2013, p. 756)

Advantages
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Table IIA.4
Stages in Diabetic Neuropathy
Stage
0
1

Description

No neuropathy
Subclinical neuropathy
Clinically evident
2
neuropathy
3
Debilitating neuropathy
(Dixit & Maiya, 2014; Mayo Clinic)

No
No

Abnormal
Quantitative
Sensory
Tests
No
Yes

Yes

Yes

Yes

Yes

Signs or
Symptoms
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FIGURES
Figure IIA.1 Clinical Manifestations of Neuropathy
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CHAPTER II
PART B: NEUROPATHY QUALITY OF LIFE TOOLS
Health Related Quality of Life (HRQOL)
HRQOL may be defined as subjective perceptions of how an illness and treatment for the
illness is experienced, particularly in how it is perceived to affect physical, mental and social
aspects, thereby providing an indication of the individuals perception of their overall well-being
(Rajabally & Cavanna, 2015). T2D, as an illness, represents a collection of challenges that may
affect several different facts of an individual’s functioning, including physical, emotional, social,
sexual, cognitive and self-perceptions surrounding health changes. The health issues
surrounding T2D are formidable, and a variety of HRQOL instruments have been used
throughout the last two decades to gain insight relating to the health perceptions experienced by
T2D patients (Luscombe, 2000). Research conducted to determine associations between
particular complications such as depression, HRQOL measures and ABC (HbA1C, BP,
cholesterol) goal attainment in 808 adult T2D patients using the National Health and Nutrition
Examination Survey (NHANES) (Shah, Mezzio, Ho, & Ip, 2015) found that longer disease
duration and severe depression highly impacted individuals abilities to achieve health related
goals. Likewise, research by Ji et al. relates findings regarding the effect of elevated BMI in an
examination of 2052 Chinese T2D patients, who were examined for the HRQOL relationships
between BMI, complications, glycemic control and comorbidities (Ji et al., 2015). Increased
complications such as hypertension, dyslipidemia, and poorer HRQOL were associated with
increasing BMI status, despite no significant differences between the groups for HbA1C. Such
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examples highlight the gravity and impact of disease duration, underlying psychological
challenges and BMI on the exacerbation of T2D.
HRQOL instruments have evolved over the last two decades, encompassing more
domains, crossing language barriers and aiming to specialize in particular disease facets, such as
in DPN (Hogg, Peach, Price, Thompson, & Hinchliffe, 2012; Vickrey, Hays, & Beckstrand,
2000; Vinik et al., 2004). Hogg et al. reviewed HRQOL diabetes-related foot disease measures
through a meta-analysis of scientific literature available from 1996 to 2011, ultimately
examining 53 studies that used a structured manner to directly assess HRQOL relating to foot
problems (Hogg et al., 2012). Measures utilizing patient reported outcome measures (PROMs)
to self-evaluate general diabetes topics were excluded. The NeuroQOL-28 was assessed as a
disease specific instrument, providing proficiency in the assessment of advancing neuropathy
and impact on HRQOL, but poor sensitivity to diabetic foot ulcers (DFU). The QOL-DN was
discussed as an assessment of diabetes oriented neuropathy, with intentions for aiding in
diagnosis and monitoring; however, Hogg et al. reports a lack of specificity for PN, thereby
limiting the instrument to health impacts of a diabetes foot disease related nature (Hogg et al.,
2012). This research further advises that the utilization of two tools would be more promising in
detailing outcomes, but impractical in a clinical setting (Jeffcoate et al., 2009). After careful
evaluation, Hogg et al. advises that each diabetes foot-specific PROM has some validity for
measuring HRQOL, but also has limitations that are unique and specific to each tool and that
these limitations should be considered when choosing an instrument. According to this research,
no one specific PROM could be viewed as a gold standard measure.
Smith, Lamping and MacLaine reviewed HRQOL related to DPN in a systematic review
in 2012 and ultimately compared the PN-QOL-97, NeuroQOL-28 and QOL-DN (Smith et al.,

58

2012). After a review of reliability, validity, content, language, development and prior use in
research, this team concluded that all three instruments warranted support for their use in a DPNspecific manner based on evidence, to some degree; however, limitations exist. The NeuroQOL28 lacks test-retest reliability, while the QOL-DN possesses this component as a strength. This
being said the QOL-DN lacks content to assess the emotional and psychological impact of DPN,
such as anxiety or depression components (Smith et al., 2012). Language variability is available
with the QOL-DN, but the PN-QOL-97 is a valid option for assessing PN if language diversity is
not a necessity. The authors suggest future research to compare the psychometric properties of
all three instruments.
What once was only thought to be able to be accomplished by a specialist during an exam
has now become a target for specific screening development in the form of self-reported QOL
measures (Vinik et al., 2005). Efforts have been rewarded, as QOL measures relating to DN
have successfully targeted and differentiated between small and large fiber deficits and levels of
neuropathy severity (Vinik et al., 2004; Vinik et al., 2008). Such efforts allow more individuals
to be screened and in a variety of locations, with or without clinical personnel, providing the
ability to detect advancing disease at earlier stages with the hopes of earlier disease assessment
and intervention. Earlier assessment of the debilitating effects of DN allows for the potential to
grasp the impact and scope of accumulating pathophysiological processes in an individual, the
formulation of targeted medical support plans and pre and post evaluations for T2D interventions
(Wong et al., 2015). Such evaluations of physical, mental, emotional, social, and sexual
functioning in additional to health perceptions, helps care providers in their efforts to effectively
treat individuals experiencing DN.
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Research indicates that obese individuals experience reduced HRQOL, with findings
indicating a more significant impact on physical functions relating to health rather than mental
capacity (Kolotkin, Crosby, & Williams, 2002). Kolotkin et al. examined HRQOL in 3353
patients of varying ethnicities in a geographically diverse study over a wide age range, 18 to 90
years of age, and found that higher BMIs, Caucasian status and women experienced obesity
related reductions in HRQOL. Such results are not uncommon, as a meta-analysis of research
examining 43,086 study participants indicated that increased BMI status relates to significant
reductions in physical QOL, with the highest impact relating to individuals who were class III
obese (Ul‐Haq, Mackay, Fenwick, & Pell, 2013). At-risk individuals for T2D include those who
are inactive. Hakkinen et al. (2009) evaluated 132 individuals for physical activity/inactivity
patterns in relationship to HRQOL using the SF-36, and found that inactive individuals had a
lower HRQOL in the pain and general health domains (Hakkinen et al., 2009). HRQOL
decreased in a linear fashion in relationship to physical inactivity and increased in individuals
who had higher physical activity levels. Individuals who were more active reported better
subjective health and weight control, while researchers reported that high activity levels reduced
the risk of T2D onset and associated complications.
Norfolk Quality of Life Diabetic Neuropathy Instrument (QOL–DN). The Norfolk
Quality of Life Diabetic Neuropathy Tool (QOL-DN) was developed as a neuropathy-screening
tool, aiming to differentiate between typical features that present in DN (see Appendix B) (Vinik
et al., 2004; Vinik et al., 2005). Twenty-eight questionnaire items were developed through 1000
structured patient interviews, combined with ADLs, general health and status items of interest
and tested on DN patients. Initial testing revealed that the QOL-DN successfully identified
domains of a fiber-specific nature relating to DPN with reliability, and discriminates between
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individuals who do and do not have DPN in an English-speaking population. The QOL-DN is
unique due to its ability to detect issues that arise related to changes in sensation in small and
large fibers, typical alterations to autonomic nervous system functioning and neuropathy severity
(Vinik et al., 2008; Vinik, Stansberry, Ruck, & Vinik, 2003).
The QOL-DN instrument is comprised of a Total QOL score, and five subscale items
(symptoms, ADLS, small fiber, large fiber, autonomic), each measuring a specific area of
interest. Furthering its impact and validation, it was translated into German and was successfully
tested as a fiber-specific QOL tool in this new population (Vinik et al., 2008). This research
demonstrated the QOL-DN’s ability to cross language barriers, and confirmed prior findings of
the same five factors previously identified in the English version. Important findings include the
Norfolk QOL-N’s ability to detect levels of neuropathy within and across different populations
(Vinik, Vinik, et al., 2014). This fiber specific, self-report questionnaire was utilized in a 25,000
person Romanian population, effectively revealing a high prevalence of undisclosed neuropathy
in 25,000 Romanian patients (Veresiu et al., 2015). The QOL–DN effectively and accurately
determined the QOL of the participants, while also establishing its ability to operate within a new
language and population to ferret out undisclosed neuropathy (Veresiu et al., 2015; Vinik et al.,
2008).
The QOL-DN has also been used to assess baseline and improved QOL in randomized,
double-masked, placebo-controlled, clinical studies and was sensitive enough to differentiate
where improvement developed within fiber types (Boyd et al., 2011; Casellini, 2007). The
questionnaire has been successfully used in research to detect both the severity and impact of
neuropathy on the QOL experiences in 61 patients diagnosed with transthyretin familial amyloid
polyneuropathy (TTR-FAP) (Coelho et al., 2012; Coelho et al., 2013; Vinik, Vinik, et al., 2014)
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and in patients with neuroendocrine tumors (Vinik et al., 2010). This questionnaire has been
effectively utilized to perform cost analyses of the financial impact of DPN within research and
used within postal surveys within research efforts (Currie et al., 2006; Happich et al., 2008).
Smith et al. (2012) analyzed the QOL-DN in relationship to other available measures in
2012 and recommended it for DPN screening (Smith et al., 2012). Furthermore, this research
points out the strengths of the QOL-DN as being able to serve effectively in multiple languages
as a fiber-specific tool, demonstrating test/re-test reliability and emphasizing the strong clinical
background that serves as the foundation for the instrument. The time to complete the
instrument is unknown at the time of the writing of the article.
The Peripheral Neuropathy Quality of Life Instrument (PN-QOL-97). Vickrey,
Hays and Beckstrand (2000) also developed a questionnaire to evaluate peripheral neuropathy
(see Appendix C) (Vickrey et al., 2000). The instrument was formed from items from the Rand36, a widely used HRQOL PROM measure (Hays & Morales, 2001), and responses from focus
group material, and evaluated in 80 patients at 3 and 6 month follow up evaluations in a clinical
setting. The instrument was re-evaluated, and in the process, pared down from 162 items to 97
items during the study through examination of construct validity, reliability, and comparisons to
HRQOL measures. Findings resulted in strong associations between the instrument’s results and
reported DN symptoms and support for reliability and validity for use in adults with DN. The
revisions ultimately arrived at an instrument that is made of two base components, a physical
component and a mental component, both of which are scored through a complex set of
calculations provided by the author.
The PN-QOL-97 was utilized in a study aiming to determine the effectiveness of
intraepidermal nerve fiber density (IENFD) in 72 sarcoidosis patients and 188 healthy
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participants who had skin biopsies performed on the lower leg (Bakkers et al., 2009). The PNQOL-97, along with a Symptoms Inventory Questionnaire (SIQ), were administered to
participants and results were compared to IENFD values. The resulting comparisons of the PNQOL-97 and SIQ helped to establish a validated realm of normative values for IENFD. A study
examining the effect of social support on QOL was examined in 154 patients with
polyneuropathy (Maxwell et al., 2013). The PN-QOL-97 and the Medical Outcome StudySocial Support Survey (MOSS-SSS) were utilized to determine QOL and social support. Results
indicated that pain and autonomic symptoms strongly related to physical and mental components
of QOL while social support only weakly correlated with the emotional/mental health
components.
Research examining the characteristics of muscle cramps in individuals over the age of
18 with polyneuropathy utilized the PN-QOL-97 as a validated measure of QOL (Maxwell et al.,
2014). Nerve conduction studies, the Toronto Clinical Neuropathy Score, the PN-QOL-97 and a
demographic questionnaire assessing qualities of the symptoms and cramps were administered to
225 patients. Of the participating patients, 63% experienced muscle cramps, and nearly 44%
described cramps of a disabling nature. This study confirmed that patients who experienced a
disabling level of pain reported a lower QOL on the PN-QOL-97 than patients without disabling
cramps and that muscle cramps were a common factor in individuals with polyneuropathy.
The PN-QOL-97 was reviewed by a research team in comparison to other QOL measures (Smith
et al., 2012). Researchers pointed out that there are several strengths of the PN-QOL-97, such as
expert review of focus group material, multi-dimensional design, psychological and emotional
domains and comprehensiveness. Test-retest reliability had been established, yet it does take at
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least 20 minutes to complete according to previously published materials and this QOL
instrument represents one of the longest instruments available for use to assess DN today.
Neuropathy-and Foot Ulcer-Specific Quality of Life Instrument (NeuroQOL-28).
The NeuroQOL-28 was developed to measure patient related QOL perceptions as they are
impacted by DN and foot ulcers (see Appendix D) (Vileikyte et al., 2003). This research related
to the development of an instrument designed to assess symptomology of DN, QOL and
psychometric properties by working with 418 patients across U.K. and U.S. diabetes centers.
Researchers found that the NeuroQOL-28 was able to reliably determine three measures relating
to physical symptoms and two measures relating to psychosocial aspects of functioning
(Vileikyte et al., 2003). When compared to the SF-12, results indicated stronger associations
with neuropathic severity, DN’s relationship to QOL, and was able to better explain variances in
QOL when compared to the SF-12.
Vileikyte and fellow collaborators utilized the NeuroQOL-28 in a slightly differently
research effort in 2005, as their team examined the associations between DN and symptoms of
depression, in an attempt to develop associations that would lead to potential targets for
interventions in future research (Vileikyte et al., 2005). The research successfully utilized the
NeuroQOL-28 to evaluate this relationship while also using the Hospital Anxiety and Depression
Scale (HADS) and demonstrated a link between neuropathy symptoms and depressive
symptoms. Related research was performed in 2011, by Bergis, Hulman and Kulzer when they
evaluated the effectiveness of the NeuroQOL-28 to detect psychological and neuropathic
symptoms in 211 diabetic patients (Bergis, Hermanns, & Kulzer, 2011). Individuals were
examined and tested by a physician and subsequently administered the NeuroQOL-28
instrument. Comparisons were made and the NeuroQOL-28 was found to be both valid and
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reliable to assess neuropathy symptoms and to relay emotional problems arising from
neuropathy-related symptoms.
With DPN rising as both a common and painful complication of diabetes, Davies et al.
employed a study which examined the severity of symptoms in individuals with PN (Davies,
Brophy, Williams, & Taylor, 2006). Surveys were sent out through the mail to known T2D
patients in order to screen and determine the presence or absence of symptomology, followed by
a more detailed neurological history collection through the Toronto Clinical Scoring System. PN
or painful PN individuals were also administered a Neuropathic Pain Scale measure and the
NeuroQOL-28. This research utilized the NeuroQOL-28 to establish that individuals with PN
experience negative effects from the disease and are more likely to develop painful PN at a later
point in time.
Further support for the validation of the NeuroQOL-28 developed with a study performed
by Vileikyte and fellow researchers in 2007, when they examined NeuroQOL-28 scores in 295
DN patients in the U.S. and U.K. over a 9-month time period in comparison to the Neuropathy
Disability Score (NDS) (Vileikyte et al., 2007). Results revealed continued validity for the
NeuroQOL-28 through detecting changes in the severity of DN.
The use of the NeuroQOL-28 in DN related research is diverse, with efforts to measure
improvements in sensation through at home light therapy among them (Lavery, Murdoch,
Williams, & Lavery, 2008). Sixty-nine individuals participated in a study where they received
sham or active treatments, with the active treatment consisting of 40 minutes of anodyne light
therapy. The MNSI was utilized in conjunction with the NeuroQOL-28, SWM and nerve
conduction studies in a repeated-measures evaluation and determined that there were no
significant changes in the sham or treatment groups.
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Finally, the translation of the NeuroQOL-28 into Brazilian Portuguese and evaluation of
this translation in a 50 person Brazilian neuropathic population validated the NeuroQOL-28 as a
reliable foot and ulcer specific instrument across different languages (Xavier et al., 2011). The
NeuroQOL-28 was evaluated in conjunction with the SF-36, and found to be reliable and valid as
a tool that could be utilized in DM populations by Brazilian medical staff.
A review of HRQOL instruments examined the NeuroQOL-28 in comparison to several
other measures, detailing its strengths and weaknesses (Smith et al., 2012). This research
determined that the NeuroQOL-28’s target population was adults with DN through self-report
measures and that at the time of the research, it was available in the US and UK, and in 10
different languages. The validation of the additional language versions was unclear despite
personal communication from the author. Upon evaluation, Smith et al. determined that the DN
version of the NeuroQOL-28 has 28 items that represent three physical domains, two
psychosocial domains and one overall measure of QOL. Researchers commented that the time
required to complete the NeuroQOL-28 was unknown. Test-retest reliability and criterion
validity was not assessed in the main validation study.
NC-Stat DPN Check. The NC-Stat DPN Check (Neurometrix Inc., Waltham, MA) is a
point-of-care nerve conduction device that has been developed with the intent to serve as a
substitute for more advanced nerve conduction study (NCS) devices (Lee et al., 2014). It is a
simple, portable device that was made to be both user- and patient-friendly. This method of
evaluation of the sural nerve allows for a quick, easy assessment (less than 10 minutes), with
results that are easily uploaded to a laptop computer for evaluation. The NC-Stat DPN Check
has been proposed as being able to serve as a potential substitute for the more expensive and less
accessible counterparts (Lee et al., 2014) and provides an opportunity for accessibility in

66

community health care that has not previously been available. This POCD requires limited
training and supplies to operate it and flexible options for testing, thus enabling a low-cost and
short time investment to screen for potential nerve damage in the lower leg in order to determine
if further evaluation is warranted at a more complex facility.
The NC-Stat DPN Check was tested as a POCD across multiple sites with 72 patients in
order to determine its potential as an alternative to traditional NCS (Perkins et al., 2008).
Patients underwent extensive testing, which included neurological examination and NCS.
Spearman correlation coefficients indicated a relationship between the POCD and other
measures ranging from .76 to .91, confirming reasonable accuracy for the device to serve as an
alternative.
Lee et al. (2014) evaluated 44 T1D and T2D subjects with the NC-Stat DPN Check
POCD and standardized NCS (Lee et al., 2014). The sural nerve conduction velocity (SNCV)
and action potential (SNAP) were recorded. Reliability and validity were evaluated via
intraclass correlation coefficients, Bland-Altman analysis, and receiver operating characteristic
curves and results indicated. Two trained testers were utilized and interrater reproducibility ICC
values were .97 for SNAP (interrater value, .83) and .94 for SNCV (interrater value, .79), with
88% sensitivity and 94% specificity for SNAP reference values and 94% sensitivity and 71%
specificity. Excellent reliability and acceptable accuracy was demonstrated by the device, and
POCD normative threshold values were validated. This validated POCD has been shown to be a
reliable and accurate alternative to traditional NCS through successful evaluation of the sensory
nerve action potential (SNAP) and sensory nerve conduction velocity (SNCV) of the sural nerve
in multiple research studies (Lee et al., 2014; Perkins et al., 2006; Perkins et al., 2008). Multiple
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methodologies have been employed in its validation within these studies, including unilateral and
bilateral applications, with one to two trials.
Glycohemoglobin Testing. Glycohemoglobin testing or HbA1C testing has been
reliably used to categorize BG values within research and has been proven as a simple, portable
method of screening for diabetes that is accurate, relatively quick to perform on-site (10
minutes), and results are easily relayed (Feng et al., 2009; Sumpio et al., 2013). This method of
screening also provides the unique caveat of accessible health care upon demand to individuals
that might not otherwise engage in or be able to afford more expensive tests such as oral glucose
tolerance testing (OGTT). When considering the validity of HbA1C screening for diabetes, it
should be noted that the Canadian Task Force on Preventive Health Care, American Task Force
and WHO recommendations all support HbA1C testing of > 6.5 for the screening and diagnosis
of diabetes (ADA, 2016; Siu, 2015; World Health Organization, 2012). In a clinical setting, if
positive results are obtained, the results should be confirmed with repeated testing.
HbA1C testing has been strongly associated as an accurate predictor of glycemic control,
especially when compared to fasting plasma glucose (FPG) (ADA, 2016; Bernal-Lopez et al.,
2011; Mannarino et al., 2013). While agreement is strong between HbA1C testing and FBG,
issues arise with nonparallel findings between HbA1C and oral glucose tolerance testing (OGTT)
(Farhan et al., 2012; Mannarino et al., 2013). Studies independently performed by Mannarino et
al. and Farhan et al. point out that there is discordance between OGTT and HbA1C regarding
T2D diagnosis outcomes, with Farhan’s findings indicating particularly discordant results when
cardiac autonomic neuropathy (CAN) is present. Such issues may lower the incidence of
diagnosis when using HbA1C as a determining test (Farhan et al., 2012). Additionally, HbA1C
testing is not appropriate in situations with individuals who have hemoglobinopathies, as it may
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not be reliable (Hare et al., 2012). Current recommendations by the American Diabetes
Association, however, align HbA1C as a valid test in equal measure to other diagnostic tests that
may be used and that one test is not preferred over the other (ADA, 2016).
The DCA Vantage from Siemens Corporation has been evaluated within research as a
point of care analyzer for HbA1C testing and found to have good correlation with laboratory
methods and acceptable precision (Lenters-Westra & Slingerland, 2010; Sanchez-Mora et al.,
2011). Within this research effort, 53 blood samples from diabetic patients over a wide range of
HbA1C values (4–14%), were examined with both a DCA Vantage Analyzer and a POCT
Analyzer and compared to on-site lab testing, and both were found to be clinically acceptable.
HbA1C testing remains as a recommended test for the screening and diagnosis of
diabetes. Increased accuracy over FPG, high portability, and financial accessibility in
comparison to OGTT make it an excellent screening test, despite limitations with certain diabetic
populations. The DCA Vantage Analyzer provides quality, on-site testing for HbA1C values,
with a proven wide range of testing capabilities that are clinically acceptable.

Summary
HRQOL relating to DPN is an important field of study, allowing for the assessment of
disease impact for the potential early intervention and offers unique caveats to physicians to aid
them in the diagnosis and treatment of DPN. HRQOL instruments vary greatly, ranging from
general to disease specific, and researchers and clinicians both must be aware of the individual
strengths and weaknesses of each instrument before utilizing them. Three HRQOL DN-specific
instruments in particular stand out as points of interest: the QOL-DN, the PN-QOL-97 and the
NeuroQOL-28. Each of these has been discussed within research literature and found to be
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valuable in relationship to diabetes foot related disease or neuropathy. Researchers who have
examined these instruments have recommended further evaluation, to compare certain aspects,
such as the psychometric properties of these tools. Overweight and obese individuals experience
reduced HRQOL, and are at risk for developing T2D, which makes them a unique population of
interest. Activity status has been shown to be linked to risk for the development of T2D.
Therefore, an overweight, obese, inactive population (OOI) is likely to be at increased risk for
PD, T2D and potentially, early complications such as DPN. While limited studies have
evaluated individuals with metabolic syndrome and obese populations, an OOI population has
not been well investigated. The primary focus in literature has been on the utilization of
HRQOL measures to assess individuals who have been diagnosed with disease, such as T2D.
We examined these three instruments to determine how to best detect early sensation loss
and signs of neuropathy in an HbA1C categorized OOI, PD and T2D population, allowing for a
beneficial appraisal of the instruments, an evaluation of potential early onset of disease and the
timing of the instruments being employed. Furthermore, we compared the three instruments
with the NC-Stat DPN Check POCD device, as a means of employing a criterion standard
measure of determining the accuracy of the instruments themselves.
We hypothesized that the QOL–DN and PN-QOL-97 would more clearly identify signs
of early or subclinical DPN when compared to the criterion standard of the NC-Stat DP Check,
that all three instruments would correlate with our criterion standard at .60 or higher, with the
QOL–DN yielding the strongest relationship and that the NeuroQOL-28 would be quickest to
complete, followed by the QOL–DN and PN-QOL-97. These investigational concepts laid the
framework for which we developed the methods for the execution of our research.
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CHAPTER II
PART C: MELATONIN & AUTONOMIC NERVOUS SYSTEM FUNCTION
Melatonin
When attempting to develop treatments for the dysfunction that arises in T2D, the
potential benefits of melatonin have just begun to be evaluated. Melatonin is a hormone that is
made by the pineal gland in the human body (Claustrat, Brun, & Chazot, 2005). Produced in
circadian patterns, this particular hormone has been found to regulate sleep and wake cycles and
the circadian rhythms within healthy humans by means of hypothalamus receptors located in the
suprachiasmatic nucleus (SCN) (Spadoni, Bedini, Rivara, & Mor, 2011). The hypothalamus acts
as a dominant brain region, taking responsibility for sensing and responding to the levels of
blood glucose within the body, and managing control of blood glucose during circadian rhythms
(Cailotto et al., 2005; Page et al., 2009; Reiter et al., 2007; Vriend & Reiter, 2015).
Impairment of melatonin synthesis may have serious consequences related to
hyperglycemia, as documented recently by Amaral et al., 2014. Rat studies involving sustained
hyperglycemia-induced detrimental effects in melatonin synthesis, in vivo and in vitro, which
suggest that given melatonin’s antioxidant effects and roles in energy homeostasis, deficiencies
in its release likely contribute toT2D progression (Amaral et al., 2014). Individuals with T2D
often suffer the consequences of disrupted sleep processes, with reduced hypothalamic activity,
and when tested, have been found to have decreased melatonin levels with phase delays (Kreier
et al., 2007). Such process interruptions contribute to increased nocturnal liver glucose
production (Radziuk & Pye, 2006), further indicating defects relating to glucose homeostasis.
The favorable effects of melatonin have been numerous, with positive outcomes in
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metabolic research (Goyal et al., 2014) and improved glycemic control (Greico, Colberg,
Somma, Thompson, & Vinik, 2013). Recent research documented protective effects on the
cardiovascular system in older populations (Paredes, Forman, Vara, Escames, & Tresguerres,
2014) and reduced electrical instability after epinephrine application, suggesting positive roles
for this easily accessible supplement (Vazan & Ravingerova, 2015). A similar study evaluated
two major neurotransmitters of the sympathetic nervous system (SNS), plasma norepinephrine
and dopamine levels, in the supine position, and found that after 60 minutes of melatonin
administration, measured norepinephrine and dopamine levels were lower (Nishiyama et al.,
2001), suggesting that melatonin administration influences cardiac vagal tone, potentially
exerting suppressive effects on sympathetic influences from the ANS.
Dysfunction within the hypothalamus, particularly related to SCN output, may be
particularly troublesome for T2D sufferers, creating irregular sleep and wake cycles, and making
it difficult for them to avoid the exacerbation of the disease (Kreier et al., 2007). These deficits
related to hypothalamic activity may contribute to the further development of T2D and cause
individuals to progress further into the complications of diabetes. Melatonin has been researched
as a synchronizer of the body’s biological clock and has demonstrated a restorative ability within
the SCN output context (Scheer, Kalsbeek, & Buijs, 2003). It is within this context that
melatonin has the potential to improve ANS balance, inflammation, oxidative stress, and
glycemic control within the T2D patient (Hussain et al., 2006; Kedziora-Kornatowska et al.,
2009; Paskaloglu, Sener, & Ayangolu-Dulger, 2004; Reiter, 1995; Scheer et al., 2003; Tutuncu
et al., 2005). It also lowers production of free radicals within the mitochondria (Okatani,
Wakatsuki, Reiter, & Miyahara, 2002) and attenuates inflammation by inhibiting NF-κB (Jung et
al., 2010). Thus, its primary effect appears to relate to the reduction of sympathetic influences,
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while potentially increasing parasympathetic function, culminating in reduction in activation of
the neuroinflammatory reflex arc.
The SNS is a powerful force, enabling the body to essentially push the gas pedal when it
needs to gain momentum for a task; however, the system is often out of balance in patients with
T2D, leaving the body in gear, so to speak. Parasympathetic nervous system (PNS) influences
bring a more calming, and balance to the SNS, effectively representing the opposite end of the
spectrum within the ANS. T2D patients experiencing cardiac autonomic neuropathy (CAN) in a
progressive state, appear to be left in variations of full throttle or vacillating dysfunction, when
every engine needs a period of rest in order to maintain reasonable performance levels.
Melatonin appears to potentially have the ability to positively influence the ANS in such a way
that it brings balance to the functions of the SNS and PNS by attenuating excessive SNS
dominance dysfunction that is frequently found in T2D individuals.

Cardiovascular Autonomic Neuropathy & Diabetes
Neuropathy comes in many forms, including those that more specifically affect the
cardiovascular system termed as cardiovascular autonomic neuropathy (CAN) (Vinik & Erbas,
2001). Incidence of the disease is incredibly high, with reported rates as high as 100% in some
research findings (Ziegler, Gries, Spuler, & Lessmann, 1992). Microvascular damage occurring
within the ANS exhibit itself in the form of CAN dysfunction, placing great risk to the individual
being affected, as ANS dysfunction is a strong predictor of sudden death with intensive glycemic
control (Vinik, Maser, & Ziegler, 2011). Mortality rates are significantly higher for individuals
experiencing CAN compared to patients without this particular pathology (Ewing & Clarke,
1986; Vinik, Maser, Mitchell, & Freeman, 2003; Vinik & Erbas, 2006).
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A unique T1D case proves the point, as Pop-Busui (2010) discussed the sudden death of a
26-year-old woman with severe CAN (Pop-Busui, 2010). Poor glycemic control over a 16-year
period, with hyperglycemic unawareness is believed to have contributed to persistent orthostatic
hypotension with BPs ranging in the 30 to 60 mmHg range. This case study revealed classic
signs of the disease upon her last clinical visit, yet sadly this case is not isolated. T2D is often
characterized by early damage to the ANS as well, which likely occurs prior to its onset
(Laitinen et al., 2011).
CAN dysfunction and its relationship to diabetes is not clearly defined, although
hyperglycemia appears to play a role, with glycation end products playing a significant role in
creating inflammation in microvascular processes (Lieb et al., 2012). A proinflammatory state
has been associated with ANS damage in diabetes (Lieb et al., 2012), and sympathovagal
imbalance may either result from or be the cause of an increased state of inflammation (Lieb et
al., 2012), which plays a key role in the development of both T2D and atherosclerosis.
This inflammatory response is controlled by the neural circuitry of the ANS. The afferent
arc consists of nerves that sense injury and infection and, in turn, activate a cholinergic antiinflammatory pathway that modulates the response (Vinik, 2012). The lymphoid organs of the
immune system are innervated by cholinergic, catecholaminergic, dopaminergic, and peptidergic
neurons, and neurotransmitters can alter the level of function of immune cells. In addition,
sensory neurons detect inflammation and can lead to the release of dopamine and
norepinephrine, causing depolarization of the vagal sensory fibers and initiation of a motor
efferent arc in the brainstem (i.e. the cholinergic anti-inflammatory pathway) (Vinik, 2012). It is
the loss of autonomic control with reduction of parasympathetic activity (a hallmark of T2D) that
appears to initiate this cascade of inflammatory responses.
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Symptoms. Symptoms associated with the disease include reduced resting heart rate
variability (HRV), elevated HR at rest (tachycardia), exercise intolerance, orthostatic
hypotension, abnormal circadian BPs, painless myocardial ischemia and intraoperative
cardiovascular lability, leading to a two to three-fold increase in mortality in diabetic patients
(Maser & Lenhard, 2005; Purewal & Watkins, 1995; Vinik & Ziegler, 2007). Others link CAN
to lower survival rates post myocardial infarction (Vinik et al., 2013).
Resting tachycardia and fixed HR or blunted HR response tend to be late symptoms of
CAN, likely due to vagal impairments that have developed over time (Vinik et al., 2013).
Abnormal HR response is a simple, yet powerful marker of CAN, identifying individuals at
higher risk. Hage et al. (2013) successfully identified blunted HR response to adenosine in
otherwise asymptomatic diabetics (Hage et al., 2013). Results indicated that individuals with
both abnormal MPI and HR were associated with the highest increased risk for cardiovascular
events, further substantiating the stealth of CAN, and necessity of screening and treatment.
Unique cases of dysfunction exist in the literature, as in the case of a 19 year old T1D
experiencing palpitations, elevated HR, and postural orthostatic hypotension (POTS) (Meyer et
al., 2015). Further examination resulted in hypotheses that related to PTSD in combination with
T1D contributed to altering autonomic balance, thus inferring that altered mental states due to
extreme stress may contribute to HR related autonomic dysregulation. Patients with POTS may
also experience fatigue and sleeping disturbances, warranting intervention. Mallien et al.
examined 38 POTS patients and 31 controls utilizing the Pittsburg Sleep Quality Questionnaire
and the Epworth Sleepiness Scale (Mallien et al., 2014). Participants were examined at a sleep
laboratory, where HRV analysis and other autonomic activity were recorded. POTS participants
experienced lower sleep quality and diminished HRV parameters. De Wandele and fellow
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researchers found dysregulation of autonomic function relating to increased sympathetic activity
during rest and lowered sympathetic response to stimuli in 39 age matched females that
underwent autonomic testing (De Wandele et al., 2014). Orthostatic intolerance, postural
tachycardia and lowered sympathetic responses to stimuli suggested dysautonomia relating to
CAN in these participants. A host of other symptoms are associated with CAN, including
gastrointestinal, genitourinary, metabolic, Sudomotor, and pupillary dysfunction, yet these are
not the focus of this research and are listed elsewhere (Vinik, Maser, et al., 2003).
Measuring Cardiac Autonomic Dysfunction. Several means exist to evaluate CAN,
and most have been described in clinical and research literature (Vinik, Maser, et al., 2003; Vinik
et al., 2013). Clinical and research evaluation and confirmation of CAN differ, however (see
Table IIC.1). Research literature lists the following as acceptable means to evaluate CAN: heart
rate response to deep breathing (an indication of beat-to-beat variations within the heart), heart
rate response to standing, Valsalva maneuver, power spectral analysis (HRV analysis), 24 hour
electrocardiogram (ECG) monitoring, systolic blood pressure (SBP) response to standing,
diastolic blood pressure (DBP) responses sustained handgrip, and hemodynamic responses to tilt
table tests (Poanta, Cerghizan, & Pop, 2010; Tarvainen, Laitinen, Lipponen, Cornforth, &
Jelinek, 2014; Vinik, Maser, et al., 2003; Vinik et al., 2013).
HR, cardiovascular testing, and orthostatic hypotension testing have been evaluated and
found to be acceptable measures for both research and clinical diagnosis of CAN (Vinik et al.,
2013), and heart rate variability (HRV) has been used as a measure of CAN dysfunction.
Tarvainen et al. (2014) performed work with these measures with 92 T2D patients, investigating
time-domain, frequency-domain, and non-linear methods (Tarvainen et al., 2014). The
investigation revealed significant decreases in HRV and mean increases in HR in T2D patients
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when compared to healthy controls, providing relative evidence of CAN pathology within the
first 5-10 years of T2D. Research is broad concerning the use of HRV, with power spectral
analysis being endorsed as a primary means of evaluating and diagnosing CAN (Spallone, 2011;
Vinik et al., 2013).
Baroreflex sensitivity measures have been used to evaluate coronary artery involvement
related to impaired endothelial function, relating to patients with IGT (Wykretowicz, 2005), with
vasodilator responses significantly being impaired in patients with IGT or diabetes. Rolim, de
Souza, & Dib (2013) and Spallone (2011) endorse baroreflex sensitivity testing as a primary
means of evaluating CAN and in response to the Toronto Consensus panel on Diabetic
Neuropathy guidelines (Rolim, de Souza, & Atala Dib, 2013; Spallone, 2011).
More recently, Sudoscan has been introduced into research to evaluate the microvascular
complications associated with neuropathy via electrochemical skin conduction (Eranki et al.,
2013; Freedman, Bowden, Smith, Xu, & Divers, 2014; Smith, Lessard, Reyna, Doudova, &
Singleton, 2014). This noninvasive skin conductive measurement evaluates sweat that is
stimulated by a gentle electrical current (undetectable) that is passed quite gently through the
soles of the feet and palms of the hands. Sudoscan is a measure of microvascular complications
included in the study. Ease-of-use makes this tool a target for screening. Yajnik et al., 2012
discusses Sudomotor dysfunction testing as a simple means of alerting clinicians to both
peripheral and cardiac dysfunction (Yajnik, Kantikar, Pande, & Deslypere, 2012), but advises
additional research and clinical outcomes.
The presence of one abnormal cardiac vagal result indicates possible early CAN, while
two abnormal cardiac vagal results confirm it (Spallone et al., 2011; Vinik et al., 2013).
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Orthostatic hypotension combined with an abnormal HR should be considered severe or
advanced CAN disease.
Glycohemoglobin Testing. Glycohemoglobin, or HbA1C, testing has been reliably used
to categorize BG values within research (Feng et al., 2009; Sumpio et al., 2013) and has been
proven as a simple, portable method of screening for diabetes that is accurate, relatively quick to
perform on-site (10 minutes), with results that are easily relayed. This method of screening also
provides the unique caveat of accessible health care upon demand to individuals that might not
otherwise engage in or be able to afford more expensive tests such as oral glucose tolerance
testing (OGTT). When considering the validity of HbA1C screening for diabetes, it should be
noted that the Canadian Task Force on Preventive Health Care, American Task Force and WHO
recommendations all support HbA1C testing of > 6.5% for the screening and diagnosis of
diabetes (American Diabetes Association, 2012; Canadian Task Force, 2012; World Health
Organization, 2011). In a clinical setting, if positive results are obtained, results should be
confirmed with repeated testing.
HbA1C testing has been shown in research to be strongly associated as an accurate
predictor of glycemic control, especially when compared to fasting plasma glucose (FPG) (ADA,
2016; Bernal-Lopez et al., 2011; Mannarino et al., 2013). While agreement is strong between
HbA1C testing and FBG, issues arise with nonparallel findings between HbA1C and oral glucose
tolerance testing (OGTT) (Farhan et al., 2012; Mannarino et al., 2013). Studies independently
performed by Mannarino et al. and Farhan et al. point out that there is discordance between
OGTT and HbA1C regarding T2D diagnosis outcomes, with Farhan’s findings indicating
particularly discordant when cardiac autonomic neuropathy (CAN) is present. Such issues may
lower the incidence of diagnosis when using HbA1C as a determining test (Farhan et al., 2012).
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Additionally, HbA1C testing is not appropriate in situations with individuals who have
hemoglobinopathies, as it may not be reliable (Hare et al., 2012). Current recommendations by
the American Diabetes Association, however, align HbA1C as a valid test in equal measure to
other diagnostic tests that may be used and that one test is not preferred over the other (ADA,
2016).
The DCA Vantage from Siemens Corporation has been evaluated within research as a
point of care analyzer for HbA1C testing and found to have good correlation with laboratory
methods and acceptable precision (Lenters-Westra & Slingerland, 2010; Sanchez-Mora et al.,
2011). Within this research effort, 53 blood samples from diabetic patients over a wide range of
HbA1C values (4–14%), and results were examined with both a DCA Vantage Analyzer and a
POCT Analyzer to be compared to on-site lab testing, and both were found to be clinically
acceptable.
HbA1C testing remains as a recommended test for the screening and diagnosis of
diabetes. Increased accuracy over FPG, high portability, and financial accessibility in
comparison to OGTT make it an excellent screening test, despite limitations with certain diabetic
populations. The DCA Vantage Analyzer provides quality, on-site testing for HbA1C values,
with a proven wide range of testing capabilities that are clinically acceptable.

Summary
Melatonin has been shown in research to have a positive effect on ANS function through
a variety of studies, many of which have addressed epinephrine, norepinephrine and glycemic
control. It is postulated that melatonin may have a significant effect on circadian rhythms in
T2D, yet this is not well researched to date, and remains to be elucidated through further testing.
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The potential for the study lies in investigating to what extent the ANS is altered in T2D
individuals at baseline testing, followed by to what extent melatonin would improve baseline
study measures of ANS function. We hypothesized that the ANS is misconducting, causing a
neuroinflammatory response, leading to impairment and that the proposed study would evaluate
this phenomenon. We further postulated that ANS function would improve in participants with
melatonin supplementation.
The overall purpose of this research was to investigate whether the underlying central,
cardiac, and peripheral defects that are observed in T2D could be improved or reversed by a
known chronotropic hormone, melatonin, given as a supplement. The physiological impact was
evaluated through the effects of a high dose supplemental melatonin on autonomic balance in
baroreflex sensitivity (BRS).
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TABLES
Table IIC.1
Cardiovascular autonomic tests and suggested indications for their use
Test

Clinical Diagnosis

Research

End Point in
Clinical Trials

Heart rate cardio vascular tests

Yes

Yes

Yes

Yes

No (low
sensitivity)

Yes

No (low
sensitivity)

Orthostatic hypotension test

QT interval

Ambulatory blood pressure monitoring
for dipping status (ABPM)
HRV time and frequency domain
indices

Baroreflex sensitivity measures

Scintigraphy studies

Muscle sympathetic nerve activity

Catecholamine assessment

Yes
Yes (additional
information and risk
stratification)
Yes (risk ratification)
Yes (additional
information and risk
stratification)
No (early additional
information and risk
stratification but low
availability)
No (low availability,
limited
standardization)
No (low ability,
limited data and
cardiovascular
autonomic
neuropathy)

No (low availability)

(Reproduced from Spallone et al., 2011; Vinik et al., 2013).

Yes

No (low
sensitivity)

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Possible (used
in lifestyle
intervention
trials and
obesity)
Possible (using
lifestyle
intervention
trials and
obesity)
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CHAPTER III
PROJECT I: NEUROPATHY SCREENING TOOLS
INTRODUCTION
Diabetes is known for its complications, with one of the most common being
microvascular damage that leads to diabetic neuropathy (DN), an insidious pathology which
comes in many forms, affecting various systems within the body, increasing a person’s risk for
amputation (Veresiu et al., 2015; Vinik et al., 2013). A common form of DN is diabetic
peripheral neuropathy (DPN), which is a primary cause for balance issues (Schwartz et al., 2008;
Vinik, Vinik, Colberg, & Morrison, 2015) and loss of sensation in the feet (Lamparter et al.,
2014); it is also a major contributor to non-traumatic lower limb amputations (Vinik et al., 2013).
DPN is a particularly significant problem for individuals with diabetes as it is relatively
common, and often leads to disability, but is difficult to diagnose due to frequent asymptomatic
onset or unusual presentation (Dixit & Maiya, 2014; Herman & Kennedy, 2005; McKinlay et al.,
2013; Veresiu et al., 2015; Vinik et al., 2013). This complication affects the nerve endings in the
feet, hands, and other regions of the body after an individual has experienced extended or acute
hyperglycemia or other pathologies that lead to the destruction of various forms of sensation
(Goh & Cooper, 2008; Goodarzi, 2014; Marcovecchio et al., 2011).
Earlier detection of such complications in at-risk individuals and in those with type 2
diabetes (T2D) or prediabetes (PD) allows for the best-case health and cost reduction scenarios
for all concerned, including optimal intervention and lifestyle changes (Papanas & Ziegler, 2012;
Phillips et al., 2014; Tabák, Herder, Rathmann, Brunner, & Kivimäki, 2012). Limited research
has sought to detect subclinical changes utilizing expensive and non-portable nerve conduction
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units, but research aiming to discover early changes in sensation using readily accessible,
portable tools has not been a primary focus (Mustafa et al., 2012; Papanas & Ziegler, 2012;
Smith & Singleton, 2006). DPN often develops silently, during early hyperglycemic processes,
yet many find out far too late in the process to effectively intervene (Monnier, Hanefeld, Schnell,
Colette, & Owens, 2013; Nichols et al., 2006; Phillips et al., 2014; Ruterbusch, 2014). Earlier
intervention in the DPN disease process would allow individuals time to respond with
appropriate choices to better direct their health, and low-cost tools to detect symptomology
before T2D or PD has been diagnosed may be useful in this effort. Several tools, such as the 1-g
and 10-g monofilaments and the 128-Hz tuning fork, have been successfully used within
research, effectively serving PD and T2D populations for screening and disease assessment
(Baraz et al., 2014; Bourcier et al., 2006; Divisova, 2012; Dros et al., 2009; Feng et al., 2009;
Robinson et al., 2013; Tracey, Greene, & Doty, 2012). The Norfolk Quality of Life Diabetic
Neuropathy Screening Tool (QOL-DN), the NC-Stat DPN Check, and hemoglobin A1C testing
(HbA1C) have been validated within T2D and limited PD populations as well, making them
likely candidates for success in early screening efforts (Boyd et al., 2011; Casellini, 2007; Lee et
al., 2014; Perkins et al., 2006; Veresiu et al., 2015; Vinik, Vinik, et al., 2014).
While each measure has been shown to be reliable and valid in T2D and PD populations,
overweight, obese and inactive (OOI) populations have not been a primary focus of studies using
these measures; however, they are at high risk for the development of T2D and associated
complications. Evaluation and screening for early signs of dysfunction in an OOI, PD and T2D
population allows for the development of the appropriate refinement of methods for earlier
detection. Thus, the purpose of this study was to evaluate the effectiveness of three neuropathy
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screening tools, the 128-Hz tuning fork, 1-g and 10-g monofilaments, and QOL–DN, in these
populations with the intent to identify early signs of DPN.

84

METHODS
Participants
Sampling. This study included a total of 34 adults of both sexes and varying ethnicities,
divided into three groups: 10 overweight, obese and inactive normoglycemic adults (OOI) (6
females, 4 males; 59.6 + 13.0 years), 13 with prediabetes (11 females, 2 males; 56.4+ 12.2
years), and 11 with T2D (7 females, 4 males; 59.6 + 12.1 years). Individuals with T1D, active
tobacco use, presence of hepatitis B, hepatitis C, HIV, pregnancy, damage to the lower
extremities, history of nerve disease (other than neuropathy), history of peripheral arterial
disease, lower limb amputations, or foot ulcers were excluded from participation. Any
individual possessing a serious medical condition that would compromise the subject’s safety or
the integrity of the study was also excluded.
Selection and Assignment. Volunteer subjects were recruited by flyers, email, word of
mouth and university announcements. Subjects were screened by phone for exclusionary factors
prior to reporting for testing. Assignment to groups was based on current HbA1C testing values
obtained onsite during study procedures. This research was approved by the Old Dominion
University Institutional Research Board and subjects participated in informed, signed consent
procedures before participating (ODU IRB ID: 15-197).

Procedures
Subjects reported to the Old Dominion University Wellness Institute to be screened and
participate in informed consent procedures prior to participation. Once they completed the
screening measures, individuals participated in all of the following testing measures.
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QOL-DN Questionnaires. The QOL-DN, a validated method instrument of assessing
neuropathy, and differentiating between autonomic, large and small fiber impairment (Boyd et
al., 2011; Veresiu et al., 2015; Vinik, Vinik, et al., 2014) and was utilized with each participant.
Individuals were given the questionnaire in a quiet area of the testing facility where they could
work undisturbed at their own pace (see Appendix B). Incomplete questionnaires were
completed before proceeding further with the study (Boyd et al., 2011; Casellini, 2007; Veresiu
et al., 2015; Vinik, Vinik, et al., 2014).
HbA1C Testing. Individuals were instructed prior to their appointment to drink several
glasses of water within 2–3 hours prior to the study to avoid POCD errors, such as high total
hemoglobin errors. Hydration instructions were assigned for the 24-hour period beforehand.
Finger-stick testing was performed with a Siemens DCA Vantage 2000 Analyzer (LentersWestra & Slingerland, 2010) and DCA Vantage HbA1C test kits utilizing sterile techniques.
HbA1C values and prior diagnoses were utilized to screen and categorize subjects as follows:
OOI 4.0–5.6%; PD, 5.7–6.4%, T2D, 6.5% and above (Mannarino et al., 2013; Mustafa et al.,
2012; Selvin, Steffes, Gregg, Brancati, & Coresh, 2011).
NC-Stat DPN Check. Nerve conduction study procedures utilized the POCD NC-Stat
DPN Check (DPN-Check, NeuroMetrix Inc., Waltham, MA) and followed previously outlined
methods as performed in Lee et al., 2014. The POCD test method involved a bilateral
examination of the lower extremity with the focus of obtaining sural nerve amplitude potential
(SNAP) and conduction velocity (SNCV) to assess large myelinated nerve fibers (Lee et al.,
2014; Perkins et al., 2006; Perkins et al., 2008). The device allows for evaluation of the SNCV
and SNAP by nonclinical personnel, assisting in DPN detection at a significantly earlier stage
when compared to bedside tests (Pambianco, Costacou, Strotmeyer, & Orchard, 2011; Sharma,
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Vas, & Rayman, 2015). The unit utilized biosensor technology paired with 2 probes coated in
conductive gel and was applied directly to the skin posterior to the lateral malleolus. The single
press of a button distributed 100 mA of current, which was detected by a single patient use
disposable biosensor. A built-in thermometer accounted for variances in temperature between
23oC and 30 oC and notified the operator of skin temperatures too cold for testing, preventing
testing until appropriate temperatures were present. Up to five attempts were utilized to collect
three sets of SNCV and SNAP values, per leg. Device errors were not recorded; however, zero
readings were recorded by hand and reattempts were made up to the 5-trial limit, as individuals
permitted. When individuals could not tolerate the acquisition of 3 data points per leg, last
observation carried forward (LOCF) methods were employed to complete the trial set (Vinik,
Shapiro, et al., 2014). The validity and effectiveness of the NC-Stat DPN Check system has
been confirmed in prior research (Perkins et al., 2006; Sharma et al., 2015). This test served as a
criterion standard for the study and all other testing was compared to this measure.
Tuning Fork Testing. A 128-Hz tuning fork was used to assess vibration perception
(Abbott et al., 2002; Shin, Seong, Lee, Kim, & Park, 2000) (See Figure III.1). Familiarization,
the site and method of testing, and all procedures for the “On/Off” method followed standardized
protocols as outlined by the Rapid Screening for Diabetic Neuropathy using the 128-Hz turning
fork (Abbott et al., 2002; Divišová et al., 2012; Meijer et al., 2005; Perkins et al., 2001; "Rapid
Screening for Diabetic Neuropathy," 2013; Shin et al., 2000). The timed tuning fork method was
employed in the same manner as Perkins et al., 2001, bilaterally (Perkins et al., 2001). The
procedural execution of both sets of tuning fork tests for peripheral neuropathy were performed
with the subjects lying in the supine position, with eyes closed during testing (Perkins et al.,
2001; "Rapid Screening for Diabetic Neuropathy," 2013).
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Monofilament Testing. Commercially produced 1-g and 10-g monofilaments were used
(North Coast Medical, San Jose, CA) with a standard lab testing table to evaluate sensation
perception. Monofilament storage and testing took place in a temperature controlled
environment, within the published parameters established by previous research (Haloua et al.,
2011; Lavery et al., 2012). Testing loads were limited to appropriate testing and rest periods.
Scheduling was spaced out over a period of six weeks, less than 10 subjects per day, followed by
a 1-day rest period before subsequent use. Monofilaments were utilized to assess sensation
according to previously published standardized guidelines (Baraz et al., 2014; Kafa et al., 2015;
"Rapid Screening for Diabetic Neuropathy," 2013). Procedures for familiarization and testing
followed the Canadian Diabetes Association for the Rapid Screening of Diabetic Neuropathy as
laid out for 10-g monofilament testing at the dorsum of the great toe, just proximal to the nail
bed (see Figure III.2). These procedures were applied to testing for the 4.17/1-g and 5.07/10-g
monofilaments and included standardized procedures for familiarization procedures, subject
response patterns, sites tested, number of stimuli and score assignment based off of prior
literature (Perkins et al., 2001; "Rapid Screening for Diabetic Neuropathy," 2013; Shin et al.,
2000). Monofilament testing was performed with the subject lying supine, eyes closed on a
laboratory testing table. The 4.17 (1-g) and 5.07 (10-g) monofilaments from a full kit of North
Coast Medical (North Coast Medical, San Jose, CA) monofilaments were utilized to assess
sensation according to previously published standardized guidelines (Baraz et al., 2014; Kafa et
al., 2015; "Rapid Screening for Diabetic Neuropathy," 2013). Individuals were allowed to keep
shoes and socks on until the time of testing in order to maintain normal body temperature, but
these items were removed just prior to commencing with screening.
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Data Analyses
Statistical analyses were performed using SPSS version 22.0 for Windows (SPSS,
Chicago, IL). Participant, group characteristics, SNAP and SNCV are presented in raw form.
Criterion and dependent variable data were logarithmically transformed to best achieve
normality for statistical analysis. Correlations were analyzed using Spearman’s coefficients for
the tuning fork, 1-g and 10-g monofilaments, QOL-DN and NC-Stat DPN Check results, and
accounted for age, HbA1c and waist measurement (in cm). Kruskal-Wallis H tests were used to
determine if there were differences between the three groups with pairwise comparisons using
Dunn’s (1964) procedure. Alpha was set at 0.05 for all analyses.
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RESULTS
Population Characteristics
Our population included 10 males and 24 females of Caucasian and African American
ethnicity, with HbA1C ranges varying from 4.4–14.0% (Tables III.1 and III.2). Fifteen of the 34
individuals reported no prior diagnosis or knowledge of hyperglycemia. Five out of 15 had PD
HbA1C values and were grouped accordingly. Without specific recruitment for OOI, 33 of the
34 subjects were overweight or obese. Twenty-eight individuals reported having no prior
neuropathy diagnosis or knowledge. Medication usage varied, with 10 of 34 participants
reporting T2D specific medication usage as part of their personal medical plan. Two individuals
with T2D reported a combination of T2D and neuropathy medication.

Sural Nerve Conduction Amplitude and Velocity Results
Overall group means for SNAP and SNCV characteristics did not significantly vary by
HbA1C level (Table III.3). Kruskal-Wallis H testing revealed no significant differences among
OOI, PD and T2D groups for SNAP and SNCV values (SNAP: R, H(2) = 1.460, p = .482; L,
H(2) = 2.369, p = .306; SNCV: R, H(2) = 1.874, p = .392, L, H(2) = 1.880, p = .391). Raw data
means and standard deviations are presented (Table III.3). Twenty-seven individuals obtained
confirmed, individualized, abnormal NCS results, of which 25 were bilateral and symmetrical
(Table III.4). Twenty-four participants presented with a combination of abnormal distal signs
bilaterally, of which two also reported altered ADLs and four reported autonomic symptoms.
Only two of the twenty-four reported changes in both ADLs and autonomic features. One
individuals presented with no signs or symptoms. Seven cases presented with normal NCS
findings, but in the presence of reported symptoms and reduced bilateral distal sensation.
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Tuning Fork Testing, Monofilaments & QOL-DN Results
The tuning fork on/off test did not correlate with our criterion variables (see Table III.5);
however, the tuning fork achieved a sensitivity of 53.8% and specificity of 75.0%. (Table III.5),
Timed tuning fork testing yielded no significant correlations or relationships within the study,
bilaterally. The 1-g total scores moderately correlated with both SNAPs [R, rs(34) =.364, p =
.024; L, rs(34) =.312, p = .047], and left 1-g scores demonstrated a moderate relationship to both
SNAPs [R, rs(34) =.393, p = .016; L, rs(34) =.301, p = .053] of the NC-Stat DPN Check.
Sensitivity for the 1-g monofilament was 73.1% and specificity was low, at 25.0%.
The 10-g monofilament did not significantly correlate to our criterion variables.
Sensitivity for the 10-g was 46.2% and specificity was 62.5%. Total QOL-DN scores negatively
correlated with both SNAPs [R, rs(34) = -.317, p = .044; L, rs(34) = -.311, p = .047], as did the
Symptoms subscale (both SNAPs) [R, rs(34) = -.332, p = .036; L, rs(34) = -.375, p = .021]. The
small fiber subscale of the QOL-DN correlated with the RSCV [R, rs(34) = -.311, p = .047] and
the ADLS subscale correlated with the RSNAP both SNAPs [R, rs(34) = -.354, p = .028]. QOLDN components spanned a wide range in sensitivity (0–65.4%) and specificity (12.5–87.50%).
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DISCUSSION
The integration of these testing methods provided an excellent framework to develop a
better understanding of the onset of dysfunctional physiological processes within PD and OOI
individuals during the beginning of disease onset and examination of relationships between
symptoms and disease. This study compared the effectiveness of the 128-Hz tuning fork, 1-g
and 10-g monofilaments, and the QOL-DN as screening measures for early DPN detection to
established NCS criterion values as measured by the NC-Stat DPN Check. Our evaluation
utilized the NC-Stat DPN Check and associated NC-Stat software to account for the age, height
and weight of the subjects in conjunction with 3 bilateral sural NCS readings to assess the
function of large myelinated nerve fibers, and thus we did not directly assess small fiber
neuropathy associated deficits. This study offers a nonclinical analysis based off of the criteria
required by Tesfaye et al. (2010) aiming to achieve minimal definition requirements for
confirmed and subclinical DSPN classification, with the intent of developing early screening
measures for DPN prone populations (Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler,
Lauria, Malik, Spallone, & Vinik, 2010).
Sural nerve conduction and amplitude values are validated quantitative physiological
markers that assist in the assessment and confirmation of DPN status with, or without the
presence of signs or symptoms. Twenty-six of 34 individuals had abnormal NCS, 24 of whom
reported symptoms and bilateral symmetrical signs upon examination (1-g, 10-g monofilaments,
128-Hz tuning fork), meeting the requirements for confirmed DSPN according to some literature
(Tesfaye et al., 2010); however, we find that this is a significant percentage of study participants
in comparison to other research conducted with this device (Perkins et al., 2006). In addition,
three individuals with abnormal NCS reported symptoms and unilateral presentation of signs,
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potentially indicating pathology that is not the focus of this study, while one individual with
abnormal NCS reported no symptoms or signs, confirming the likelihood of subclinical
neuropathy. Six individuals obtained normal NCS studies, but had the presence of signs and
reported symptoms, while one individual had normal NCS, but the presence of signs and no
reported symptoms.
Perkins et al. 2006 experienced significant findings, yet their study only evaluated
individuals with diagnosed diabetes (T1D and T2D), whereas our study examined a wide range
of individuals, including “healthy” individuals that were recruited for our OOI population that
we believed might be prone to DPN, as well as PD and T2D individuals. The fact that we report
bilateral, abnormal findings in 71% of the individuals we tested, leaves room for questions. We
applied rigorous testing preparation and methods, and while it is possible that there is an error we
are unaware of, our findings may be questioned as valid. It is also possible that the NC-Stat
DPN Check’s current software components and algorithms are too sensitive for the subject
population. For clarification, we compared our SNAPs to Perkins et al. and found that, overall,
our SNAP values for our groups (see Table III.3) contained values ranging from 2–25μV, with
means ranging from 6.6 to 10.5μV, compared to Perkins et al., who contained means of 5.6μV.
Many of their participants (16) had undetectable levels, whereas we were able to achieve three
readings on all but 4 individuals to whom LOCF was applied. At present, we interpret our
readings as valid given that we acquired three readings on each leg, across a diverse collection of
individuals, all of whom were likely to develop DPN. In support of our findings, the individuals
with abnormal findings self-reported symptoms via QOL-DN and had documented distal
sensation loss via 128-Hz tuning fork, and 1-g or 10-g monofilaments. It is, however, possible
that our readings are altered in some way that we are unaware of at present.
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In an attempt to offer specific recommendations of normal or abnormal findings based on
applied individual characteristics, our assessment differed from previous research by evaluating
each individual participant according to age, height and weight and determining appropriate
cutoffs for normal and abnormal findings, thereby individualizing results to each participant with
the built-in NC-Stat software. This method of analyses seemed particularly appropriate given the
nature of the potential impact of overweight, obese status within our population. Having noted
discrepancies between the two in the study he performed that analyzed both measures, Lee et al.
2014 notes that the SNCV values tend to be lower with a traditional NCS when compared to the
NC-Stat DPN Check (Lee et al., 2014). This would prove to an interesting point to consider, if
the same type of error were true, as it would likely boost the number of individuals who had
abnormalities even higher.
To detect early DPN in normoglycemic OOI individuals, we had postulated that the 128Hz tuning fork and QOL-DN would provide the best mechanisms for detection; however, our
results only indicated partial support for this theory. The tuning fork on/off test did not correlate
well with our NC-Stat DPN Check SNAP criterion variables, however, the QOL-DN, on several
measures, did. This finding is different than some prior research, as the QOL-DN has not always
been found to correlate with electrophysiological measures (Vinik et al., 2005; Vinik et al.,
2008).
The QOL-DN ranged in sensitivity (0–65.4%) and specificity (12.5–87.5%), differing
from previous research that resulting in high specificity and sensitivity. While there is no
definitive answer for this, plausible considerations for this finding include the unusual
distribution of our population, and our small pilot size across three groups in our attempts to
discover DPN at its earliest point possible. Previous research expressed concern relating to the
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QOL-DN: Hogg et al., 2012 reported the QOL-DN as a means to aid in diagnosis and
monitoring, but expressed a lack of specificity for PN, stating that it may be limited its use to
health impacts of a diabetes foot disease related nature (Hogg et al., 2012). We did not find this
to be true in our study as QOL-DN measures not only correlated, but also provided vital
standardized data relating to self-reported symptoms, ultimately contributing to our goal of the
early identification of DPN.
Detecting such diabetes complications is an unfolding evolution that involves multiple
dynamics. DPN may present in a completely silent manner, without pain, burning or symptoms
of annoyance. In such cases, individuals will not disclose physical symptoms that they aren’t
currently experiencing. Individuals with early DPN may experience the disease in a varied
manner, with some individuals experiencing asymptomatic disease patterns, ultimately requiring
hands on screening to identify the silent progression of the disease. Future research should likely
continue to examine the QOL-DN for early DPN detection, as several subscales indicate
correlations.
The 1-g monofilament proved to be useful within our study, with (30) individuals
experiencing abnormal findings. This measure indicated high sensitivity (73.1%) and poor
specificity (25.0%), yielding concerns. However, validation of 1-g physical findings was seen
through moderate correlations back to our criterion SNAP variables. Our results relate to
previous research efforts that reported high sensitivity and low specificity, as is the case of
Takasande et al. 2011 and reviews performed by Feng et al. (Feng et al., 2009; Taksande, Ansari,
Jaikishan, & Karwasara, 2011).
The 10-g monofilament testing lacked significant correlational relationships, yet the
usefulness of this tool has been well established in T2D and limited PD populations in other
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research. Our correlational findings did not add support for its use in normoglycemic obese
populations, but insensate feet relate to neuropathy in later stages and this research focused
instead on early detection. In contrast, Ylitalo et al. examined cardiometabolic and neuropathy
factors in obese individuals and found that the 10-g monofilament was a useful tool for such
research (Ylitalo, Sowers, & Heeringa, 2011).
We had hypothesized that the QOL-DN would be the most sensitive measure to detect
undisclosed DPN in our population, and sensitivity results did not support this. The most
sensitive tools for early DPN detection was the 1-g monofilament, which was reasonably
sensitive at 73.1% but poorly specific at 25.0%, and the tuning fork on/off test, which was less
sensitive (53.8%) and more specific (75.0%) in nature. Despite low sensitivity and specificity,
the Total QOL-DN, Symptoms, ADLS and Small Fiber component aspects of the QOL-DN
measure, should be considered, as this questionnaire proved to be invaluable to the study. The
QOL-DN and its subscales are likely to be more successful in a more balanced study that is
seeking both small and large fiber deficits related to early DPN detection, as this measure has
been previously validated to detect both. Our criterion measure, the NC-Stat DPN Check was
targeted towards screening for large fiber, and thus may not correlate as well with a well-rounded
screening measure that targets multiple areas of neuropathy, such as the QOL-DN.
Finally, our results reflect a strong indication of neuropathy in this population,
suggesting that careful screening of individuals at earlier stages may be quite beneficial in the
early detection of DPN, even prior to hyperglycemia diagnosis. Smith and Singleton found
elevated HbA1C status in such populations to be a concern for the development of large fiberrelated neuropathy complications, as was found in our cohort (Smith & Singleton, 2013).
Diabetes-related complications, such as decreased motor and sensory nerve conduction
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velocities, may arise out of acute bouts of hyperglycemia experienced though postprandial
excursions, which may be best reflected by HbA1C values (Marcovecchio et al., 2011).
Our study certainly has some limitations. As it is a pilot study, generalizations of
findings may not be made to large populations. Lack of random assignment and use of
volunteers for subjects created potential selection bias, with clinical population research targeting
and low available funding heavily influencing this method. The HbA1C testing machine that
was used within the study is a validated machine, yet oral glucose tolerance testing is preferred
by some researchers, particularly for individuals with cardiac autonomic neuropathy (CAN)
(Farhan et al., 2012). We did not test for CAN and, therefore, cannot account for unknown
discrepancies. Temperature and humidity have been found to affect monofilament results, by
affecting the potential validity of the instrument in extremely high temperatures as well as high
testing volumes in short periods of time (Booth & Young, 2000; Haloua et al., 2011).
Temperature was accounted for by limiting monofilament storage and use to normal climate
controlled room temperatures and monitored these values. Humidity was monitored, but not
controlled beyond what the laboratory air-conditioning and heating systems accounted for.
Preparation for monofilament usage followed previously stated guidelines and recommendations,
with testing amounting to far less than 100 compressions per day per instrument (Booth &
Young, 2000). The NC-Stat DPN Check device was used solely to test the sural nerve;
therefore, deficits in nerve function relating to other nerves of the lower leg were not confirmed
through this device and two nerves were not evaluated, as some literature advises. The QOL-DN
has been previously validated for individuals with diabetes and neuropathy, yet its specific
validation to effectively target OOI individuals has not been performed and, therefore, this
should be taken this into account when interpreting our findings.
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CONCLUSION
This study aimed to detect DPN signs and symptomology prior to PD diagnosis in
overweight, obese, and inactive adults using low-cost, established tools and compared these tools
to a validated measure of nerve conduction. The 1-g monofilament was more useful for
detection in this population than the 10-g monofilament. The tuning fork on and off test
demonstrated reasonable use for this population, although it did not correlate with our criterion
standard. The QOL-DN correlated on Total QOL and several subscales, providing valuable,
standardized symptom information which may be incorporated into community screening
models. Future research should continue to aim to refine and develop low-cost screening
methods aimed at disclosing asymptomatic DPN earlier.
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TABLES
Table III.1
Participant Characteristics
Variable
Gender
Male
Female
Ethnicity
Caucasian
African American
Diabetes Diagnosis
None
Prediabetes
T2D
Neuropathy Diagnosis
No Prior Diagnosis
Prior Diagnosis
Medication
No Medication
Not T2D Specific
T2D Specific
T2D and Neuropathy
HbA1C Category
OOI
PD
T2D
BMI Category
Normal
Overweight
Obese

Frequency Percent
10
24

29.4
70.6

22
12

64.7
35.3

15
8
11

44.1
23.5
32.4

28
6

82.4
17.6

8
14
10
2

23.5
41.2
29.4
5.9

10
13
11

29.4
38.2
32.4

1
9
24

2.9
26.5
70.6
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Table III.2
Gender and Group Characteristics
N
Min
Max
Mean
Std. Err
Std. Dev
Age
Males
10 37.00
79.00
61.00
4.279
13.532
Females
24 35.00
74.00
57.20
2.364
11.581
Height
Males
10 1.58
1.85
1.745
0.024
0.078
Females
24 1.48
1.74
1.66
0.013
0.064
Wt.
Males
10 83.18
133.10
105.86
6.520
20.618
Females
24 65.36
122.73
89.40
3.083
15.103
Wt. By Group
OOI
10 76.60
106.60
87.93
3.460
10.940
PD
13 65.90
133.10
98.03
7.350
23.260
T2D
11 78.40
127.70
101.29
5.590
17.680
BMI
Males
10 28.20
41.50
34.85
1.570
4.966
Females
24 24.70
43.90
32.99
1.156
5.664
BMI by Group
OOI
10 27.2
35.6
30.9
1.003
3.170
PD
13 24.7
43.9
34.2
1.860
6.707
T2D
11 27.0
41.5
35.1
1.516
5.029
HbA1C by Gender
Males
9
4.4
7.1
6.0
0.289
0.915
Females
21
5.2
14.0
6.5
0.365
1.790
HbA1C by Group
OOI
10
4.4
5.6
5.3
0.114
0.362
PD
13
5.6
6.4
5.9
0.06
0.218
T2D
11
6.5
14.0
7.8
0.632
2.095
Wt. = Weight in kg; OOI = Overweight, obese, inactive; T2D = Type 2 diabetes;
BMI = Body mass index; HbA1C = hemoglobin A1C
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Table III.3
NCS Results By Group
NC-Stat DPN Check - Sural Nerve
N

Min

Max

Mean

Std.
Error

Std.
Dev.

SNAP-R (μV)
OOI
10
2.0
14.3
6.631
1.444
4.567
PD
13
2.0
24.7
7.691
1.674
6.037
T2D
11
2.0
25.0
9.875
2.133
7.076
SNAP-L (μV)
OOI
10
2.3
21.7
7.129
1.834
5.798
PD
13
3.0
21.7
7.277
1.186
4.277
T2D
11
3.0
21.7
10.572
2.064
6.847
SNCV-R (μV)
OOI
10 35.3
55.7
46.2
1.902
6.016
PD
13 30.0
57.0
48.2
1.871
6.747
T2D
11 35.3
57.0
45.5
1.816
6.022
SNCV-L (μV)
OOI
10 41.3
55.0
47.265
1.519
4.803
PD
13 43.0
55.0
49.637
1.072
3.865
T2D
11 37.3
57.0
46.876
1.946
6.455
*Displayed in untransformed form, as raw data
SNAP = sural nerve amplitude potential; SNCV = sural nerve conduction
velocity
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Table III.4
Sural NCS, Signs and Symptoms
Variable

Group
OOI PD T2D
7
1
4
3
27
10
9
8

Total

Normal
Abnormal*
Tuning Fork
Normal
13
3
5
Abnormal*
21
7
7
Monofilaments
1-g
Signs
N = 34
Normal
3
1
0
Abnormal*
31
9 12
10-g
Normal
3
1
0
Abnormal*
31
9 13
None Reported
11
7
1
Symptoms
N = 34
Reported**
23
3 12
None Reported
21
7
8
Autonomic
N =34
Reported**
13
3
5
None Reported
26
8 10
ADLS
N = 34
Reported**
8
2
3
AbNCS, Signs
17
3
9
& Symptoms
AbNCS, Signs
9
5
1
NCS, Sign & or Symptoms
Symptom
AbNCS, No
Combinations Signs or
1
1
0
Symptoms
NNCS, Signs &
7
1
3
Symptoms
*Bilateral testing; abnormal findings on at least one limb;
**Self-reported on QOL-DN
AbNCS = Abnormal nerve conduction study; NNCS =
Normal nerve conduction study
Sural NCS
N = 34

5
6

2
9
2
9
4
7
6
5
8
3
5
3
0
3
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Table III.5
Spearman's Partial Correlations (Log Transformed)
NC-Stat DPN Check - Sural Nerve
SNAP-R
SNAP-L
SNCV-R
SNCV-L
Tuning Fork
N = 34
N = 34
N = 34
N = 34
On/Off
0.221
0.137
0.235
-0.089
Sig
0.121
0.235
0.106
0.319
Timed–R
-0.066
-0.019
-0.019
-0.099
Sig
0.365
0.461
0.459
0.302
Timed–L
-0.063
-0.052
-0.018
-0.081
Sig
0.371
0.392
0.463
0.355
Monofilaments
N = 34
N = 34
N = 34
N = 34
Total 1-g
0.364*
0.312*
-0.060
-0.141
Sig
0.024
0.047
0.377
0.229
1-g R
0.229
0.206
0.024
0.077
Sig
0.112
0.138
0.451
0.342
1-g L
0.393*
0.301*
-0.191
-0.313
Sig
0.016
0.053
0.155
0.046
Total 10-g
0.098
0.088
0.032
0.030
Sig
0.304
0.321
0.432
0.438
10-g R
0.096
0.160
0.005
-0.066
Sig
0.306
0.200
0.489
0.364
10-g L
0.137
0.070
0.031
0.054
Sig
0.235
0.356
0.436
0.388
QOL-DN
N = 34
N = 34
N = 34
N = 34
Total
-0.317*
-0.311*
0.162
-0.117
Sig
0.044
0.047
0.197
0.269
Symptoms
-0.332*
-0.375*
0.213
-0.003
Sig
0.036
0.021
0.129
0.493
Large Fiber
-0.297
-0.284
0.107
-0.163
Sig
0.056
0.064
0.286
0.195
Small Fiber
-0.241
-0.187
-0.311*
-0.366
Sig
0.099
0.161
0.047
0.023
ADLS
-0.354*
-0.263
0.104
-0.065
Sig
0.028
0.080
0.293
0.366
Autonomic
-0.236
-0.245
0.149
-0.044
Sig
0.105
0.096
0.216
0.408
Accounts for HbA1C, Age and Waist in cm; *Significance at the .05 level.
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FIGURES
Figure III.1 128-Hz Tuning Fork

Reproduced with permission by the Canadian Diabetes Association. April 2016 ("Rapid
Screening for Diabetic Neuropathy," 2013).
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Figure III.2 Monofilament Application

Reproduced with permission by the Canadian Diabetes Association. April 2016 ("Rapid
Screening for Diabetic Neuropathy," 2013).
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CHAPTER IV
PROJECT II: NEUROPATHY QUALITY OF LIFE TOOLS
INTRODUCTION
Diabetes is an overwhelming disease that places significant demands on individuals,
often leading to distress and ultimately degradation of consistent self-care behaviors (Guo et al.,
2015; Karlsen, Oftedal, & Bru, 2012). Such stressors and inconsistent monitoring behaviors
invite damage caused by extended or acute hyperglycemia (Vinik et al., 2013). Hyperglycemia
promotes early microvascular complications related to diabetic neuropathy (DN), including
altered eyesight, kidney and psychosocial functioning, all of which may bring significant impact
on an individual. An individual’s outlook on life, how he or she experiences it, interacts with
others, and chooses activities may be affected by a DN diagnosis and individual symptomology.
Such adverse outcomes on an individual body system, and the ability to perform tasks and
psychosocial functioning is referred to as health-related quality of life (HRQOL) (Luscombe,
2000). HRQOL is an important concept within diabetes care management, particularly due to
the rising impact of the disease itself, as projected estimations for 2035 indicate diabetes will
impact over 592 million individuals worldwide across the globe (Guariguata et al., 2013).
Research over the past several decades has made great strides in developing several
HRQOL assessments that specialize in assessing DN-related measures and address HRQOL as a
significant factor (Bredfeldt, Altschuler, Adams, Portz, & Bayliss, 2015; Smith et al., 2012;
Vickrey et al., 2000; Vileikyte et al., 2003; Vinik et al., 2004). Within the realm of HRQOL, DN
has been of particular interest, with individuals dedicating significant research effort to the
validation of neuropathy-specific measures. Individuals at risk for or who are experiencing DN
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should be promptly screened in order to facilitate optimal health outcomes (Marrero et al., 2014;
Sinclair, Dunning, & Rodriguez-Mañas, 2015).
DN is often experienced in T2D and PD, raising questions as to when DN develops
(Marrero et al., 2014; Papanas & Ziegler, 2012) and how soon it affects QOL. Furthermore,
overweight, obese, or inactive status (OOI) places an individual at increased risk for disease,
including potential progression to PD and T2D and other forms of physiological dysfunction, yet
sparse research is available relating to how these individuals may or may not experience DN
(Miscio et al., 2005). Neuropathy screening is considered a standard care for individuals
diagnosed with T2D, but not for OOI individuals. Therefore, the purpose of this study was to
compare three measures of QOL, the NQOL–DN, the PN-QOL-97, and the NeuroQOL-28, in
OOI, PD and T2D adults to determine which instrument is the most effective at detecting DN at
various stages while comparing the findings back to a criterion standard, the NC–Stat DPN
Check (NeuroMetrix, Waltham, MA).
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METHODS
Participants
Sampling. This study included a total of 34 adults of both sexes and varying ethnicities,
divided into three groups: 10 overweight, obese and inactive normoglycemic individuals (OOI)
(6 females, 4 males; 59.6+ 13.0 years), 13 individuals with prediabetes (11 females, 2 males;
56.4+12.2 years), and 11 individuals with T2D (7 females, 4 males; 59.6+12.1 years).
Individuals with T1D, active tobacco use, presence of hepatitis B, hepatitis C, HIV, pregnancy,
damage to the lower extremities, history of nerve disease (other than neuropathy), history of
peripheral arterial disease, lower limb amputations, or foot ulcers were excluded from
participation. Any individual possessing a serious medical condition that would compromise the
subject’s safety or the integrity of the study was also excluded.
Selection and Assignment. Volunteer subjects were recruited by flyers, email, word of
mouth and university announcements. Subjects were screened by phone for exclusionary factors
prior to reporting for testing (see Appendix A). Assignment to groups was based on current
HbA1C testing values obtained onsite during study procedures.
Protection of Subjects. Participants were closely monitored during the study. Sterile
techniques were used to collect blood samples and perform HbA1C testing. This research was
approved by the Old Dominion University Institutional Research Board and subjects participated
in informed, signed consent procedures before participating (ODU IRB ID: 15-197).

Procedure
Questionnaires were filled out after individuals were screened and consented into the
study and prior to other data collection measures (see Appendices B, C and D). Completion
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times were tracked for each instrument, allowing a comparison of the time investment needed to
utilize each chosen method. Individuals were placed in a quiet room within the Wellness
Institute with a volunteer research assistant who timed their completion of each instrument in
minutes and seconds. Questionnaires were checked by volunteer research assistants and
investigators for completeness before proceeding to HbA1C testing. Incomplete questionnaires
were completed before proceeding with the study. Digital copies of all questionnaires were
acquired directly from the authors (QOL–DN, PN-QOL-97 and NeuroQOL-28) via email
correspondence, including scoring rubrics. Printed copies were used with each participant and
are attached as appendices (see Appendices B, C and D).
Norfolk Quality of Life Diabetic Neuropathy Tool. The Norfolk Quality-of-Life
Diabetic Neuropathy tool (QOL-DN) has been found to be reliable across different populations
and sensitive to both small and large fiber impairment and improvements in neuropathy (see
Appendix B) (Boyd et al., 2011; Casellini, 2007; Veresiu et al., 2015; Vinik, Vinik, et al., 2014).
PN-QOL-97. This instrument has been identified as a validated measure for identifying
DPN and successfully used in research (Maxwell et al., 2013; Maxwell et al., 2014; Vickrey et
al., 2000). It is a PN-specific HRQOL measure that offers multiple psychometric properties to be
considered (see Appendix C) (Smith et al., 2012; Vickrey et al., 2000).
NeuroQOL-28. The NeuroQOL-28 questionnaire instrument has been validated as a
neuropathy-and foot ulcer-specific QOL tool and subsequently utilized in myriad studies
evaluating QOL identifying key factors involved in the DPN experience (see Appendix D) (Dixit
& Maiya, 2014; Vileikyte et al., 2003).
HbA1C Testing. Hemoglobin A1C (HbA1C) finger-stick testing was performed with a
Siemens DCA Vantage 2000 Analyzer (Lenters-Westra & Slingerland, 2010) and DCA Vantage
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HbA1C test kits utilizing sterile techniques. HbA1C values were utilized to screen and
categorize subjects as follows: OOI 4.0–5.6%; PD, 5.7–6.4%, T2D 6.5% and above (Mannarino
et al., 2013; Mustafa et al., 2012; Selvin et al., 2011) HbA1C finger-stick testing followed a
standardized protocol determined from Selvin et al. (2011) and Lenters-Westra and Slingerland,
(2010) (Lenters-Westra & Slingerland, 2010; Selvin et al., 2011). HbA1C testing was performed
after individuals have been screened, and consented into the study, and after all other paperwork
has been filled out. Individuals were instructed prior to their appointment to drink several
glasses of water within 2–3 hours prior to the study to avoid errors on the test, such as high total
hemoglobin errors. Individuals were also instructed to stay well hydrated for the 24-hour period
beforehand.
NC-Stat DPN Check. NC-Stat DPN Check (DPN-Check, NeuroMetrix Inc., Waltham,
MA) procedures followed previously outlined methods as performed in Lee et al. (2014) (Lee et
al., 2014). The POCD test method involved a bilateral examination of the lower extremity with
the focus of obtaining sural nerve amplitude potential (SNAP) and conduction velocity (SNCV)
(Lee et al., 2014; Perkins et al., 2006; Perkins et al., 2008). The device allows for evaluation of
the SNCV and SNAP by nonclinical personnel, assisting in DPN detection at a significantly
earlier stage when compared to bedside tests (Pambianco et al., 2011; Sharma et al., 2015). The
unit utilized biosensor technology paired with 2 probes was applied directly to the skin posterior
to the lateral malleolus. A single press of a button distributed 100 mA of current, which was
detected by a one use disposable biosensor. A built-in thermometer accounted for variances in
temperature between 23oC and 30oC and notified the operator if skin temperatures were too cold
for testing. Thee SNCV and SNAP values were attempted for each leg with up to five attempts
to collect the trials. Device errors were not recorded; however, zero readings were recorded by
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hand and re-attempts we made up to the 5 trial limit, as individuals permitted. The validity and
effectiveness of the NC-Stat DPN Check system has been confirmed in prior research (Perkins et
al., 2006; Sharma et al., 2015). This test served as a criterion standard for the study and all other
testing was compared to this measure.

Data Analyses
Statistical Evaluation. Questionnaires were considered valid if complete biographic
information, including age and sex was provided (Veresiu et al., 2015). Summary statistics, in
the form of continuous data is presented with means and standard deviations. Pertinent
Spearman’s partial correlations are presented. NC-Stat DPN Check, measuring (3 trials) the
right sided sural nerve amplitude potential (RSNAP) served as the comparable criterion standard,
determining confirmed DSPN or subclinical DSPN.
Multiple regressions were run to attempt to predict the right SNAP criterion through
modeling that accounted for HbA1C, age, BMI and selected correlated predictor variables from
each questionnaire. Comparisons involved running separate multiple regression analyses with
limited covariate and predictor variables with the aim to predict DPN. Covariates and predictors
were entered at once, including accounting for known factors such as HbA1C, age, and BMI as a
substitute measure for weight and height, in order to best preserve the regression model DOF
(Herrera-Rangel, Aranda-Moreno, Mantilla-Ochoa, Zainos-Saucedo, & Jáuregui-Renaud, 2014).
Selected neuropathy-related components were entered into each regression model based on
potential relationships presented in Spearman’s partial correlations and appropriate choices that
meet the assumptions of regression, avoiding multicollinearity within regression models.
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Selections were first made from the highest correlations, with additional predictors options if
multicollinearity issues could not be effectively resolved within the model.
Linearity was assessed by scatterplot analyses, partial regression plots and a plot of
studentized residuals against the predicted values. Homoscedasticity, independence of
observations (research design and Durbin-Watson), linear relationships, outliers (+3 std. dev.),
influential leverage cases, and multi-collinearity components (correlations, tolerance, VIF
values) were evaluated and addressed for each model independently.
Regression results were compared via confidence intervals, standard errors and
regression coefficients in an effort to determine if one survey could be named as the optimal
predictor survey with post hoc testing as necessary. All analyses were performed using SPSS
Version 22.0 and significance was set at the p < 0.05 level.
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RESULTS
Population Characteristics
Our population included 10 males and 24 females of Caucasian and African American
ethnicity, with HbA1C ranges varying from 4.4–14.0% for all subjects (Tables IV.1 and IV.2).
Fifteen of 34 individuals reported no prior diagnosis or knowledge of T2D or PD. Five of 15
individuals had PD HbA1C values and were grouped accordingly. A total of 33 out of 34
individuals were overweight or obese. Twenty-eight individuals reported having no prior
neuropathy diagnosis or knowledge. Medication usage varied, with 10 of 34 participants
reporting T2D specific medication usage as part of their personal medical plan. Two individuals
with T2D reported a combination of T2D and neuropathy medication.

Sural Nerve Conduction Amplitude and Velocity Results
Overall group means for SNAP and SNCV characteristics did not significantly vary by
HbA1C level (Table IV.3). Kruskal-Wallis-H testing revealed no significant differences among
OOI, PD and T2D groups for SNAP and SNCV values (SNAP: R, H(2) = 1.460, p = .482; L,
H(2) = 2.369, p =.306; SNCV: R, H(2) = 1.874, p =.392, L, H(2) = 1.880, p =.391). Raw data
means and standard deviations are presented (Table IV.5). Twenty-seven individuals obtained
confirmed, individualized, abnormal NCS results, of which 25 were bilateral and symmetrical
(Table IV.4). Twenty-four participants presented with combinations of abnormal distal signs
bilaterally, meeting criteria for confirmed DSPN, and one case presented with no signs or
symptoms, indicating the presence of subclinical neuropathy. Seven cases presented with normal
NCS findings, but in the presence reported symptoms and reduced bilateral distal sensation.
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Correlations
Spearman’s partial correlations were run between NC-Stat DPN Check criterion standard
variables, which were the right and left SNAP and SNCV values and all questionnaire data
components while accounting for age and HbA1C values. Significant correlations were
identified and are presented (Table IV.5). The QOL-DN symptom component moderately
correlated with the right SNAP criterion [R, rs(34) -.365, p = .044]. The PN-QOL-97 physical
component score moderately correlated with both the right and left SNAP criterions [R, rs(34)
=.375, p = .038; L, rs(34): .366, p = .043], as did the mental component scores; however, the
relationship was considerably stronger [R, rs(34) = .522, p = .003; L, rs(34) = .451, p = .011].
NeuroQOL-28 neuropathy specific components moderately strongly correlated to the left SNAP
[ rs(34) = -.426, p = .017], and the NeuroQOL-28 overall QOL judgment score strongly
[RSNAP, rs(34) =.541, p = .002] and moderately correlated [LSNAP, rs(34) =.396, p = .028] to
our criterion SNAP values.

Completion Times
Completion times analyses revealed that the QOL-DN (M = 5.17; SD = 1.83) was the
quickest, on average to complete, followed by the NeuroQOL-28 (M = 5.58; SD = 3.56) and
QOL-97 (M = 13.23; SD = 3.606) (Table IV.6).

QOL-DN Questionnaires
A multiple regression was run to attempt to predict the right SNAP criterion with a
regression model that accounted for HbA1C, age, BMI, QOL-DN Symptoms and Total QOL
Scores as predictors. The multiple regression model significantly predicted the right SNAP
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value, F(5,28) = 6.118, p <.001, adj. R2 = .52. Age (p =.000) and Total QOL (p = .019)
significantly added to the prediction. Regression coefficients and standard errors can be found in
Table IV.7.

PN-QOL-97 Questionnaires
A multiple regression was run to attempt to predict the right SNAP criterion with a
regression model that accounted for HbA1C, age, BMI, and PN-QOL-97 Physical and Mental
Scores as predictors. This model significantly predicted the right SNAP value, F(5,25) = 7.465,
p < .0005, adj. R2 = .52. Age (p =.000) and HbA1C (p = .025) significantly added to the
prediction. Regression coefficients and standard errors can be found in Table IV.8.

NeuroQOL-28 Questionnaires
A multiple regression was run to attempt to predict the right SNAP criterion with a
regression model that accounted for HbA1C, age, BMI, and the NeuroQOL-28 Neuropathy
Specific Component and Overall QOL Judgment as predictors. The multiple regression model
significantly predicted the right SNAP value, F(5,28) = 7.238, p < .0005, adj. R2 = .49. Age (p =
.000) and Overall QOL Judgment (p = .017) significantly added to the prediction. Regression
coefficients and standard errors can be found in Table IV.9.
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DISCUSSION
Although the QOL-DN, PN-QOL-97 and NeuroQOL-28 have been validated for use in
research as neuropathy instruments to detect DPN, further analysis of these instruments has been
recommended (Bredfeldt et al., 2015; Smith et al., 2012). We sought to determine which of
three instruments, the QOL-DN (Vinik et al., 2005), the PN-QOL-97 (Vickrey et al., 2000) or the
NeuroQOL-28 (Vileikyte et al., 2003) would be the best predictor of neuropathy when compared
to our criterion standard measurements in OOI, PD and T2D populations. The QOL-DN
Symptoms component correlated with our LSNAP, but not with the RSNAP, thus the fact that
the regression results revealed a predictor relationship between the Total QOL and RSNAP was
not surprising. Examination of bilateral results will be reported elsewhere.
We had anticipated that our first hypothesis would likely be supported, with the QOL-DN
more clearly identifying early, or subclinical PN, and the Total QOL-DN (p = .019) component
supports this hypothesis. Our results indicate that QOL-DN, but not the PN-QOL-97, predicted
our criterion standard RSNAP value within our regression models, although the PN-QOL-97’s
Mental Score was relatively close to significance (p = .073). The NeuroQOL-28 Overall
Judgment of QOL (p = .017) demonstrated significant predictive qualities for early detection,
giving further validation to this short questionnaire, yet asymmetry existed in its correlational
relationship across the RSNAP and LSNAP variables. Normal variants within our target
population could account for such asymmetries. Twenty-six of 34 individuals had abnormal
NCS. Of these 26, 24 reported symptoms (recorded via QOL-DN) and the presence of bilateral
symmetrical signs as evidenced by 1-g and 10-g monofilaments, 128-Hz tuning fork, and
reported symptoms, meeting the requirements for confirmed DSPN (reported elsewhere).
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In hypothesizing which instrument would be most effective to detect DPN in our OOI,
PD and T2D population, we had predicted correlation of .60 or higher between these tools and
the NC-Stat DPN Check criterion SNAP and SNCV values. However, our results indicate that
all three measures failed to meet this level; although they correlated to our criterion, the
association was not as strong as clinically desirable. Correlations revealed significant
relationships between the RSNAP and the Neuropathy Overall Judgment QOL (rs = .523), and
PN-QOL-97 Mental Scores (rs = 505) for the RSNAP, but not for the QOL-DN.
Early detection is considered critical, yet is difficult to accomplish with currently
available methods. Papanas and Ziegler (2012) emphasize the importance of early DPN detection
in their research, advising small fiber evaluation as a means to catch the pathophysiological
process in the earliest stages (Herrera-Rangel et al., 2014; Papanas, Vinik, & Ziegler, 2011;
Papanas & Ziegler, 2012). Clinical exams readily identify small fiber pathology, often using
Neurotips (pain and warmth detection), or a cold 128-Hz tuning fork (thermoreceptor evaluation)
(Vinik et al., 2013). Large fiber neuropathy, which is the primary focus of the NC-Stat DPN
Check tool, may also be evaluated through hands-on measures (NC-Stat DPN-Check, 1-g, 10-g
monofilaments, 128-Hz tuning fork) in clinical or on site applications to test pressure and large
fiber sensitivity changes. Small fiber dysfunction, however, is difficult to detect, often requiring
skin biopsy for confirmed status, paired with abnormal QST and clinical exams, requiring
clinical appointments. Such clinical tests are useful, if one can get individuals to report for
testing at a clinical site or participate in on-site screening that utilizes them. However, we
emphasize the necessity of research to develop easy-to-use screening tools that may be utilized in
short time commitment community screening efforts. The often silent beginnings of small fiber
dysfunction do not readily lead individuals to seek the clinical assessment necessary to catch the
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pathology. Unless experiencing symptoms, such as brief pins-and-needles, pricks, or shock
sensations, they have little to move them towards clinical evaluation.
While we knew that each instrument had its strengths and weaknesses as we entered this
study, one thing we did not fully consider was that each may pick up on different components of
fiber loss, meaning one may be more adept at detecting small fiber, another identifies with large
fiber loss and another may do well with both of these and autonomic as well. Our criterion
focused on large fiber measurement, and future study designs may want to incorporate multiple
means to assess the effectiveness of these QOL tools, ones that address small, large and
autonomic neuropathy components, to better detect the abilities of each individual instrument for
screening. This might include simple bedside tests, such as a cold tuning fork and Neurotips, in
order to evaluate small fiber components.
The further development of paper questionnaires to effectively screen for small fiber
component dysfunction should be a priority, as much of the general public does not seek medical
attention until symptoms have become obvious. Ultimately, the focus of patient reported
outcomes such as the QOL-DN, PN-QOL-97 and the NeuroQOL-28 is DPN screening and
detection, thus evaluating these instruments for different facets of the targeted disease population
and determining each tool’s viability in that subset was a useful objective of the current study.
Both the QOL-DN and NeuroQOL-28 likely identified key subjective measures that align well
with objective screening measure in early hyperglycemic processes within our small pilot
population. The QOL-DN was effectively employed to identify key symptomology necessary
for the diagnosis of DPN, aiding and assisting in a patient centered, cumulative approach. Both
of these instruments are available in US and UK versions, with the NeuroQOL-28 reported to be
available in 10 additional languages and the QOL-DN available in 8 (Smith et al., 2012),
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indicating widespread availability for use in research and screening efforts. Additional strengths
of the QOL-DN are highlighted in research efforts by Vinik et al. (2005), where the QOL-DN
demonstrates a well-rounded approach, uncovering multiple neuropathy-related components,
including complications, medication use, autonomic factors, fiber specific domains and validated
use for revealing undisclosed neuropathy (Veresiu et al., 2015; Vinik et al., 2005). Our study
showed similar results, disclosing DPN in individuals who were unaware of their deteriorating
physiological state, revealing promise for the QOL-DN in revealing disease in diverse population
settings. The NeuroQOL-28 focuses on painful symptoms, reduced sensation, ADLS, overall
diffused sensory and motor changes, emotional changes and overall QOL, which likely explains
its usefulness in our study (Vileikyte et al., 2003). These facets relate to our research, as the
completion of results reflect a strong indication of neuropathy in this population, suggesting that
careful screening of individuals at earlier stages may be quite beneficial in the DPN detection
process, even prior to acute hyperglycemia diagnosis. Elevated HbA1C status in such
populations is associated with the development of decreased motor and sensory nerve conduction
velocities, which may arise out of acute bouts of hyperglycemia experienced though postprandial
excursions (Marcovecchio et al., 2011; Smith & Singleton, 2013). Our participants were likely
to report a variety of component changes, including psychometric properties that are evaluated
and reported by this measure. Currently, each questionnaire has its strengths and should be
applied accordingly.
Previous research has reported unknown completion times for the NeuroQOL-28 and
QOL-DN (Smith et al., 2012). Our study, therefore, is the first to document time to completion
for all three measures. Our finding that completion times were shorter for the QOL-DN and
NeuroQOL-28 suggests that these two would ultimately make better choices for community
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screening efforts, as evaluations will need to take these times into account for optimal
participation. Both instruments can be employed within a short time, and the choice between
which measure to use in future early DPN investigations is a difficult one, as these instruments
are typically applied in populations that are likely further along in their disease process than the
ones in this pilot work. On a practical note, quickly completed PROMs provide more leeway for
integration into community screenings, but the measure also must be able to be quickly scored to
be of immediate use to the individual. Of the 3 measures, the scoring is easiest for the
NeuroQOL-28, which can be done by hand in a face-to-face setting as necessary within less than
5 minutes. The QOL-DN requires scoring, that although simple, requires additional time to
provide feedback, likely needing contact information or a second reporting to disseminate
results. The PN-QOL-97, while thorough, requires more elaborate scoring and calculations
accomplished through programs such as Excel, and same day reported outcomes would not be
realistic without the cooperation of multiple researchers with designated roles. Although not
done in this study, examining these measures directly in the field, within whatever screening
context they are being honed for, would have allowed for evaluation of these measures within the
context of administering the instruments in a less controlled atmosphere and should be
considered for future evaluations.
Our study has limitations that should be considered. We performed a pilot study, and
generalizations may not be made to large populations. Lack of random assignment and use of
volunteers for subjects created potential selection bias, with clinical population research targeting
and low available funding heavily influencing this method. The HbA1C machine that was used
within the study is a validated machine (Lenters-Westra & Slingerland, 2010), yet oral glucose
tolerance testing is preferred by some research scientists, particularly for individuals with cardiac
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autonomic neuropathy (CAN) (Farhan et al., 2012). We did not test for CAN and, therefore,
cannot account for unknown discrepancies. The NC-Stat DPN Check device was used solely to
test the sural nerve; therefore, deficits in nerve function relating to other nerves of the lower leg
were not confirmed through this device. Previous research has not investigated the validity of
the QOL-DN, PN-QOL-97 and the NeuroQOL-28 within an overweight, obese and inactive
population and, therefore, this should be taken this into account when interpreting our findings.
Furthermore, each of these instruments detects particular types of neuropathy, and we only
assessed large fiber components with our NC-Stat DPN check device.
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CONCLUSION
Both the QOL-DN and NeuroQOL-28 significantly predict neuropathy criterion standard
components in OOI, PD and T2D subjects, adding validity to their use as screening measures as
early DPN detection tools. The PN-QOL-97 effectively identified multiple DPN-related issues;
however, its ability to predict our criterion standard was not statistically significant. Time
completion studies revealed that the QOL-DN and NeuroQOL-28 may be posed as excellent
short screening measures, completed in approximately 6 minutes or less, with reasonable scoring
for both; however, if immediate feedback is needed, the NeuroQOL-28 is likely to be a better fit
with time constraints and limited staff. Consideration should be given to adding fiber specific
domains to the NeuroQOL-28 and psychological measures assessing the impact of depression to
the QOL-DN, thus adding potential to both instruments to more closely align with different
facets potentially experienced by the target population, hopefully increasing the power of their
constructs. Asymmetry in NCS findings warrants proposing that future research consider how
falls and injuries may contribute to the uneven pathogenesis of SNAP values in subacute and
acute hyperglycemic populations and to further explore other options for effective screening for
early DPN. Priority should be given to investigations seeking to evaluate the effectiveness of
these tools to detect DN within early, DN prone, predefined populations, providing new
opportunities to increase the effectiveness of these and other instruments in subclinical
population screening efforts.
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TABLES
Table IV.1
Participant Characteristics
Variable
Gender
Male
Female
Ethnicity
Caucasian
African American
Diabetes Diagnosis
None
Prediabetes
T2D
Neuropathy Diagnosis
No Prior Diagnosis
Prior Diagnosis
Medication
No Medication
Not T2D Specific
T2D Specific
T2D and Neuropathy
HbA1C Category
OOI
PD
T2D
BMI Category
Normal
Overweight
Obese

Frequency Percent
10
24

29.4
70.6

22
12

64.7
35.3

15
8
11

44.1
23.5
32.4

28
6

82.4
17.6

8
14
10
2

23.5
41.2
29.4
5.9

10
13
11

29.4
38.2
32.4

1
9
24

2.9
26.5
70.6
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Table IV.2
Gender and Group Characteristics
N
Min
Max
Mean
Std. Err
Std. Dev
Age
Males
10 37.00
79.00
61.00
4.279
13.532
Females
24 35.00
74.00
57.20
2.364
11.581
Height
Males
10 1.58
1.85
1.745
0.024
0.078
Females
24 1.48
1.74
1.66
0.013
0.064
Wt.
Males
10 83.18
133.10
105.86
6.520
20.618
Females
24 65.36
122.73
89.40
3.083
15.103
Wt. By Group
OOI
10 76.60
106.60
87.93
3.460
10.940
PD
13 65.90
133.10
98.03
7.350
23.260
T2D
11 78.40
127.70
101.29
5.590
17.680
BMI
Males
10 28.20
41.50
34.85
1.570
4.966
Females
24 24.70
43.90
32.99
1.156
5.664
BMI by Group
OOI
10 27.2
35.6
30.9
1.003
3.170
PD
13 24.7
43.9
34.2
1.860
6.707
T2D
11 27.0
41.5
35.1
1.516
5.029
HbA1C by Gender
Males
9
4.4
7.1
6.0
0.289
0.915
Females
21
5.2
14.0
6.5
0.365
1.790
HbA1C by Group
OOI
10
4.4
5.6
5.3
0.114
0.362
PD
13
5.6
6.4
5.9
0.06
0.218
T2D
11
6.5
14.0
7.8
0.632
2.095
Wt. = Weight in kg; OOI = Overweight, obese, inactive; T2D = Type 2 diabetes;
BMI = Body mass index; HbA1C = hemoglobin A1C
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Table IV.3
NCS Results By Group
NC-Stat DPN Check - Sural Nerve
N

Min

Max

Mean

Std. Err

Std.
Dev

SNAP-R (μV)
OOI
10
2.0
14.3
6.631
1.444
4.567
PD
13
2.0
24.7
7.691
1.674
6.037
T2D
11
2.0
25.0
9.875
2.133
7.076
SNAP-L (μV)
OOI
10
2.3
21.7
7.129
1.834
5.798
PD
13
3.0
21.7
7.277
1.186
4.277
T2D
11
3.0
21.7
10.572
2.064
6.847
SNCV-R (μV)
OOI
10 35.3
55.7
46.2
1.902
6.016
PD
13 30.0
57.0
48.2
1.871
6.747
T2D
11 35.3
57.0
45.5
1.816
6.022
SNCV-L (μV)
OOI
10 41.3
55.0
47.265
1.519
4.803
PD
13 43.0
55.0
49.637
1.072
3.865
T2D
11 37.3
57.0
46.876
1.946
6.455
*Displayed in untransformed form, as raw data
SNAP = sural nerve amplitude potential; SNCV = sural nerve conduction
velocity
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Table IV.4
Sural NCS, Signs and Symptoms
Variable

Group
OOI
PD
7
1
27
10

Total

T2D

Normal
4
Abnormal*
9
Tuning Fork
Normal
13
3
5
Abnormal*
21
7
7
Monofilaments
1-g
Signs
N = 34
Normal
3
1
0
Abnormal*
31
9
12
10-g
Normal
3
1
0
Abnormal*
31
9
13
None Reported
11
7
1
Symptoms
N = 34
Reported**
23
3
12
21
7
8
Autonomic None Reported
N =34
Reported**
13
3
5
None Reported
26
8
10
ADLS
N = 34
Reported**
8
2
3
AbNCS, Signs
17
3
9
& Symptoms
AbNCS, Signs
9
5
1
NCS, Sign & or Symptoms
Symptom
AbNCS, No
Combinations Signs or
1
1
0
Symptoms
NNCS, Signs
7
1
3
& Symptoms
*Bilateral testing; abnormal findings on at least one limb; **Selfreported on QOL-DN
AbNCS = Abnormal nerve conduction study; NNCS = Normal
nerve conduction study
Sural NCS
N = 34

3
8
5
6

2
9
2
9
4
7
6
5
8
3
5
3
0
3
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Table IV.5
Spearman Partial Correlations
RSNAP LSNAP RSNCV LSNCV
QOL-DN
N=34
N=34
N=34
N=34
Corr. -0.289
-0.352
-0.004
-0.242
Total Score
Sig.
0.128
0.061
0.985
0.205
Corr. -0.275
-0.322
-0.058
-0.290
Large Fiber
Sig.
0.149
0.088
0.765
0.127
Corr. -0.251
-0.185
-0.340
-0.361
Small Fiber
Sig.
0.189
0.336
0.071
0.054
Corr. -0.291 *-0.417 0.047
-0.102
Symptoms
Sig.
0.126
0.024
0.808
0.597
Corr. -0.331
-0.260
0.066
-0.074
ADLS
Sig.
0.079
0.164
0.734
0.701
Corr. -0.188
-0.297
-0.091
-0.188
Autonomic
Sig.
0.328
0.117
0.638
0.329
PN-QOL-97
N=34
N=34
N=34
N=34
Corr. 0.350
*0.399
0.107
0.166
Physical
Sig.
0.063
0.032
0.579
0.389
Corr. *0.505 *0.479
0.052
-0.101
Mental
Sig.
0.005
0.009
0.791
0.603
NeuroQOL-28
N=34
N=34
N=34
N=34
Corr. -0.194
-0.334
-0.288
-0.279
Total Score
Sig.
0.314
0.077
0.129
0.142
Corr. -0.305 *-0.464 -0.177
-0.204
Neuropathy Specific
Sig.
0.108
0.011
0.358
0.287
Corr. *0.523 *0.426
0.194
0.025
Overall QOL Judgement
Sig.
0.004
0.021
0.312
0.897
All correlations account for HbA1C, age, height and weight.
* significance at the .05 level
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Table IV.6
Instrument Completion Times

QOL-DN
NeuroQOL-28
QOL-97

Std.
N Mean Std. Dev.
Error
34
5.17
1.834
0.315
34
5.58
3.566
0.612
34 13.23
3.606
0.618
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Table IV.7
QOL-DN Regression Results
Unstandardized
Std.
Coeff.
Coeff.
Std.
Model
B
Error
Beta
(Constant)
28.084
7.291
Age
-.311
.066
-.629
HbA1C
.262
.593
.069
Body
1 Mass
-.110
.149
-.101
Index
Symptoms
3.613
2.523
.347
Total
-2.719
1.096
-.550
QOL
a. Dependent Variable: RLLOCF3Trials

95.0% Conf. Int.
for B
Lower
Upper
Bound Bound
13.150 43.018
-.446
-.177
-.954
1.477

t
3.852
-4.738
.441

Sig.
.001
.000
.663

-.741

.465

-.416

.195

1.432

.163

-1.555

8.780

-2.481

.019

-4.964

-.474
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Table IV.8
PN-QOL-97 Regression Results
Unstandardized
Std.
Coeff.
Coeff.
Std.
Model
B
Error
Beta
(Constant) -47.420 43.910
Age
-.348
.077
-.730
HbA1C
2.608
1.090
.374
Body Mass
-.207
.156
-.178
1 Index
Physical
4.470 11.653
.076
Score
Mental
12.102
6.456
.349
Score
a. Dependent Variable: RLLOCF3Trials

95.0% Conf. Int.
for B
Lower
Upper
Bound
Bound
-137.853 43.014
-.507
-.190
.362
4.853

t
-1.080
-4.525
2.392

Sig.
.290
.000
.025

-1.326

.197

-.528

.114

.384

.705

-19.529

28.470

1.874

.073

-1.195

25.399
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Table IV.9
NeuroQOL-28 Regression Results
Unstandardized
Std.
Coeff.
Coeff.
Std.
Model
B
Error
Beta
(Constant)
-.235 18.513
Age
-.357
.067 -.721
HbA1C
.918
.549
.243
Body Mass
.036
.151
.032
Index
1
Neuropathy
-5.358
6.438 -.129
Specific
Overall
QOL
15.748
6.180
.422
Judgement
a. Dependent Variable: RLLOCF3Trials

95.0% Conf. Int.
for B
Lower
Upper
Bound
Bound
-38.157 37.688
-.494
-.220
-.207
2.042

t
-.013
-5.344
1.671

Sig.
.990
.000
.106

.236

.815

-.273

.345

-.832

.412

-18.545

7.829

2.548

.017

3.089

28.406
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CHAPTER V
PROJECT III: MELATONIN AND THE AUTONOMIC NERVOUS SYSTEM
INTRODUCTION
The complications relating to diabetes are numerous, potentially relating to most regions
of the body as microvascular pathology develops over an extended period, yet no complication
of the disease may be as dangerous as cardiac autonomic neuropathy (CAN) (Vinik & Erbas,
2001; Ziegler et al., 1992). Mortality rates are significantly higher for individuals experiencing
CAN when compared to patients without this particular pathology (Ewing & Clarke, 1986;
Vinik, Maser, et al., 2003; Vinik & Erbas, 2006). CAN dysfunction and how it relates to
diabetes is not clearly defined, although hyperglycemia appears to be related, with glycation end
products playing a significant role in creating inflammation in microvascular processes
(Hardeland, Cardinali, Brown, & Pandi-Perumal, 2015; Lieb et al., 2012; Tarvainen et al., 2014).
A proinflammatory state has been associated with ANS damage in diabetes (Hardeland et al.,
2011; Lieb et al., 2012) and sympathovagal imbalance may either result from or be the cause of
an increased state of inflammation (Lieb et al., 2012), which plays a key role in the development
of both T2D and atherosclerosis.
Interest has developed in melatonin as a substance that may provide answers for elements
of dysfunction that arise in T2D, particularly those associated with circadian disorders (Ferrell &
Chiang, 2015; Scheer et al., 2003; Spadoni et al., 2011). Melatonin regulates sleep patterns and
wake cycles within healthy individuals, and is produced in circadian patterns (Claustrat et al.,
2005; Spadoni et al., 2011). Sleep and wake cycles are often disturbed in T2D, and impaired
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melatonin production is suspected, and thought to be related to the consequences of
hyperglycemia (Reutrakul & Van Cauter, 2014).
Interruption in sleep and wake cycles may be particularly difficult for T2D patients,
speeding along symptoms of the disease (Kreier et al., 2007). Melatonin synchronizes the
biological clock (Reiter et al., 2007; Scheer et al., 2003), increasing restorative capabilities,
lowering inflammation (Jung et al., 2010), and attenuates neurotransmitters of the sympathetic
nervous system (Nishiyama et al., 2001; Vazan & Ravingerova, 2015). Thus, it has been
hypothesized that melatonin may have promise to improve ANS balance, inflammation,
oxidative stress, and glycemic control within the T2D patient (Hussain et al., 2006; KedzioraKornatowska et al., 2009; Paskaloglu et al., 2004; Reiter, 1995; Scheer et al., 2003; Tutuncu et
al., 2005).
Given melatonin’s effects on resetting the circadian clock of the ANS, we postulated that
it might help improve ANS function in T2D patients. Thus, the purpose of this research was to
investigate whether the underlying central, cardiac, and peripheral defects observed in T2D could
be improved or reversed by this known chronotropic hormone given as a daily supplement.
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METHODS
Participants
Sampling. A total of 10 adults of both sexes and varying ethnicities, 40–75 years of age,
who had diagnosed T2D were recruited from a local population. Exclusionary criteria included:
congestive heart failure, recent myocardial infarction, unstable arrhythmia, any cardiovascular
event in the previous year, liver or kidney disease, severe orthostatic hypotension, active tobacco
use, type 1 diabetes, hepatitis B or C, presence of HIV, active malignancy (diagnosed or treated
with in the last year), nighttime shift work, current or recent use of supplemental melatonin,
pregnancy and/or breast-feeding, or other serious medical conditions that investigators believed
would compromise the subject’s well-being or participation in the study.
Protection of Subjects. This research was approved by the Old Dominion University
Institutional Research Board and Eastern Virginia Medical School’s Institutional Review Board,
and subjects participated in informed, signed consent procedures before participating (ODU IRB
ID: 15-260). Documented, informed consent was obtained from each subject prior to
participation. Throughout the study, patients were evaluated by a medical professional at each
visit (baseline, 4 and 8 weeks) to the Eastern Virginia Medical School (EVMS) Strelitz Diabetes
Center. Potential side effects were recorded for both the placebo and melatonin portions of the
study.

Procedures
This study utilized a single over-the-counter daily dose of melatonin (10 mg) to
determine its effect on both autonomic balance and baroreflex sensitivity. Up to 10 mg doses are
safe for adults, (Burgess, Revell, & Eastman, 2008; Burgess, Revell, Molina, & Eastman, 2010)
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and even as little as 0.5 mg can affect circadian rhythm entrainment (Hack, Lockley, Arendt, &
Skene, 2003). Individuals were screened by phone as potential candidates for the study utilizing
inclusion/exclusion criteria (see Appendix F) before scheduling volunteers to arrive in a fasted
state for a 2-hour appointment at the EVMS Strelitz Diabetes Center, in Norfolk, VA. During
visit one, the inclusion/exclusion form was completed (see Appendix F), and individuals meeting
study requirements were consented into the study prior to receiving an exam that included
height, weight, an electrocardiogram, blood pressure measurements (supine, standing, seated),
medication recording, health condition disclosure, basic diabetes screening and a neurological
physical to determine the health of the individual to participate in the research study (see
Appendix E). Qualified candidates continued with testing, which included sleep questionnaires,
HbA1C finger-stick testing, Sudoscan testing, HRV and baroreflex sensitivity testing (see
Appendix G). Each of the 3 visits followed the same pattern, with HbA1C testing on visits 1 and
3, and 4-week melatonin or placebo assignment on visits 1 and 2.
HbA1C Testing. A Siemens DCA Vantage 2000 Analyzer (Lenters-Westra &
Slingerland, 2010), DCA Vantage HbA1C test kits, alcohol prep pads, lancets, medical gloves,
anti-bacterial wipes, and a Hazard Sharps container were utilized for finger-stick testing on visits
1 and 3.
Melatonin. After qualifying for the study and giving their informed consent, subjects
were randomly assigned a tablet order. Subjects received a single 4-week quantity of 10 mg
melatonin capsules or placebo capsules and were instructed to consume one capsule every
evening 30 minutes before bedtime. The crossover dose (melatonin or placebo) was distributed
to each subject after 4 weeks and compliance reassessed after the second 4 weeks until each
subject had taken both melatonin and placebo. Commercially-produced pure melatonin capsules
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(Life Extension, Ft. Lauderdale, FL) contained 10 mg each. Placebo capsules contained white
flour.
Autonomic Nervous System Function Testing. Before and after each of the two 4week trials (melatonin and placebo), the ANSAR device (ANSAR; ANX 3.0 software; ANSAR
Group, Inc., Philadelphia, PA) was utilized to assess systemic (vagal) autonomic function and
sympathetic balance (Vinik & Erbas, 2006). Subjects underwent three tests of autonomic
function (R-R intervals): 1) deep breathing (expiratory/inspiratory ratio; E/I); 2) Valsalva
maneuver (breath holding); and 3) postural change (standing from a seated position). All ANS
testing was done at the same time of day both before and after supplementation to minimize
individual diurnal variations of any residual melatonin following each overnight period.
Power Spectral Analysis. Power spectral analysis of HRV was performed with
previously validated methods (La Rovere, Pinna, Maestri, & Sleight, 2012) under resting
conditions with the ANSAR device for determination of low frequency (LF) and high-frequency
(HF) components. The LF component of the power spectrum of HRV primarily is now
considered to reflect baroreflex function. The HF component primarily reflects parasympathetic
activity. LF/HF ratios were calculated to provide a measure of ANS balance. The total spectral
power (TSP) was calculated, along with the standard deviation of all normal R-R intervals
(SDNN), a measure of both sympathetic and parasympathetic action on HRV, and the root-mean
square of the difference of successive R-R intervals (RMSSD), a measure primarily of
parasympathetic activity (Vinik & Ziegler, 2007). Abnormalities in SDNN and RMSSD precede
inflammation in adults with newly-diagnosed T2D (Lieb et al., 2012). All power spectral
analyses were conducted at baseline and again after both 4-week intervals (10 mg melatonin and
placebo).
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Baroreflex Sensitivity Testing. IBSF was measured with the ANSAR device using
validated methods (Dimitropoulos, Tahrani, & Stevens, 2014; La Rovere et al., 2012). Sudoscan
(Aspire Medical Solutions, NY) testing was also used to quantify changes in sudomotor and
small nerve fiber function (i.e., peripheral sympathetic tone) and, together with BSF, to
determine parasympathetic balance. The physiological impact was evaluated through the effects
of a high dose supplemental melatonin on autonomic balance in baroreflex sensitivity (BRS).
Sleep Quality. Although melatonin supplements may or may not improve sleep quality
in older adults (Baskett et al., 2003; Baskett et al., 2001; Wade et al., 2007), to account for any
possible effects of changes in sleep quality alone due to exogenous melatonin, subjects
completed the Pittsburgh Sleep Quality Index (PSQI), (Buysse, Reynolds, Monk, Berman, &
Kupfer, 1989; Buysse et al., 1991; Lemoine, Wade, Katz, Nir, & Zisapel, 2012; Nunes et al.,
2008; Yu et al., 2011), a validated, self-rated questionnaire assessing sleep quality and
disturbances over a 1-month time interval, before and after each 4-week supplementation period.
Nineteen individual items generated seven “component” scores: subjective sleep quality, sleep
latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication,
and daytime dysfunction (see Appendix G).

Data Analyses
Statistical Evaluation. Repeated measures analysis of variance (ANOVA) was used to
compare pre- and post-supplementation values for melatonin and placebo. Data were
normalized. Relationships among autonomic function, baroreflex sensitivity, sleep quality
measures, and melatonin dose were determined with Spearman’s partial correlations.
Friedman’s ANOVA was employed for non-normally distributed data. Comparison of ANS
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assessment variables were performed after age and HbA1C adjustment (Agelink et al., 2001;
Rodrigues et al., 2010). The level of significance for all analyses was set at p < 0.05.
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RESULTS
Ten individuals participated in a double blinded, randomized crossover study comparing
4 weeks of placebo to 4 weeks of 10 mg of melatonin supplementation. Participant
characteristics are displayed in Table V.1. HbA1C values did not significantly differ from visit 1
to visit 3. Careful logging was kept of all potential side effects and events during the study.
After medical examination, the only side effect reported possibly related to melatonin
administration was sleepiness, as reported by one subject.

Autonomic Function & Power Spectral Analysis
Spearman’s partial correlations accounted for age and HbA1C, and key correlations of
interest are included in Table V.2 for review. Friedman’s ANOVA tests were run to determine if
there were significant differences between baseline, placebo and melatonin time points relating
to autonomic ratio tests (E/I Ratio, Valsalva Ratio, 30:15 Ratio) and for all HRV variables.
Ratio testing results indicate that there were increases from the baseline condition to placebo and
from baseline to melatonin; however, none were statistically significant (see Table V.3).
Assessment of individual ANSAR results indicated that that nine of ten individuals presented
with initial ANS dysfunction, ranging from mild to advanced, with the ninth specifically
demonstrated what was likely to be sympathetic withdrawal. Only one participant presented
with no evidence of dysfunction at initial baseline evaluation. Four of these individuals also had
abnormal Sudomotor function, further validating ANSAR findings.
Orthostatic hypotension (OH) testing revealed that none of our participants were
experiencing it. This was tested twice each visit; once with ANSAR BP testing values (seated to
standing) and once with clinic measures values (lying to standing). Likewise, HR was evaluated
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twice each visit for tachycardia (90–130 bpm) (Dimitropoulos et al., 2014), and none
experienced tachycardia, or even notable HR elevation/events throughout testing. All
participants were within a normal or slightly bradycardic range at baseline, placebo and
melatonin conditions. BP values did not vary significantly from baseline to placebo or baseline
to melatonin within the conditions of deep breathing, Valsalva or postural change (30:15), with
the exception of SBP response to deep breathing and SBP response to Valsalva (reported in
Baroreflex Sensitivity).
Individual evaluation of frequency domain components, revealed that Valsalva LFnu was
significantly different between the baseline, placebo and melatonin conditions (p = .045).
Pairwise comparisons revealed significant differences between baseline and melatonin
conditions (p = .042), but not between baseline and placebo (p =.353) or placebo and melatonin
(p = .371) (see Table V.3). Valsalva HFnu was significantly different between the baseline,
placebo and melatonin conditions (p = .045). Pairwise comparisons revealed significant
differences between baseline and melatonin conditions (p = .042), but not between baseline and
placebo (p = .353) or placebo and melatonin (p = .371). Analysis of other power spectral
analysis components (LF, HF and LF/HF ratio) did not reveal any significant differences across
the conditions, at any time point.
Standing SDNN, a time domain component, was significantly higher in the melatonin
measurement (p = .032) than baseline or placebo time measurements. Pairwise comparisons
revealed significant differences between placebo and melatonin (p = .042), but not between
baseline and placebo (p = .371) or baseline and melatonin (p = .353). There were no other
significant interactions relating to time domain variables. See Table V.3 for nonparametric
Friedman ANOVA results.
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Baroreflex Sensitivity
BP and HR were examined across all conditions (deep breathing, Valsalva, 30:15) via
Friedman’s ANOVA, and heart rates did not significantly differ across any of the tested
conditions. SBP response, however, significantly differed across two tests. SBP changes related
to deep breathing [X2 (2, N = 10) = 6.821, p = .033] with pairwise comparisons indicate
differences between baseline and the melatonin condition (p = .042). SBP changes during
Valsalva [X2 (2, N = 10) = 7.947, p = .019] were also present, with pairwise comparisons
indicating significant differences between the placebo and melatonin conditions (p = .030).
A one-way repeated measures ANOVA examined differences in Sudoscan results at
baseline, and after placebo and melatonin conditions. There were no outliers and the data were
normally distributed at each time point, with the assumption of sphericity met by Mauchly’s test
of sphericity. There were no statistically different changes between the conditions over time,
F(2,18) = .055, p = .844, η2 = .006. There were no statistically significant differences between
the means at the different time points (p > .05).

Sleep Quality
A Friedman’s test was conducted to determine if there were significant differences
between the baseline, placebo and melatonin Sleep Questionnaire scores. Median Sleep Quality
scores were generated for all sleep components (subjective sleep quality, sleep latency, sleep
duration, sleep efficiency, sleep disturbances, sleep medication, daytime dysfunction, and global
PSQI (see Appendix G. Subjective sleep quality scores were significantly different between the
baseline, placebo and melatonin scores, X2 (3, N = 10) = 12.929, p = .002. Post hoc analysis
revealed statistically differences in SSQ scores from placebo to melatonin (p < .011). An
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evaluation of subjective sleep quality revealed significant differences between the groups (p <
.002) (Table V.5). Pairwise comparisons were performed with a Bonferroni correction for
multiple comparisons and subjective sleep quality were significantly different between placebo
(Mdn = .00) and melatonin (Mdn = 1.00) interventions (p < .011), not between the placebo and
baseline or baseline and melatonin interventions (see Table V.6). Friedman’s test was performed
on sleep latency, sleep duration, sleep efficiency, sleep disturbances, sleep medication, daytime
dysfunction, and global PSQI, to determine if there were differences between baseline, placebo
and melatonin; however, differences were not statistically significant on these measures (see
Table V.5).
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DISCUSSION
This study aimed to determine baseline ANS function in individuals with T2D with the
intent to investigate to what extent melatonin would improve individual measures. We
hypothesized that the ANS misconducts in T2D, causing a neuroinflammatory response and
leading to impairment, and that ANS function would improve in participants through melatonin
supplementation. However, our results indicate unexpected significant changes from melatonin
supplementation in the HRV variables of LFnu and HFnu. LFnu significantly increased from
baseline after melatonin supplementation (p =.042), as did HFnu (p =.032) during the Valsalva
portion of ANSAR testing. Heathers (2014) discusses the interpretation of HRV variables in
great depth, explaining that the LF component’s dominance is an ongoing debate, with
multifaceted points to consider (Goldstein, Bentho, Park, & Sharabi, 2011; Heathers, 2014) and
not to be confused with HRV components with normalized units, such as LFnu and HFnu.
Theoretically, Heathers submits that one may view that LFnu and HFnu are extremely close in
nature, more clearly representing a continuum of outcomes, representative of not just a deviation
or change but potential changes that happen over a period or continuum and represent small
deviations of measurement rather than two separate variables (Heathers, 2014). Such an
explanation may be plausible over a dynamic activity, such as Valsalva conditions, where a
continuum applies, yet only one specific reading is evaluated, suggesting that our results are
worthy of additional exploration. An interesting finding in our study was a decrease in SBP
during the Valsalva melatonin condition. When viewed collectively with HFnu and LFnu
findings, it becomes of greater interest as we found a positive effect on lowering SBP during
dynamic activity. Likewise, SBP dropped during the DB portion of the melatonin condition
when compared to baseline, showing another adaptation that is likely due to our 4-week
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intervention. Although not measured in the present study, research relating to melatonin
supplementation in T2D should likely utilize 24-hr halter monitors that would capture a range of
values and continuums to evaluate, during sleep, ADLS and activities, paired with clinically
controlled ANSAR testing protocols.
We had hypothesized that ANS function would improve with melatonin supplementation,
creating a positive effect and this was found to be partly true within our study. Power spectral
measures, such as LF, which is generally thought to represent a balance of both the
parasympathetic and sympathetic branches of the ANS and HF, a reflection of parasympathetic
balance, did not significantly change across any of our testing conditions, despite changes in
other measures of consideration. SDNN, however, which is a time domain component
representing the standard deviation of normal RR intervals, rose in the standing condition in our
population of T2D subjects. Subbalakshmi, Adhikari, Poornima, and KN (2015) investigated
correlates of SDNN in T2D and found that higher heart rates, DBP and Q-T dysfunction were
related to a reduction in SDNN in such individuals (Subbalakshmi et al., 2015). Our subjects
were screened via ECG at each visit, and monitored for cardiac abnormalities throughout the
study, and abnormal Q-T interval, DBP and elevated HR findings were not found in our cohort.
Depressed or lowered values of SDNN have been associated with increases in risk of sudden
death, particularly in patients with known heart issues (Farrell et al., 1991; Kleiger, Miller,
Bigger, & Moss, 1987). Previous research indicates that E:I Ratio and SDNN are valid markers
for monitoring CAN, yet our study revealed no significant differences in the evaluation of these
ratios across baseline, placebo and the melatonin conditions (Subbalakshmi, Adhikari, Rao, &
Jeganathan, 2012). Our findings suggest a potential positive effect on SDNN in a small pilot
population of adults with T2D. Furthermore, our entire cohort was overweight or obese (BMI
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Range: 28.7-47.0), with 9 individuals with a BMI over 30, with most participants on BP
lowering medications. HRV parameters have been researched in similar cohorts with
nonsignificant findings; however, this study indicates that individuals with overweight, obese
status may benefit from melatonin supplementation to increase SDNN or impact key
physiological processes, or potentially positively impact this HRV features before more extreme
forms of dysfunction are diagnosed (Stuckey, 2013).
Baroreflex sensitivity was evaluated in our study, yet HR responses to SBP did not reveal
any significant relationships, indicating that vagal cardiac activity most likely did not
significantly change in relationship to HR. Some participants experienced mild bradycardia
(58/59 BPM) during resting conditions, indicating higher parasympathetic tone and possible
sympathetic withdrawal. Of interest, SBP did change in relationship to DB when considering the
baseline to placebo and baseline to melatonin conditions. When examining the data, it is
apparent that the placebo SBP rose higher during the placebo condition in comparison to
baseline, whereas the melatonin SBP dropped significantly, moving the opposite direction. We
cannot explain the rise in SBP across our participants, but it appears that the melatonin had a
positive effect on SBP during DB. In a similar manner, SBP for Valsalva relating to the placebo
and melatonin condition moved the same directions, with the melatonin SBP dropping and the
placebo elevating, although neither was significant in relationship to baseline, the resulting SBPs
were significantly different when compared to each other. Our results are similar to Cavallo,
Daniels, Dolan, Bean, and Khoury (2004) who performed BP research with T1D individuals who
utilized ambulatory BP monitors and took 10 mg of melatonin daily (Cavallo et al., 2004). This
research documented decreases in SBP during sleep; however, our research differs in that they
documented declines in DBP as well while we did not.
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Our evaluation of Sudoscan measures to assess small fiber and autonomic nerve activity
(baroreflex) found no significant differences between baseline, placebo and melatonin
conditions, yet Sudoscan has become a validated and useful tool for measuring sudomotor
changes at the microvascular level (Calvet, Dupin, Winiecki, & Schwarz, 2013). Our results
suggest that a 4-wk 10 mg melatonin intervention does not impact measurable small fiber and
baroreflex changes, although the potential effects of longer supplementation or different
melatonin doses were not evaluated.
Subjective sleep quality significantly improved between the baseline and melatonin
conditions, with 80% of subjects reporting improvements in sleep quality that were likely related
to taking melatonin. While other measures (sleep latency, daytime dysfunction, global PSQI)
improved from baseline to melatonin condition, the effect was not statistically significant.
Similar research has indicated positive results in various PSQI sleep scores while utilizing 4 mg
of melatonin supplementation one hour before bedtime over a 21-day time period, which differs
from our methodology of administering 10 mg 30 minutes prior to bedtime over a 4-week period
(Nunes et al., 2008). As observed in our subjects, 10 mg of melatonin at bedtime likely induces
a positive, measurable effect on sleep quality in individuals with T2D.
Given that melatonin is secreted in the brain in all mammals, with primary synthesis
rising from the pineal gland in a circadian manner orchestrated by the superchiasmatic nucleus,
our introduction of a 10 mg supplementation of melatonin aimed to assist in what would,
naturally be processes that are regulated by light and dark; however, how melatonin is used and
orchestrated within the body can also be affected by medication usage. Our subjects had
numerous health comorbidities and took numerous prescribed and over-the-counter medications
during the course of the study, along with the melatonin supplements. Use of SSRIs to treat
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depression is common in T2D, for example, and have debatable brain interactions (Härtter et al.,
2001). BP medications have varying interactions with melatonin, as melatonin has been found to
lower BP nocturnally in beneficial ways and NSAIDS are known to reduce the efficacy of or
suppress melatonin synthesis, which may have contributed to a type II error in our study (Aygün,
Kaplan, Odaci, Onger, & Altunkaynak, 2012; Grossman et al., 2006; Murphy, Myers, & Badia,
1996; Reiter, Guerrero, Escames, Pappolla, & AcuÑA-Castroviejo, 1997). Melatonin may
protect against neurotoxicity, and combats oxidative effects. We did not, however, account for
potential effects of other medications in this pilot study, although individuals with major
psychotic conditions were excluded from participation.
For the future, a larger cohort, with stricter medication parameters for admission to the
study would be recommended. While our testing measures were rigorous, an additional A1C
value would be advantageous, as would a longer trial period, including a minimum time period
of 8 weeks on 10 mg melatonin in order to evaluate potential positive effects. There are a
number of limitations to consider with this study. We did not control the medications of
individuals participating in the study and do not know how their individual medications relate to
our melatonin intervention. We used HbA1C to check diabetes status, despite literature that
indicates that it is not ideal for working with individuals that might have CAN; however, our
participants did have a prior medical history to confirm their diagnoses. Melatonin and placebo
tablets were distributed to the participants, and although compliance was monitored, we also
trusted that they would regularly participate in the study measures by being responsible to
comply with instructions.
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CONCLUSION
Some beneficial effects on autonomic nervous system function, such as improved SDNN
HRV measures, decreased SBP during deep breathing and Valsalva maneuvers, may result from
supplementation with 10 mg of melatonin at bedtime over a 4-week time period in adults with
T2D who have signs of CAN dysfunction. Its effect on other HRV parameters (LFnu and HFnu)
warrants additional investigation to evaluate the backdrop of dynamics activities, such as
Valsalva breathing maneuvers. Its positive impact on sleep quality is promising, but sleep
quality studies involving T2D individuals should measure the effects of different doses over
longer periods of time and possibly include control groups without diabetes. Future research
should focus on examining melatonin’s potential impact on SDNN in T2D individuals who
exhibit normal BP and HR status, in an effort to determine how protective mechanisms may be
developed in this population.
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TABLES
Table V.1
Participant Characteristics
Variable
Age
Weight
BMI
Category
HbA1C

Cohort
Baseline
Placebo
Melatonin
Overweight
Obese
Baseline, Visit
1
Final, Visit 3

10
N
10
10
10
10
1
9
10
10

Mean
62.8
218.340
218.600
217.620
28.700
36.433

Std.
Dev.
6.030
31.134
30.592
31.156
5.486

Std.
Error
1.907
9.845
9.674
9.852
1.829

7.0%

0.865

0.274

6.9%

0.596

0.188

Min
54
172.600
174.200
171.600
30.500

Max
70
277.800
280.400
276.400
47.000

-

-
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Table V.2
Spearman's Partial Correlations
Variable

Melatonin Valsalva
LF/HF

Melatonin Valsalva
TSP

Placebo Valsalva
TSP

Correlation/Significance Value
Melatonin Valsalva LFnu
.976, p =.000
Melatonin Valsalva HFnu
-.976, p =.000
Time Domain SDNN
Baseline.693, p =.026
Time Domain SDNN Placebo
.729, p =.017
Time Domain SDNN Melatonin
.891, p =.001
Time Domain RMSSD
Baseline.697, p =.025
Time Domain RMSSD Placebo
.867, p =.001
Time Domain RMSSD Melatonin
.745, p =.013
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Table V.3
Log10 Transformed Nonparametric Friedman’s ANOVA Results
Mean Rank
Baseline Placebo Melatonin

N

Test Statistics
Test
Sig.
Statistic

ANSAR Testing
E/I Ratio
1.600
2.300
2.100
10
0.273
Valsalva Ratio
1.850
2.150
2.000
10
0.794
30:15 Ratio
1.450
2.450
2.100
10
0.071
Deep Breathing
LF/HF
1.800
1.800
2.400
10
0.301
LF nu
1.800
1.800
2.400
10
0.301
HF nu
2.200
2.200
1.600
10
0.301
TSP
1.700
2.100
2.200
10
0.497
SDNN
1.600
1.900
2.500
10
0.122
RMSSD
1.750
2.050
2.200
10
0.575
Valsalva Ratio
LF/HF
1.500
2.000
2.500
10
0.082
LF nu
1.400
2.100
2.500
10
*0.045
HF nu
2.600
1.900
1.500
10
*0.045
TSP
2.100
1.900
2.000
10
0.905
SDNN
2.100
2.000
1.900
10
0.905
RMSSD
2.450
1.500
2.050
10
0.097
30:15
LF/HF
2.500
1.800
1.700
10
0.150
LF nu
2.500
1.600
1.900
10
0.122
HF nu
1.850
2.150
2.000
10
0.794
TSP
2.200
1.900
1.900
10
0.741
SDNN
1.900
1.500
2.600
10
*0.032
RMSSD
2.100
1.900
2.000
10
0.889
*Significance is set at .05; see pairwise comparisons table for details.

DOF

2.600
0.462
5.282

2
2
2

2.400
2.400
2.400
1.400
4.200
1.105

2
2
2
2
2
2

5.000
6.200
6.200
0.200
0.200
4.667

2
2
2
2
2
2

3.800
4.200
0.462
0.600
6.889
0.235

2
2
2
2
2
2
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Table V.4
Log10 Transformed Nonparametric Pairwise Comparisons
Variables &
Comparisons
Rank
Valsalva
LF nu
Pairwise
Comparisons
Baseline/Placebo
Baseline/Mel
Placebo/Melatonin

Baseline Placebo
1.400
2.100
Test
Std.
Statistic
Error
-0.700
0.447
-1.100
0.447
-0.400
0.447

Melatonin
2.500
Std. Test
Statistic
-1.565
-2.46
-0.894

N
10

Valsalva
Baseline Placebo
HF nu
2.600
1.900
Pairwise
Test
Std.
Comparisons
Statistic
Error
Melatonin/Placebo
0.400
0.447
Baseline/Melatonin
1.100
0.447
Placebo/Baseline
0.700
0.447

Melatonin
1.500
Std. Test
Statistic
0.894
2.46
1.565

N
10

30:15
Baseline Placebo
SDNN
1.900
1.500
Pairwise
Test
Std.
Comparisons
Statistic
Error
Baseline/Placebo
0.400
0.447
Placebo/Melatonin
-1.100
0.447
Baseline/Melatonin -0.700
0.447
*Significance level is set at .05

Melatonin
2.600
Std. Test
Statistic
0.894
-2.46
-1.565

N
10

N
10
10
10

N
10
10
10

N
10
10
10

Test Statistics
Test
Sig.
Statistic DOF
*0.045 6.200
2
Adj.
Sig.
Sig.
0.118
0.353
0.014 *0.042
0.371
1.000
Test
Sig.
Statistic DOF
*0.045 6.200
2
Adj.
Sig.
Sig.
0.371
1.000
0.014 *0.042
0.118
0.353
Test
Sig.
Statistic DOF
*0.032 6.889
2
Adj.
Sig.
Sig.
0.371
1.000
0.014 *0.042
0.118
0.353
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Table V.5
Friedman’s ANOVA Sleep Questionnaire Results
Mean Rank
Baseline

Placebo Melatonin

N

Test Statistics
Test
Sig. Statistic DOF

Sleep Questionnaire
Subjective Sleep
Quality
1.800
1.450
2.750
10 *0.002
Sleep Latency
2.200
2.100
1.790
10 0.393
Sleep Duration
1.850
1.850
2.300
10 0.368
Sleep Efficiency
1.750
2.250
2.000
10 0.210
Sleep Disturbances
2.000
2.000
2.000
10 1.000
Sleep Medication
1.700
2.000
2.300
10 0.135
Daytime Dysfunction
2,25
1.900
1.850
10 0.368
Global PSQI
2.400
1.850
1.750
10 0.130
*Significance is set at .05; see pairwise comparisons table for details.

12.929
1.867
2
3.125
0.000
4.000
2.000
4.083

2
2
2
2
2
2
2
2
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Table V.6
Nonparametric Pairwise Comparisons
Variables &
Comparisons
Rank
Baseline
Subjective Sleep
Quality
1.800
Pairwise
Test
Comparisons
Statistic
Baseline/Placebo
0.350
Placebo/Melatonin
-1.300
Baseline/Melatonin
-0.950
*Significance level is set at .05

Placebo Melatonin
1.450
Std.
Error
0.447
0.447
0.447

2.750
Std. Test
Statistic
0.783
-2.907
-2.124

N

Test Statistics
Test
Sig. Statistic DOF

10

*0.002

N
10
10
10

Sig.
0.434
0.004
0.034

12.929
Adj.
Sig.
1.000
0.011
0.101

2

2
2
2
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Table V.7
Sudoscan Results
Baseline
Std.
Lg10+1Transformed Mean Dev
1.748 0.142
Feet Mean ESC
Feet Mean
Asymmetry
Hands Mean ESC
Hands Mean
Asymmetry

Placebo

Melatonin

N

Mean
1.761

Std.
Dev Mean
0.173 1.746

Std.
Dev
0.186

10

0.679 0.142

0.825

0.325 0.679

0.436

10

1.704 0.166

1.631

0.233 1.682

0.121

10

0.814 0.367

0.815

0.404 0.754

0.280

10
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CHAPTER VI
CONCLUSIONS
The impact of T2D is significant, affecting increasing numbers of individuals within the
United States and across the globe in the range of 390−392 million and beyond at the present
time. Despite current efforts, diabetes diagnoses have dramatically increased over the past two
decades, rising from 7.6 million globally in 2004 to 21.9 million in 2014. Estimated impact by
the year 2035 is projected to be in the 590 million range globally. Despite medical and research
efforts, the disease has continued to increase in prevalence. With such rising numbers and
increasing health impact, the research community must continue to seek out new ways to prevent
and effectively manage the disease.
The research efforts within this dissertation include three distinct investigations related to
neuropathy screening and treatment. Project I investigated the effectivenss of the 128-Hz tuning
fork, 1-g and 1-g monofilament and the QOL-DN as potential early screening tools while
comparing each measure back to the portable NC-Stat DPN Check nerve conduction device.
These screening tools have been reported to be effective for the screening of DPN in T2D
populations when used together or in conjunction with other bedside tests. Each screening tool
has unique functions as to what type of sensation they are reported to detect and this should be
considered when choosing screening options. Previous research has focused on T2D and limited
PD populations for their research; however, we utilized these screening options within a mixed
population of OOI, PD and T2D subjects. Our results indicated that the 1-g monofilament and
the QOL-DN show promise for development for the screening of early DPN and each correlates
well with the portable NC-Stat DPN Check device. Additionally, the 128-Hz tuning fork
performed well as a measure within the study, despite a lack of correlation back to our criterion.
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HRQOL measurements have become an interest in research, with emphasis developing
on unique subsets of health linked to particular diagnoses such as DN. Several DN-related QOL
instruments have been developed and implemented within research in the past several decades in
an effort to detect DN-related health deficits, in hopes of revealing and treating related
complications and improving QOL. Research efforts, beyond meta-analyses, to compare which
measures might be most effective in an active research population have not been prevalent thus
far, nor have many instruments been compared to nerve conduction studies. Portable nerve
conduction units, such as the NC-Stat DPN Check have more recently come available; thus, in
keeping with advancing neuropathy screening efforts, we sought to compare three accepted DN
specific QOL measures in an OOI, PD and T2D population, while comparing our results back to
the validated NC-Stat DPN Check device. Our results indicate that the QOL-DN and
NeuroQOL-28 effectively predicted our neuropathy derived criterion, making them effective
tools to administer in an OOI, PD and T2D population for early screening and detection of DPN.
Effectively administered in approximately 6 minutes or less, both instruments are research
screening friendly. The NeuroQOL-28 is the easiest to administer and score on site, making it
ideal for community screening efforts.
Research literature proposes that T2D disrupts circadian rythms, alters autonomic
function and places individuals with diabetes at significant risk for cardiovascular events.
Studies have evaluated the effect of melatonin and found it to be beneficial for resetting sleep
patterns in healthy adults. We sought to determine the effectiveness of resetting the ANS in
individuals with T2D, with the hope of improving sleep patterns and positively altering HRV
measures by adminisering a 10 mg dose of over-the-counter melatonin. Our investigation
revealed that there were significant differences between HRV variables relating to LFnu and
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HFnu in the Valsalva condition when comparing the baseline to melatonin and placebo
treatments. This indicates a unique phenomenon to be evaluated further in order to investigate
the continuum of how dynamic movement HRV measures are affected by melatonin
supplementation. SBP in deep breathing and SBP in the Valsalva maneuver were significantly
lowered following melatonin supplementation, indicating a positive effect. SDNN was
signficantly different from baseline to melatonin and between the placebo and melatonin
condition, also indicating a beneficial effect from a 4-wk 10 mg melatonin supplementation.
Sleep quality measures showed significant changes in subjective sleep quality measures,
suggesting that melatonin had a positive impact on perceived sleep quality.
While these pilots studies show promising results, more research in all of these areas is
needed. Future research should focus on the continued development of effective methods for
early detection, disease assessment, management and reversal in DN prone populations to
facilitate the best possible health outcomes.
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A. SCREENING QUESTIONNAIRE
Screening Questionnaire
Name: ____________________________________ Date: _____________________
Please answer the following questions as completely and honestly as possible.
Current Age: __________________ Gender: ___________________
Circle One
Yes

No

Have you ever been told you have high blood sugar, prediabetes or diabetes?

Yes

No

Do you have a first degree relative that has diabetes?

Yes

No

Have you been told that you have type I diabetes?

Yes

No

Have you been told that you have type 2 diabetes?
If yes, how long have you had diabetes? _________ years/diagnosis date

Yes

No

Have you been told you have hepatitis B or C?

Yes

No

Have you been told you have HIV?

Yes

No

Do you currently have a sore, ulcer, cut or other damage to either foot?

Yes

No

Have you ever had any part of either lower extremity amputated?

Yes

No

Do you have any numbness or pain in your feet?

Yes

No

Do you have any type of foot deformity?

Yes

No
Have you been diagnosed with peripheral vascular disease or nerve problems in
your lower extremities?

Yes

No

Have you been diagnosed with kidney or liver problems, or are you on dialysis?

Yes

No

Are you currently on any medications? (Please list at the bottom)

Yes

No

Do you have any type of visual impairment?

Yes

No

Do you smoke?

If yes to any of the above, please explain:
______________________________________________________________________
______________________________________________________________________
To be filled out by research staff: Height: _______________ Weight: ____________
BMI: _____________Waist circumference: _____________ Seated BP: ___________
Approved to be in the study? _______________ HbA1C Value: _____________
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B. QOL-DN
Quality of Life Questionnaire (QOL-DN)
Diabetic Neuropathy Version

Name:_______________________________ Date: __________
Subject #: _______________________________Visit: _________
Date of Birth: ___________________________Gender: Male Female

Race:

White

Black

Hispanic

1

2

Other:
Native American
Pacific Area
Native American includes American Indian, Eskimo, and Aleut
Pacific Area Embraces Polynesian (including Hawaiian and Samoan), Micronesian (including
Guamanian), and Melanesian
Do you have diabetes?

Yes

No

Do you have neuropathy (nerve damage)?

Yes

No

Do you have any known medical condition that causes pain or weakness?
-- If yes, what condition:
How long have you had any symptoms of neuropathy? _______Years
Are the symptoms the same on the right as on the left? .....
No…which is worse?
Left
Right

Yes

Months

Yes
…only one side?

Are the symptoms usually worse at night? ..........................

No

Yes

Left

Right

No

How many medications or other treatments have you used for any of these symptoms (both in the past and
presently)?
Please write the number on the line. __________________________________________
Have you ever been told that you have neuropathy? .......... Yes
Have you ever had ulcer(s) on your feet?............................ Yes
Have you ever had gangrene? ............................................ Yes
Have you had any toes (or fingers) amputated?.................. Yes

No
No
No
No

In the past 4 weeks, have you had a problem with involuntary urinating when laughing or coughing?
Yes No
(MALES ONLY) In the past 4 weeks, have you had a problem with obtaining or maintaining erections?
Yes
No
(FEMALES ONLY) In the past 4 weeks, have you had a problem with vaginal dryness during intercourse?
Yes
No
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Part I: Symptoms
Have you had any of the following symptoms in the past 4 weeks? Please Check all that apply.

Answer these questions according to the following scale:

Severe
problem

Moderate
problem

Mild
problem

Not a
problem

Part II: Activities of Daily Life

Very mild
problem

Feet
Legs
Hands
Arms
None
1. Numbness................................................................ .......................................... ............. ……….....
2. Tingling, Pins and Needles……..........…................ .......................................... ............. ……….....
3. Electric Shocks ........................................................ .......................................... ............. ……….....
4. Other Unusual Sensations....................................... .......................................... ............. ……….....
5. Superficial Pain....................................................... .......................................... ............. ……….....
6. Deep Pain ................................................................. .......................................... ............. ……….....
7. Weakness.................................................................. .......................................... ............. ……….....

0

1

2

3

4

D
D

D
D

D
D

D
D

D
D

D

D

D

D

D

D
D

D
D

D
D

D
D

D
D

D
D
D
D
D

D
D
D
D
D

D
D
D
D
D

D
D
D
D
D

D
D
D
D
D

D

D

D

D

D

D

D

D

D

D

8. In the past 4 weeks, has pain kept you awake or woken you at night?
10.
In the
the past
past 4 weeks, has
havethe
you
burned
or injured
been unable
9. In
touch
of bed
sheets,yourself
clothes, and
or wearing
shoesto feel it?
11. In the past 4 weeks, have any symptoms kept you from doing your usual activities
during the day?
12. In the past 4 weeks, have you had difficulty doing fine movements with your
fingers, like buttoning your clothes, turning pages in a book, picking up coins
from a table?
13. In the past 4 weeks, have you felt unsteady on your feet when you walk?
14. In the past 4 weeks, have you had any problem getting out of a chair without
pushing with your hands?
15. In the past 4 weeks, have you had a problem walking down stairs?
16. In the past 4 weeks, have you been unable to feel your feet when walking?
17. In the past 4 weeks, have you been unable to tell hot from cold water with your hands?
18. In the past 4 weeks, have you been unable to tell hot from cold water with your feet?
19. In the past 4 weeks, have you had a problem with vomiting, particularly after meals
(but not due to flu or other illness)?
20. In the past 4 weeks, have you had a problem with diarrhea and/or loss of bowel
control?
21. In the past 4 weeks, have you had a problem with fainting or dizziness when you
stand?

In the past 4 weeks, how much difficulty have you had performing the following activities:
22. Bathing/Showering?……………………………………………………..…...
23. Dressing? …………………………………………………………….…...
24. Walking? …………………………………………………………...…….
25. Getting on or off the toilet? …………………………………………..…..
26. Using eating utensils? …………………………………………………....

D
D
D
D
D

D
D
D
D
D

D
D
D
D
D

D
D
D
D
D

D
D
D
D
D

Not at all

A little

Somewhat

Moderately

Severely
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0

1

2

3

4

27. Cut down on the amount of time you spent on work or other activities?………

D

D

D

D

D

28. Accomplished less than you would like?……………………………………….

D

D

D

D

D

29. Were limited in the kind of work or other activities you could perform?……....

D

D

D

D

D

30. Had difficulty performing the work/other activities (it took extra effort)?……..

D

D

D

D

D

Answer these questions according to the following scale:
In the past 4 weeks, have you had any of the following problems with your work or
other regular daily activities as a result of your physical or emotional
health?

31. In general, would you say your health now is:

Excellent
D

Very Good
D

Good
D

Fair
D

Poor
D

32. Compared with 3 months ago, how would you rate your health in general now?

Much
Worse
D

Answer these questions according to the following scale:

0

1

2

3

4

33. In the past 4 weeks, to what extent has your physical health interfered with your normal
social activities with family, friends, neighbors, or groups?

D

D

D

D

D

34. In the past 4 weeks, how much did pain interfere with your normal work (including
work both outside the home and housework)?

D

D

D

D

D

35. In the past 4 weeks, how much did weakness or shakiness interfere with your normal
work (including work both outside the home and housework)?

D

D

D

D

D

Not at all

Severely

Somewhat
Worse
D

Moderately

About
the Same
D

Somewhat

Somewhat
Better
D

A little

Much
Better
D
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Manual and Scoring Algorithm for QOL-DN
1) Description:
The QOL-DN is a self-administered questionnaire, designed to capture and quantify the impact
of diabetic neuropathy on the quality of life of individual patients with diabetic neuropathy.
Fourteen of the items are of a health-related, biographical nature and are not scored. These are on
the front page, and they are not numbered nor scored. The remaining 35 scored questions are
numbered items that comprise the entire scale, and they are arranged thematically so that the
wording of the questions and the type of response is grouped together. However, the content and
topic of each individual question concerns particular functions or symptoms that are related to
the following themes:
Total Quality of Life Score
Physical Functioning/Large Fiber Neuropathy
Activities of Daily Living (ADLs)
Symptoms
Small Fiber Neuropathy
Autonomic Neuropathy
These scales and the administration of the questionnaire are described in detail below. In general,
items 1-7 (Part I) are a simple inventory of symptoms of neuropathy. The presence of the
symptom is checked in whichever box applies, and an absence of a symptom is checked under
“none.” Positive responses are scored as 1; and negative responses, as 0. Items 8-35 (Part II)
pertain to Activities of Daily Life, and most of these are scaled on a 5-point Likert scale ranging
from 0 (“Not a problem”) to 4 (“Severe problem”). However, Questions 31 and 32 are scored
differently. In Question 31, “Good”, the middle item, is scored as O. “Very Good” is scored as –
1, Excellent” is scored as –2. “Fair is scored as 1, and “Poor” is scored as 2. In Question 32,
“About the Same”, the middle item, is scored as 0. "Somewhat better" is scored as –1, "Much
better" is scored as -2. "Somewhat worse" is scored as 1, and "Much worse" is scored as 2.
A final important point of the overall instrument is that the patient/subject is instructed to rate
most items over the last 4 weeks, so responses should be interpreted as cumulative over that
time period - not merely an inventory of the patient’s status at the moment of filling out the
questionnaire.
2) Administering the questionnaire:
Administering the questionnaire to the patient or experimental subject is very straightforward:
the patient simply fills out the paper form. It is important that the patient is in a quiet area, free of
undue distractions, and patients are encouraged to answer the questions themselves (i.e. spouses
and significant others should not fill out the questionnaire or influence the patient’s responses).
These are subjective patient responses. The responses are coded and scored when they are
entered into the appropriate database, and the algorithm is supplied below. All questions should
be answered. The gender-specific sexual functions questions located on the biographical page
should obviously be answered according to gender. It is not recommended to compare responses
on this questionnaire directly to the patient’s medical history or any other sources of similar
information such as other pain questionnaires, etc.
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3) Data Accumulation:
De-identified data are accumulated in database format (e.g. MS Excel 2000) and entered by a
HIPAA certified research assistant. The original hard copies of the responses are retained as
source documents in the patient/subject’s medical record. The database is secured by password
access to authorized users only. The structure is that of a single table containing all fields for a
single questionnaire.
4) Sub-scales and Scoring Algorithm:
The scales listed above were determined based on an exploratory factor analysis, so the questions
have loaded into their respective domains. All symptoms (1-7) are scored as either a 1 or a 0,
indicating a presence or absence of the symptom. With the exception of Questions 31, and 32,
the other items are scored according to the 5-point Likert Scale (0-4, “No Problem” to “Severe
Problem”). In Question 31, “Good”, the middle item, is scored as O. “Very Good” is scored as –
1, Excellent” is scored as –2. “Fair is scored as 1, and “Poor” is scored as 2. In Question 32,
“About the Same”, the middle item, is scored as 0. "Somewhat better" is scored as –1, "Much
better" is scored as -2. "Somewhat worse" is scored as 1, and "Much worse" is scored as 2.
The Total QOL and five domains should be summed as follows:
Total QOL Σ(1-7, 8-35)
Physical Functioning/Large Fiber Σ(8, 11, 13-15, 24, 27-35 )
Activities of Daily Living (ADLs) Σ(12, 22, 23, 25, 26)
Symptoms Σ(1-7, 9)
Small Fiber Σ(10, 16, 17, 18)
Autonomic Σ(19, 20, 21)
These scales and subscales are calculated without weighting of any kind, and reported as the
integer sum of the listed questionnaire items.
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C. PN-QOL-97

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

SCORING ALGORITHM
PERIPHERAL NEUROPATHY QOL-97 SCORING FORM

Scale/Item Numbers

1

Physical Health Dimensions
Physical Functioning-11
3a
0
3b
0
3c
0
3d
0
3e
0
3f
0
3g
0
3h
0
3i
0
3j
0
14c
100

Response (raw score)
2
3
4
5

Subtotal Final Score
0-100 point scale

100
100
100
100
100
100
100
100
100
100
50
Total

25
____

0


11 =

____
____
____
____
____
____
____
____
____
____
____
____

Role Limitations Due to Physical Health-6
4a
0
25
50
4b
0
25
50
4c
0
25
50
4d
0
25
50
1
18b
100
75
50
14e
100
75
50
Total

75
75
75
75
25
25
____

100
100
100
100
0
0


6=

____
____
____
____
____
____
____

40
25
40
40
25
25
25
____

20
0
20
20
0
0
0


0
0
0
7=

____
____
____
____
____
____
____
____

Disease-Targeted Pain
7
8
16
17
24a
24b
24g

1

100
100
100
100
100
100
100

50
50
50
50
50
50
50
50
50
50
75

6

80
75
80
80
75
75
75

60
50
60
60
50
50
50
Total

For question 18a–18h recode to missing if the response is “Don’t know.”
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SCORING ALGORITHM (cont.)
PERIPHERAL NEUROPATHY QOL-97 SCORING FORM

Scale/Item Numbers

1

Response (raw score)
2
3
4
5

Energy/Fatigue-5
9a
9e
9g
9i
18d

100
100
0
0
100

75
75
25
25
75

50
50
50
50
50
Total

25
25
75
75
25
____

Upper Extremities
14a
14b
14d
14g
24c
24f

100
100
100
100
100
100

75
75
75
75
75
75

50
50
50
50
50
50
Total

Balance
15
18e
18f
18g
18h
22e
24d
24e

100
100
100
100
100
100
100
100

75
75
75
75
75
75
75
75

Mental Health Dimensions
Self Esteem
22a
31a
31b
31c
31d
31e

0
100
0
100
0
0

25
75
25
75
25
25

6

Subtotal Final Score
0-100 point scale

0
0
100
100
0


5=

____
____
____
____
____
____

25
25
25
25
25
25
____

0
0
0
0
0
0


6=

____
____
____
____
____
____
____

50
50
50
50
50
50
50
50
Total

25
25
25
25
25
25
25
25
____

0
0
0
0
0
0
0
0


8=

____
____
____
____
____
____
____
____
____

50
50
50
50
50
50
Total

75
25
75
25
75
75
____

100
0
100
0
100
100


6=

____
____
____
____
____
____
____
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SCORING ALGORITHM (cont.)
PERIPHERAL NEUROPATHY QOL-97 SCORING FORM

Scale/Item Numbers

1

Response (raw score)
2
3
4
5

Emotional Well Being-7
9b
9c
9d
9f
9h
9j
9k

0
0
100
0
100
0
100

25
25
75
25
75
25
75

50
50
50
50
50
50
50
Total

75
75
25
75
25
75
25
____

0
0
0

25
25
25

50
50
50
Total

0
0
0

25
25
25

50
50
50
Total

6

Subtotal Final Score
0-100 point scale

100
100
0
100
0
100
0


7=

____
____
____
____
____
____
____
____

75
75
75
____

100
100
100


3=

____
____
____
____

75
75
75
____

100
100
100


3=

____
____
____
____

75
75
75
____

100
100
100


3=

____
____
____
____

25
75
25
75
25
75
75
____

0
100
0
100
0
100
100


7=

____
____
____
____
____
____
____
____

Stigma
23a
23b
23c

Cognitive Function
13d
13e
13f

Role Limitations Due to Emotional Problems
5a
0
25
50
5b
0
25
50
5c
0
25
50
Total
General Health Dimensions
General Health Perceptions-7
1
100
75
50
11a
0
25
50
11b
100
75
50
11c
0
25
50
11d
100
75
50
11e
0
25
50
11f
0
25
50
Total
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SCORING ALGORITHM (cont.)
PERIPHERAL NEUROPATHY QOL-97 SCORING FORM

Scale/Item Numbers

1

Response (raw score)
2
3
4
5

100
100
0
0
0

75
75
25
25
25

6

Subtotal Final Score
0-100 point scale

Sleep
18a
29a
29b
29c
29d

Disease-Targeted Social Functioning
6
100
75
10
0
25
14f
100
75
18c
100
75
19
100
75
22b
100
75
22c
0
25
22d
0
25
22f
0
25

50
50
50
50
50
Total

25
25
75
75
75
____

0
0
100
100
100


5=

____
____
____
____
____
____

50
50
50
50
50
50
50
50
50
Total

25
75
25
25
25
25
75
75
75
____

0
100
0
0
0
0
100
100
100


9=

____
____
____
____
____
____
____
____
____
____

Sexual Function2
25
26

100
100

66.7
75

33.3 0
50
25
Total ____

0


2=

____
____
____

Health Distress
13a
13b
13c

0
0
0

25
25
25

50
50
50
Total

100
100
100


3=

____
____
____
____

2

75
75
75
____

Recode questions 25 and 26 to missing if the response to question 28 is “no”.
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SCORING ALGORITHM (cont.)
PERIPHERAL NEUROPATHY QOL-97 SCORING FORM

Scale/Item Numbers

1

Response (raw score)
2
3
4
5

6

Subtotal Final Score3
0-100 point scale

Single Items
Severity
21

100

75

0

-

_____ =

____

0

-

_____ =

____

0

-

_____ =

____

Disability days
12
20

50

25

(recoding not relevant)

Health Change
2

100

Overall Health Rating
30

(no recoding necessary)

75

Satisfaction with Sexual Functioning4
27
100
75
Sexual Activity5
28

3

50

50

25

25

(recoding not relevant)

Note: The total number of items in each scale is listed as the divisor for each subtotal.

However, where all items in a scale are not answered, the divisor will be lower.
4

Recode question 27 to missing if the response to question 28 is “no”.

5

Item 28 on sexual activity is not counted as a quality-of-life item, but it is used for the scoring

of the sexual function scale and the satisfaction with sexual functioning item.
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Physical Health Summary Score:
(((Pain Scale - 65.48214286) / 21.91750078) * 0.19922 )

= ___________________

(((Physical Functioning - 72.96401515) / 25.74274538) * 0.20156 )

= ___________________

(((Balance - 79.18080357) / 19.11524675) * 0.19139 )

= ___________________

(((Social Functioning - 80.53993056) / 19.63613561) * 0.12088 )

= ___________________

(((Role limitations—Physical Health - 65.84375000) / 33.29916333) * 0.11810 )

= ___________________

(((Energy/fatigue - 56.80000000) / 23.41394154) * 0.12125 )

= ___________________

(((Sleep Scale -71.14375000) / 18.40712984) * 0.12537 )

= ___________________

(((Upper Extremities -91.89583333) / 11.21486152) * 0.12555 )

= ___________________

(((General Health Perceptions - 58.61904762) / 20.30108094) * 0.086309 )

= ___________________

(((Emotional Well Being - 71.40714286) / 17.15597900) *-0.08927 )

= ___________________

(((Cognitive Functioning - 76.75000000) / 20.07002509) *-0.03316 )

= ___________________

(((Self-esteem -79.91666667) / 16.93850049) *-0.05138 )

= ___________________

(((Health Distress - 68.25000000) / 25.46321911) * 0.02889 )

= ___________________

(((Role limitations—Emotional - 66.66666667) / 38.61162968) * 0.02849 )

= ___________________

(((Stigma - 93.54166667) / 14.76342984) *-0.00849 )

= ___________________

(((Sexual Function - 68.67094937) / 34.22217052) * 0.043288 )

= ___________________

Subtotal = ___________________

(((Subtotal - 0.0161271) / 0.9981705) * 10) + 50

= Physical Health Summary Score
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Mental Health Summary Score:
(((Pain Scale - 65.48214286) / 21.91750078) * -0.05253 )

= ___________________

(((Physical Functioning - 72.96401515) / 25.74274538) * -0.07308 )

= ___________________

(((Balance - 79.18080357) / 19.11524675) * -0.07198 )

= ___________________

(((Social Functioning - 80.53993056) / 19.63613561) * 0.06578 )

= ___________________

(((Energy/fatigue - 56.80000000) / 23.41394154) * 0.05238 )

= ___________________

(((Role limitations—Physical Health - 65.84375000) / 33.29916333) * 0.06440 )

= ___________________

(((Sleep Scale - 71.14375000) / 18.40712984) * -0.01279 )

= ___________________

(((Upper Extremities - 91.89583333) / 11.21486152) * -0.03518 )

= ___________________

(((General Health Perceptions - 58.61904762) / 20.30108094) * 0.094966 )

= ___________________

(((Emotional Well Being - 71.40714286) / 17.15597900) * 0.29507 )

= ___________________

(((Self-esteem - 79.91666667) / 16.93850049) * 0.21516 )

= ___________________

(((Cognitive Functioning - 76.75000000) / 20.07002509) * 0.20817 )

= ___________________

(((Role limitations—Emotional - 66.66666667) / 38.61162968) * 0.15108 )

= ___________________

(((Health Distress - 68.25000000) / 25.46321911) * 0.15045 )

= ___________________

(((Stigma - 93.54166667) / 14.76342984) * 0.13053 )

= ___________________

(((Sexual Function - 68.67094937) / 34.22217052) * 0.076409 )

= ___________________

Subtotal = ___________________
(((Subtotal - 0.0137913) / 0.9993292) *10 ) + 50

= Mental Health Summary Score

221

SAS Code:
physic1=
(((DTPAIN-65.48214286)/21.91750078)
(((PHYFUN-72.96401515)/25.74274538)
(((BALANC-79.18080357)/19.11524675)
(((DTSFUN-80.53993056)/19.63613561)
(((PHROLE-65.84375000)/33.29916333)
(((ENERGY-56.80000000)/23.41394154)
(((SLEEP5-71.14375000)/18.40712984)
(((UPPERE-91.89583333)/11.21486152)
(((PERCEP-58.61904762)/20.30108094)
(((EMOTWB-71.40714286)/17.15597900)
(((COGFUN-76.75000000)/20.07002509)
(((SELFES-79.91666667)/16.93850049)
(((HDISTR-68.25000000)/25.46321911)
(((EMROLE-66.66666667)/38.61162968)
(((STIGMA-93.54166667)/14.76342984)
(((SEX2 -68.67094937)/34.22217052)

* 0.19922 ) +
* 0.20156 ) +
* 0.19139 ) +
* 0.12088 ) +
* 0.11810 ) +
* 0.12125 ) +
* 0.12537 ) +
* 0.12555 ) +
* 0.086309) +
*-0.08927 ) +
*-0.03316 ) +
*-0.05138 ) +
* 0.02889 ) +
* 0.02849 ) +
*-0.00849 ) +
* 0.043288 );

mental1=
(((DTPAIN-65.48214286)/21.91750078)
(((PHYFUN-72.96401515)/25.74274538)
(((BALANC-79.18080357)/19.11524675)
(((DTSFUN-80.53993056)/19.63613561)
(((ENERGY-56.80000000)/23.41394154)
(((PHROLE-65.84375000)/33.29916333)
(((SLEEP5-71.14375000)/18.40712984)
(((UPPERE-91.89583333)/11.21486152)
(((PERCEP-58.61904762)/20.30108094)
(((EMOTWB-71.40714286)/17.15597900)
(((SELFES-79.91666667)/16.93850049)
(((COGFUN-76.75000000)/20.07002509)
(((EMROLE-66.66666667)/38.61162968)
(((HDISTR-68.25000000)/25.46321911)
(((STIGMA-93.54166667)/14.76342984)
(((SEX2 -68.67094937)/34.22217052)

*-0.05253 ) +
*-0.07308 ) +
*-0.07198 ) +
* 0.06578 ) +
* 0.05238 ) +
* 0.06440 ) +
*-0.01279 ) +
*-0.03518 ) +
* 0.094966) +
* 0.29507 ) +
* 0.21516 ) +
* 0.20817 ) +
* 0.15108 ) +
* 0.15045 ) +
* 0.13053 ) +
* 0.076409 );

t_physic=(((physic1-0.0161271) /0.9981705) *10) +50;
t_mental=(((mental1-0.0137913) /0.9993292)
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D. NEUROQOL-28

NEUROPATHY-SPECIFIC
QUALITY OF LIFE
Questionnaire
Instructions
UK Version

Patient Identification
Visit
Visit Date

 These questions ask about the effect your FOOT PROBLEMS may
have on your daily life and well-being. By foot problems we mean
lost or reduced feeling in your extremities, pain, discomfort and/or
ulcers (open sores) on your feet and, in some cases unsteadiness
while walking or standing.
 Please note that many questions have two parts. Answer every
question by ticking one box for each part (tick two boxes per line).
Please make sure you answer all questions.
 Please concentrate on how you have felt IN THE PAST 4 WEEKS
for all of the questions.
 There are no right or wrong answers. If you are unsure about how to
answer a question, you can ask the person who gave you the
questionnaire. Please DO NOT ask a relative or friend to help you.
 All of your responses will be held strictly confidential.
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In the past 4 weeks
how often have you
experienced the
following symptoms?

All
the
time

Most
of the
time

Some
of the
time

Occasio
nally

Never

How much bother did
this cause you?
Very
Some
None
much
bother

1. Burning in your legs
or feet
2. Excessive heat or
cold in your legs or
feet
3. Pins and needles in
your legs or feet
4. Shooting or stabbing
pain in your legs or
feet
5. Throbbing in your
legs or feet
6. Sensations in your
legs or feet that
make them jump
7. Irritation of the skin
caused by something
touching your feet,
such as bedsheets or
socks

A. Have these painful symptoms
reduced your quality of life?

In the past 4 weeks
how often have you
experienced the
following symptoms?
8. Numbness in your
feet

All
the
time

Very
much

Most
of the
time

Some
of the
time

Quite a
lot

Occasio
nally

A
little

Somewhat

Not at all

How much bother did
this cause you?
Never

Very
much

Some
bother

None
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9. Inability to feel the
difference between
hot and cold with
your feet
10. Inability to feel
objects with your
feet

B. Have these last three symptoms
reduced your quality of life?

In the past 4
weeks how often
have you
experienced the
following
symptoms?

Very
much

Quite a lot

A
little

Somewhat

Not at all

How much bother did
this cause you?
All
the
time

Most
of the
time

Some
of the
time

Occas
ionall
y

Never

Very
much

Some
bother

None

11. Weakness in
your hands

12. Problems with
balance or
unsteadiness
while walking
13. Problems with
balance or
unsteadiness
while standing

C. Have these last three
symptoms reduced your
quality of life?

Very
much

Quite a lot

Somewhat

A little

Not at all
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The following questions ask about how your FOOT PROBLEMS affect
your daily activities, relationships and feelings.
Are you in PAID WORK?
In the past 4
weeks, HOW
MUCH have your
foot problems
interfered with
your:

Yes

No

If YES please go to Question 14.
If NO please go to Question 15.
How important is this
aspect of your life to you?

Very
much

Quite a
lot

Some
what

A little

Not at all

Very
much

Some
what

Not
at all

14. Ability to
perform your
paid work?
15. Ability to
perform tasks
around the house
or garden?
16. Ability to take
part in leisure
activities?
D. Have these changes in daily
activities as a result of your
foot problems reduced your
quality of life?

Very
much

Quite a lot

Somewhat

Not at all

How important is this
aspect of your life to you?

In the past 4 weeks:
Very
Much
17. How much
have your foot
problems
interfered with
your
relationships
with people
close to you?

A little

Quite a
lot

Some
What

A little

Not at all

Very
much

Some
what

Not
at all
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18.Have you felt
more physically
dependent than
you would like
to be on people
close to you as a
result of your
foot problems?
19.Have you felt
more
emotionally
dependent than
you would like
to be on people
close to you as a
result of your
foot problems?
20. has your role in
the family
changed as a
result of your
foot problems?

E. Have these changes in
relationships with other
people as a result of your
foot problems reduced your
quality of life?

Very
much

Quite a lot

Somewhat

A little

Not at all

How much bother did
this cause you?

How much do
you agree with
the following
statements:
21. People treat me
differently
from other
people as a
result of my
foot problems.

Compl
etely
agree

Partly
agree

Neither
agree or

Partly
disagree

Completely
disagree

Very
much

Some
bother

None
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22. I feel older
than my years
as a result of
my foot
problems.
23. My self confidence is
affected as a
result of my
foot problems.

24. My foot
problems make
my life a
struggle.

25. I generally feel
frustrated
because of my
foot problems.
26. My foot
problems
cause me
embarrassment
.

27. I feel depressed

because of my
foot problems

F. Have these
feelings about
yourself as a
result of your
foot problems
reduced your
quality of life?

Very
much

Quite a lot

Some
what

A little

Not at all
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Very
much

Quite a lot

Some
what

A little

Not at all

Excellent

Very good

Good

Fair

Poor

28. Overall, I
would say
problems with
my feet
reduced my
Quality of
Life:

29. Overall, I
would rate my
quality of life
as:
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Assessment of Neuropathy- Specific Quality of Life (NeuroQoL)
The 35 item Neuropathy- Specific Quality of Life instrument (NeuroQoL) is an
hierarchically organized scale (Fries and Singh, 1996; Spilker and Revicki, 1996) that assesses
patients subjective reports (Gill and Feinstein, 1994) of functioning and quality of life in six
specific domains. Following the hierarchical model, the base of each domain is assessed with
items that measure specific somatic experiences, social and personal dysfunctions and emotional
states, and end with an overall assessment of quality of life or satisfaction with experiences in
that domain.
Thirteen items assess specific somatic experiences in three domains: i.e., Pain (items 17), Lost/reduced feeling (items 8-10); and Diffuse sensory-motor symptoms (items 11-13).
Specific functional, social and emotional experiences are assessed in three domains with an
additional 14 items: Restrictions in activities of daily living (items 14–16), and Disruptions in
social relationships (items 17-20), and Emotional distress (items 21- 27). The frequency of these
experiences, somatic, social and affective, are reported on 5 point scales (never, to all of the
time). A participant's score for a domain is the mean of the items in that scale with higher scores
representing more severe symptoms or greater disruption in functioning.
For each of these 27, specific items, patients are asked to judge the degree to which the
somatic experience, restriction of activities, social function and emotional states have been a
bother and/or important to them (O’Boyle, McGee and Joyce,1994). The bother /importance
items were scored as 1=none; 2= some; 3= very. Weighted scores were calculated by multiplying
the scale score by the corresponding bother/importance score. Multiplying the frequency of
experience by its bother and importance provides a more detailed picture of the degree to which
the specific experience impacts satisfaction or quality of life.
In accord with the hierarchical model (Fries and Singh, 1996; Spilker and Revicki, 1996)
and the accepted definition of quality of life as an overall judgment of satisfaction (Spilker B (ed)
(1996). Quality of life and pharmacoeconomics in clinical trials; Leventhal H & Colman S.
Quality of life: a process view. Psychol Health 12:753-767), a single item assesses quality of life
in each of the six domains (items A, B, C, D, E & F).
The two final items in the scale complete the hierarchical approach by assessing overall
satisfaction or quality of life, one item requesting that the patient make a judgment specific to his
or her experience with foot problems, and a final item asking for an overall judgment of quality
of life (Spilker B (ed) (1996). Quality of life and pharmacoeconomics in clinical trials).
Satisfaction with quality of life in each domain and overall satisfaction are assessed using
five point scales (not at all to very much). (NOTE: as the 6-item (lettered) QoL scale
significantly correlates with a 1-item overall DN impact on QoL scale (item 28) at .88, item 28
could replace a 6-item scale if a shorter version of the NeuroQoL is needed. A short version of
the NeuroQoL should, therefore, include items 1-13 (symptoms); 14-27 (psychosocial
functioning); 28 (DN-specific impact on QoL) and 29 (overall QoL)).
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E. NEUROLOGICAL FORM

Effect of Melatonin on ANS Study
PATIENT NAME:
SUBJECT ID:
DATE:
PHYSICAL EXAMINATION
SITE:
HEAD, NECK
EYES
EARS, NOSE, THROAT
LYMPH NODES
CHEST, LUNGS
HEART
ABDOMEN
MUSCULOSKELETAL
EXTREMITIES
PERIPHERAL
VASCULAR
SKIN
OTHER:

NORMAL

ABNORMAL

COMMENT

ANEMIA
CYANOSIS
JAUNDICE
CLUBBING
JVP
EDEMA

SUPINE BP

PULSE

SITTING BP

PULSE

STANDING BP

PULSE

BMI
Exam performed by:______________________________
Transcribed by:______________________________

HEIGHT
WEIGHT

Inches
Lbs.
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F. INCLUSION/EXCLUSION SCREENING FORM
Melatonin and Autonomic Nervous System (ANS) Function
INCLUSION/EXCLUSION SCREENING FORM
Subject Name __________________Subject #______Visit Date______________
INCLUSION CRITERIA
Must be “YES” for inclusion in the study.
YES
NO Subjects may be males or non-pregnant, non-lactating females age
40-75 years of age
YES

NO Subject must have been diagnosed with type 2 diabetes mellitus

EXCLUSION CRITERIA
Must be “NO” for Inclusion in the study.
YES

NO History of congestive heart failure

YES

NO Recent myocardial infarction or cardiovascular event within last year

YES
NO History of major macrovascular events such as myocardial infarction or
stroke within the last 6 months
YES

NO History of unstable or irregular heartbeat

YES

NO Presence of end-stage renal disease (undergoing renal dialysis)

YES

NO Presence of moderate or severe hepatic insufficiency

YES

NO Presence of severe orthostatic hypotension

YES

NO Current tobacco use

YES

NO Presence of Type 1 diabetes

YES

NO Presence of hepatitis B or C

YES

NO Presence of HIV

YES

NO Presence of active malignancy (diagnosed or treated in last year)

YES

NO Night time shift work

YES

NO Current or recent use of supplemental melatonin (within 6 months)
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YES

NO Amputation of any portion of a hand or a foot

YES
NO Other serious medical conditions which would compromise the subject’s
participation, in the opinion of the investigator
YES

NO Participation in another clinical trial concurrently or within the last month

FINAL DETERMINATION OF ELIGIBILITY (CHECK ONE)
Based on medical history, physical exam, and lab tests patient has met all study criteria and
can be enrolled in the study.
Patient failed the screening process required for entry into the study. Please indicate reason
for screen failure.
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________

Transcribed By________________________ Date_________________

Reviewed By________________________ Date _________________
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G. PSQI
PITTSBURGH SLEEP QUALITY INDEX (PSQI)
INSTRUCTIONS: The following questions relate to your usual sleep habits during the past month only.
Your answers should indicate the most accurate reply for the majority of days and nights in the past month.
Please answer all questions.
During the past month, when have you usually gone to bed at night?
USUAL BED TIME
_
During the past month, how long (in minutes) has it usually take you to fall asleep each night?
NUMBER OF MINUTES
During the past month, when have you usually gotten up in the morning?
USUAL GETTING UP TIME _
_

During the past month, how many hours of actual sleep did you get at night? {This may be different than the
number of hours you spend in bed.)
HOURS OF SLEEP PER NIGHT
_

INSTRUCTIONS: For each of the remaining questions, check the one best response.
Please answer all questions.

During the past month, how often have you had trouble sleeping because you...

(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)
(j)

Not during the Less than
past month
once a week
...cannot get to sleep within 30 minutes D
D
...wake up in the middle of the night or
early morning
D
D
...have to get up to use the bathroom
D
D
...cannot breathe comfortably
D
D
...cough or snore loudly
D
D
...feel too cold
D
D
...feel too hot
D
D
...had bad dreams
D
D
...have pain
D
D
Other reason(s), please describe

Once or twice Three or more
a week
times a week
D
D
D
D
D
D
D
D
D
D

D
D
D
D
D
D
D
D

How often during the past month have
you had trouble sleeping because of this?
No problem
at all

Only a very
slight problem

Somewhat of
a problem

A very
big problem

D

D

D

D
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During the past month, how would you
rate your sleep quality overall?
Very good

Fairly good

Fairly bad

very bad

D

D

D

D

During the past month, how often have you taken medicine (prescribed or "over the counter") to help you
sleep?
Not during the
past month
D

Less than
once a week
D

Once or
twice a week
D

Three or more
times a week
D

No problem
at all

Only a very
slight problem

Somewhat of
a problem

A very
big problem

D

D

D

D

During the past month, how often have
you had trouble staying awake while driving, eating meals, or engaging in social activity?
No problem
at all

Only a very
slight problem

Somewhat of
a problem

A very
big problem

D

D

D

D

9. During the past month, how much of a problem has it been for you to keep up enough enthusiasm to get
things done?
No problem
at all

Only a very
slight problem

Somewhat of
a problem

A very
big problem

D

D

D

D

No bed Partner/
room, but not
same bed
D

Partner in same
roommate in
same bed
D

Partner or
other room

Partner in room

D

D

10. During the past month, how much of a problem has it been for you to keep up enough enthusiasm to get
things done?
No problem
at all

Only a very
slight problem

Somewhat of
a problem

A very
big problem

D

D

D

D

235

If you have a roommate or bed partner, ask him/her how often in the past month you have had...

...loud snoring
...long pauses between breaths
while asleep
...legs twitching or jerking while
you sleep
...episodes of disorientation or
confusion during sleep
Other restlessness while you sleep;
please describe

Not during the
past month

Less than
once a week

Once or
twice a week

Three or more
times a week

D

D

D

D

D

D

D

D

D

D

D

D

D
D

D
D

D
D

D
D
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